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Abstract 
Hyperglycaemia is a main feature of diabetes, and this pathology is a main complication of 
pregnancy. Diabetic patients often require tighter glycaemic control in pregnancy, as glucose 
metabolism changes, and insulin dosages need to be adjusted. Throughout gestation, the 
placenta is therefore subjected to periods of hyperglycaemic insult. Thus, we wished to study 
how brief periods of hyperglycaemia affected the feto-placental vasculature, through study of 
important permeability molecules, pro-permeability VEGFa, anti-permeability VEGFb, and 
junctional stability molecule VE-cadherin. A 15mM concentration of glucose was chosen 
because it is a level seen postprandially in diabetic pregnancies. We explored this by explant 
and perfusion methods. 
We tested two chorionic villous explants methodologies to validate them for 4h and 24h 
duration studies, and found that a free-floating methodology which sought to replicate the in 
utero flow was not appropriate, as this resulted in high basal levels of endothelial VEGF and low 
junctional VE-cadherin, a feature that we hypothesised to be a wound healing response. 
Therefore, we chose the stationary explants methodology, with no simulation of flow, for our 
subsequent experiments. 
The stationary method, where chorionic villi were incubated with hyperglycaemia (lSmM 
glucose) vs. euglycaemia (SmM glucose) for the two different durations (4h and 24h) revealed 
that lSmM glucose was affecting junctional stability and the pro-permeability molecule VEGF-A 
after a 24h hyperglycaemic insult, but that VEGF was not affected by 4h. Given that 4h is a 
physiologically important timepoint (representing a postprandial glucose peak seen in diabetic 
pregnancies), we continued with this timepoint in further experiments. 
Whilst we found no effect of lSmM glucose insult after a 4h incubation on total VEGF 
expression, we found that the recently discovered anti-permeability VEGFb splice variant was 
decreased in hyperglycaemia compared to euglycaemic explants. Furthermore, the there was a 
significant negative correlation between total VEGF and VEGFb levels, indicating that the ratio 
of the two molecules was changing in diabetic explants compared to normal explants. The 
diabetic explants showed no further down-regulation of VEGFb on lSmM glucose insult, 
indicating a tolerance of the diabetic placental vessels to hyperglycaemia. 
We then investigated whether total VEGF and/or VEGFb were important predictors of vascular 
dysfunction as measured by an increased in leakage to 76Mr dextran-TRITC tracer in a well 
established perfusion model. The vascular bed was perfused with lSmM glucose administered 
to the maternal circuit. After a 3h hyperglycaemic perfusion, we observed high total VEGF, low 
VEGFb, and a loss of VE-cadherin from the endothelial junctions. These changes corresponded 
to a mild increase in leakage to 76Mr dextran tracer measured by counting vessels showing 
'hotspots' of tracer at perivascular regions (18% of vessels leakage in the hyperglycaemic 
perfusions vs. 10% leakage in the euglycaemic perfusions). The percentage of vessels exhibiting 
tracer leakage showed a significant negative correlation with VEGFb (Spearman r value -0.8857) 
but not total VEGF, indicating that the former may be an important predictor of vascular 
dysfu nction. 
It would be clinically important to be able to predict placental vascular dysfunction in diabetic 
pregnancies. Further experiments are needed to see whether the VEGFa/VEGFb ratio can 
predict vascular leakage under hyperglycaemia and the other main feature of diabetic 
pregnancies, hyperinsulinaemic insult, and whether the hyperglycaemic insult resulting in the 
diabetic phenotype is reversible upon euglycaemic conditions being restored. Our studies so 
far have shown that the diabetic phenotype can be partly replicated, in terms of vascular 
leakage, with a single lSmM hyperglycaemic insult. Chronic insult may well prove to result in 
the fully leaky vessels observed in diabetic placentae. VEGFb might be an important predictor 
of this leakage, and may be clinically used for assessment of risks in diabetic pregnancies. 
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Chapter 1 
General introduction 
1 
1.1 The placenta 
The function of the human placenta is vital for implantation, growth and healthy development 
of the embryo and fetus. The human placenta is a haemochorial organ, where the maternal 
blood comes in direct contact with the (chorionic) trophoblast of the placenta. The maternal 
circulation and the feto-placental circulation do not mix whilst allowing vital nutrient and gas 
exchange. It connects the developing fetus to the uterine cavity (Figure 1.1), and acts as an 
important discriminatory barrier between the mother and the fetus. Any abnormality in the 
structure and/or function of the placenta can result in fetal morbidity and mortality. Maternal 
diabetes, which is a major complication of pregnancy, does not spare the placenta and results 
in morbidity with long-term consequences. 
Figure 1.1: The pregnant human uterus, showing a third month gestation fetus, placenta, and uterine wall . 
The placenta is embedded in the decidualised endometrium, and connected to the fetus via the umbilical 
cord. Taken and adapted from Boyd and Hamilton (1970) with permission from John Wiley and Sons. 
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1.1.1 Placental function 
The main functions of the human placenta are to carry out the exchange of gases and nutrients 
from the mother to the fetus (and vice versa), to produce hormones, predominantly 
progesterone, for the maintenance of the pregnancy (Munro et 01., 1983), and to protect 
against eventual xenobiotic substances in the maternal blood. In order to carry out the first 
function, exchanging gases such as oxygen, carbon dioxide and nutrients such as amino acids, 
free fatty acids, carbohydrates and vitamins, the placenta has an intricate and complex vascular 
system (Burton and Jauniaux, 1995). The maternal blood comes from the maternal spiral 
arteries and enters the trophoblastic lacunae (also called the intervillous space or 'blood lakes'), 
and the exchange of gases takes place between these and the terminal villi derived from the 
trophoblast layer of the embryo. The maternal blood then drains from the blood lakes via 
uterine veins (Figure 1.2). The fetal blood is transported from the umbilical cord's two arteries, 
through the placental circulation to the exchange sites in the terminal villi, and back to the fetus 
through the single vein in the umbilical cord, and to the fetus (Figure 1.2) (Heifetz, 1996; Boyd 
and Hamilton, 1970). 
The placenta is highly permeable to gases, so the exchange of these is by simple diffusion. The 
diffusion of oxygen and carbon dioxide is so quick that the rate-limiting step in this exchange is 
the blood flow to and from the site of exchange. Interestingly, fetal haemoglobin has a higher 
affinity for oxygen and a lower affinity for carbon dioxide than the maternal adult haemoglobin 
(Blackburn, 2003), therefore favouring the transfer of oxygen to the fetus and of carbon dioxide 
to the mother. 
As for the transfer of nutrients across the placental barrier, the main nutrients transported are 
carbohydrates, amino acids, lipids and vitamins and minerals, and each of these has its own 
system for transport. 
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Figure 1.2: Diagram of a cross-section of the placenta, showing a chorionic villous tree with vessels 
directly connected to the umbilical vein (red) and the umbilical arteries (blue). The maternal blood flows 
(white arrows) into the blood lakes through spiral arteries, and drains from the intervillous space from the 
uterine veins. Fetal blood flows (white arrows) from the fetus through the umbilical arteries, through the 
placental circulation and back to the fetus from the umbilical vein. The blue dotted lines represent a 
cotyledon. The space (in red) surrounding the chorionic villous tree is the maternal blood from the 
maternal spiral arteries. The basal plate, chorionic plate, and decidual septa have also been annotated. 
Taken and adapted from Boyd and Hamilton (1970) with permission from John Wiley and Sons. 
Glucose is the main source of carbohydrate for the fetus, as the fetus can carry out very little 
gluconeogenesis. Transfer of glucose from the maternal circulation is carried out by protein-
mediated facilitated diffusion through the syncytiotrophoblast, with a number of glucose 
transporters (GLUTs) present in this layer of the placenta in pregnancy, and through the 
endothelial paracellular cleft to the fetal circulation. However, the location of GLUT receptors 
in the placenta changes throughout pregnancy (Figure 1.3). 
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Figure 1.3: Location of GLUT transporters in early and late pregnancy and effect on glucose flux. In early 
pregnancy (A), the glucose transporters' location is such that there is increased placental uptake of 
glucose, therefore less transport to the fetus, whilst in late pregnancy (B), glucose transporters are 
arranged so that there is increased transport to the fetus. Red arrows : glucose path, the relative width of 
which corresponds to the relative amount of glucose present in that area, with bolder lines representing 
higher glucose levels. 
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The primary glucose transporter involved in glucose flux across the placenta, GLUTl, is present 
throughout gestation in the placenta, and it is found in the membranes facing both the 
maternal and the fetal circulations (liisley, 2000; Baumann et 01., 2002), although its exact 
localisation changes throughout pregnancy (see section 5.1.3. for more detail). GLUT3 is 
present at term, but only in the endothelial lining of the vasculature, where it removes the 
remaining glucose from the fetal arterial blood after passage through the fetal circulation, 
thereby increasing the glucose gradient across the placenta and maximising glucose transfer to 
the fetus, whilst in the first trimester it is present in the cytotrophoblast (Baumann et 01., 2002; 
Ilisley, 2000; Clarson et 01., 1997). In contrast, GLUT8 is expressed at term, but seems to be less 
important in early pregnancy (Limesand et 01., 2004). GLUT12 seems to have different roles in 
early and late pregnancy, being found in the trophoblast in the first trimester, but being 
completely absent from this layer at term, and being instead present in the smooth muscle and 
stroma (Gude et 01., 2003). Interestingly, GLUT4, the insulin-sensitive glucose transporter, is 
present in the syncytiotrophoblast in early pregnancy but is only found in the stromal layer at 
term, indicating a role in maternal-fetal glucose transport only in early pregnancy, but at term a 
role in the transport of glucose to the placenta in response to fetal insulin (Xing et 01., 1998). 
The significance of these changes in glucose transporter expression and location thoughout 
pregnancy is as follows. In the first trimester of pregnancy, the expanding trophoblast requires 
considerable amounts of glucose. Therefore, the glucose transporters are arranged in such a 
way that there is increased transport to the placenta, but less transport to the fetus (Figure 
1.3A). In the third trimester, where the fetus is rapidly growing and therefore requires more 
glucose, the transporters are arranged such that there is a greater glucose gradient across the 
placenta and therefore increased transport to the fetus (Figure 1.3B). 
Glucose is initially uptaken by the syncytiotrophoblast, and then, once in the 
syncytiotrophoblast's cytoplasm, it can be transferred to the fetal circulation via the endothelial 
lining of the capillaries. The rate-limiting step for glucose transport to the fetus seems to be the 
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former, as in the syncytiotrophoblast it is also metabolised into glucose-6-phosphate or 
glycogen for placental nutrition, and therefore not all glucose which is transported to the 
placenta is transferred to the fetus (narrowing red arrows in Figure 1.3A-B) (Baumann et 01., 
2002). 
The transport of amino acids is essential for the fetus for protein synthesis and metabolism. 
This is evidenced by the presence of essential amino acids in fetal plasma. Some amino acids 
can be synthesised by the fetus itself. The transport of amino acids occurs via the microvilli and 
basal membrane of the syncytiotrophoblast. The fetal-maternal ratio of amino acids in blood is 
generally between 1 and 4, indicating that there is active transport of amino acids from mother 
to fetus (Yudilevich and Sweiry, 1985). 
Lipids can be transported from the maternal circulation; however, the trophoblast can 
synthesise oleic, palmitic and palmitoleic acids, and small amounts of stearic, lauric and 
myristiric acids (Coleman and Haynes, 1987). Lipids are normally bound to proteins within the 
maternal plasma, such as free fatty acids to serum albumin, so there are lipoprotein lipases on 
the maternal surface of the placenta which are able to release the lipids from the proteins. 
They can then either cross the syncytiotrophoblast membrane by simple diffusion, or cross by 
binding to membrane bound and cytosolic fatty acid binding proteins (Haggarty, 2002). Once in 
the cytoplasm of the syncytiotrophoblast, they can either be metabolised or transported out of 
the trophoblast by cytoplasmic binding proteins. In the adult, the liver is responsible for the 
elimination or biotransformation of bile acids and many other lipid-soluble exogenous 
compounds; however, the fetal liver is immature, so the placenta takes over this task (Marin et 
01.,2003). 
The transfer of water depends on osmotic and hydrostatic pressure, and can move across the 
placenta passively; however, there may be a water channel in the trophoblast to facilitate such 
a transfer (Stulc, 1997). Calcium, potassium, magnesium and phosphate are all transported 
actively across the placenta, whilst sodium and chloride are thought to transfer passively, and 
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this is evidenced by the fact that the former group's levels are higher in the fetal circulation 
than in the maternal circulation, whilst the levels of the latter group are similar in both 
circulations (Shennan and Boyd, 1987; Stulc, 1997). Vitamins and minerals also are transferred 
to the fetal circulation. 
The placenta is not only involved in the transfer of nutrients, but also in the production of 
hormones, which go on to have endocrine, paracrine and autocrine effects. Progesterone is 
produced by the placenta and released into both maternal and fetal circulations; it shares this 
production with the corpus luteum until the 9th week of pregnancy, after which it becomes 
solely responsible for the production of this hormone. Progesterone inhibits uterine 
contraction and suppresses the menstrual cycle. At 9 weeks, the placenta also becomes the 
main producer of oestrogens, which act as growth hormones for the mother's reproductive 
organs, such as breasts, uterus, cervix and vagina, whilst the fetus is protected from oestrogen's 
effects by its conjugation with sulphate and glucoronide (Page, 1993). Human chorionic 
gonadotrophin is produced by the trophoblast and released to the maternal circulation in very 
early pregnancy to maintain the corpus luteum; it also acts in an autocrine fashion to stimulate 
formation of the syncytiotrophoblast and differentiation of villous trophoblast (Malassine and 
Cronier, 2002). The syncytiotrophoblast produces human placental lactogen, releasing it in 
both the maternal and fetal circulations; in the fetus, it regulates embryonic development and 
intermediary metabolism, it stimulates the production of hormones, and may be involved in 
angiogenesis (Handwerger and Freemark, 2000; Corbacho et al., 2002). Placental growth 
hormone is secreted by the placenta to the maternal circulation and may have a role in 
maternal adjustment to pregnancy and placental development (Lacroix et al., 2002). The 
placenta also produces a number of vasoactive autacoids and eicosanoids (Gude et al., 1998) 
including endothelins (Grabau et al., 1997), adrenomedullin (AI-Ghafra et al., 2003), nitric oxide 
(Gude et al., 1994), and many others, which may be involved in blood flow control in the 
placenta. The placenta also produces large amounts of acetylcholine (King et al., 1991), 
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released by organic cation transporter subtypes 1 and 3 into the extracellular space (Wessler et 
al., 2001). Acetylcholine is thought to act on through nicotinic acetylcholine receptors to have a 
role in the regulation of nutrient transport, blood flow and fluid levels in placental vessels, and 
also seems to have a role in vascularisation (Sastry, 1997). 
Finally, the placenta has a protective function. Although some bacteria, protozoa, viruses and 
other xenobiotic molecules can pass through the placental barrier, the placenta has a number 
of mechanisms to defend the fetus from potentially toxic substances. Some of the features of 
these mechanisms include export pumps in the maternal-facing membrane of the 
syncytiotrophoblast, multidrug resistance-associated protein family members, a placenta-
specific ATP-binding cassette protein, cytochrome P4S0 enzymes to metabolise drugs and 
xenobiotics, and phase I and" xenobiotic metabolising enzymes amongst others (Marin et al., 
2003; Pasanen, 1999). Although many molecules are not passed through the placenta, 
immunoglobulin G class is transported through the placenta by pinocytosis, and these 
antibodies provide an important passive immunity when the baby is born (as reviewed by 
Schneider and Miller (2010)). The placenta is referred to as providing resistance in series, with 
both the syncytium and endothelial junctions presenting a physical barrier for transport (Leach 
and Firth, 1992). 
1.1.2 Placental structure 
The term placenta derives from the Greek plak6enta, meaning flat, round pancake. This is an 
accurate description of its appearance. On average the placenta has a diameter of 22cm, a 
thickness of 2.Scm in the centre, and weighs 470g. The umbilical cord generally inserts in the 
centre of the placenta, but this can vary between individuals, and an abnormal pOSitioning does 
not necessarily indicate pathology (Benirschke and Kaufmann, 2000). 
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The fetal side of the placenta, where the umbilical cord attaches, is called the chorionic plate 
(annotated in Figure 1.2). The chorionic plate is covered by the amnion, and chorionic vessels 
branch normally in a star-like pattern from the umbilical cord insertion. These vessels are 
continuous with the microvascular component of the chorionic villous trees. 
There are three layers in the chorionic villous tree, each with different cell types. The first layer 
from the fetal circulation is composed of fetal vascular cells which surround the blood vessels, 
including endothelial cells, pericytes, and vascular smooth muscle cells. Then, there are 
mesenchymal cells in the villous core, which include Hofbauer cells and fibroblasts. Lastly, in 
direct contact with the maternal circulation and completely covering the surface of villous trees 
is the trophoblast, which can be of two types: undifferentiated cytotrophoblasts and fully 
differentiated syncytiotrophoblast. The syncytiotrophoblast bathes in the maternal blood and 
is a functional unit in the transport of oxygen and nutrients to the fetus, whilst cytotrophoblasts 
act as stem cells for the syncytiotrophoblast, and are responsible for the invasion of uterine 
spiral arteries. 
The maternal surface (or basal plate, as annotated in Figure 1.2) is a heterogeneous mixture of 
fetal (trophoblast) and maternal (decidual) tissue as the trophoblast invaded the decidua in 
early pregnancy with subsequent remodelling of uterine spiral arteries (Boyd and Hamilton, 
1970). The placenta at term is composed of 10-40 cotyledons (lobes of the placenta, blue 
dotted line in Figure 1.2), which are incompletely separated from each other by decidual septa. 
Between the chorionic and basal plates are the chorionic villous trees. In between the 
chorionic villous trees are the intervillous blood lakes, where the maternal blood comes in 
contact with the placental villi (Boyd and Hamilton, 1970). 
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1.1.2.1 The chorionic villous tree 
The [umbilical] vessels join on the uterus 
like the roots oj plants and through them 
the embryo receives its nourishment. 
Aristotle. On the Generation of Animals (ca. 340 B.C.) 
This quote from Aristotle compares the placental vasculature to the structure of a tree, where 
the largest roots and branches from the trunk of the tree (equivalent to stem villi) are large 
conduit vessels, which then branch into smaller roots and branches, and it is only at the 
smallest vessels at the ends of the branches and roots (equivalent to terminal villi) which 
participate in the uptake of nutrients. This is a great visual representation of the chorionic 
villous tree, which contains three types of chorionic villi in the mature placenta: stem, 
intermediate and terminal villi. 
Stem villi represent the 'trunk' of the chorionic villous trees (Figure 1.4), and are thus located 
near the chorionic plate. They vary in size between 80llm in diameter for the smallest stem villi 
to 3mm for the largest, and they make up between 20 to 25% of the total volume of the villi 
(Benirschke and Kaufmann, 2000). They are covered by a thick layer of trophoblast (which will 
degenerate at term and be mostly replaced with perivillous fibrinoid; this degeneration is more 
marked in larger stem villi than smaller ones). The vasculature of stem villi consists of arteries 
and veins (or arterioles and venules in the smaller stem villi) surrounded by the adventitia 
which continues without a sharp demarcation into the stroma, which contains fibroblasts, 
myofibroblasts (the central core of which is called the perivascular sheath) and Hofbauer cells; 
larger stem villi also contain peripheral arterioles and venules (Demir et 01., 1997, Benirschke 
and Kaufmann, 2000). The vascular walls of stem villi also contain occasional mast cells. Stem 
villi form from immature intermediate villi (Demir et 01., 1997; Castellucci et 01., 2000). These 
large villi provide mechanical support of the villous trees structures, but they have little 
involvement in the materna-fetal exchange (Benirschke and Kaufmann, 2000). The 
myofibroblasts present in the perivascular sheath of stem villi may allow the regulation of blood 
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flow by regulating the longitudinal contraction of the anchoring villi (Farley et af., 2004), 
therefore decreasing intervillous blood volume and increasing utero-placental flow impedance 
(Chernyavsky et af., 2010) . 
The mature intermediate villi (hereafter referred to as intermediate villi) are the intermediate 
branches of the tree, which link the stem villi to the terminal villi (Figure 1.4). They vary in size 
between 6 6 - 1 5 0 ~ m m in diameter (about the same diameter of terminal villi), and they make up 
about 25% of total villous volume. Intermediate villi are defined by their stroma having less 
than 50% vascular lumen. Another important function of intermediate villi is vasoregulation 
and intravillous blood distribution regulation, which is allowed by the presence of terminal 
arterioles. Intermediate villi also produce hormones (Castellucci et af., 2000). 
Figure 1.4: Structure of a chorionic villous tree. Stem, intermediate and terminal villi shown. Taken from 
Benirschke and Kaufmann (2000) with kind permission from Springer Science and Business Media. 
The terminal villi are the smallest and most distant from the stem villi. Terminal villi sprout 
from the surface of intermediate villi, and are characterised by highly dilated sinusoids and a 
high degree of capillarisation. They have much thinner trophoblast than stem villi and so are 
able to participate in the feto-maternal exchange function of the placenta in the first and 
second trimesters. They connect to the mature intermediate villi through narrow necks, and 
resemble grapes (the terminal villi) on a vine (the intermediate villi) (Figure 1.4). It is these 
terminal villi which participate most in the gas and nutrient exchange between the two 
circulations. The average diameter of terminal villi is between 30-80J..lm, and they form about 
40% of villous volume, but due to their small diameters, they constitute 50% to the total 
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villous surface (Benirschke and Kaufmann, 2000). They are characterised by thin trophoblast 
and a stroma with connective tissue with few fibres and cells and rare macrophages. The 
vessels found in terminal villi are capillaries, some of which are sinusoidally dilated. The latter 
are in close contact with the trophoblast, forming the "epithelial plate", which is the most 
suitable place for the exchange of nutrients, gases and water, as the diffusional distance 
between maternal and fetal blood is reduced to around 3.7j.lm here (Feneley and Burton, 1991). 
1.1.3 Vascular development in the developing placenta 
The development of the human placenta begins around 6 days post conception (p.c.), as soon 
as the embryo has implanted. This first placental development period is divided into the pre-
lacunar stage (days 6-8 p.c.) and the lacunar stage (days 8-13 p.c.) (Mihu et al., 2009). The pre-
lacunar stage is characterised by the trophoblast's differentiation into two layers, an inner 
single cell layer of mononucleate cytotrophoblast cells around the blastocyst cavity, and the 
syncytiotrophoblast layer, a multinucleate layer formed from the fusion of cytotrophoblast cells, 
which is directly facing the maternal tissue (Boyd and Hamilton, 1970). This is followed by the 
lacunar period, which is characterised by the proliferation of the syncytiotrophoblast and the 
appearance of lacunae within this layer; the lacunae are initially small, but they merge with 
each other and will become the intervillous blood lakes once the trophoblast has eroded the 
spiral arteries' walls (Benirschke and Kaufmann, 2000). 
The syncytiotrophoblast continues to penetrate deeper and deeper into the endometrial 
stroma, until it reaches the endothelial lining of the sinusoids. This is then eroded away, and 
therefore the lacunae become continuous with the spiral arteries (Kaufmann and Kingdom, 
2000). The extravillous trophoblast that invades the spiral arteries is phenotypically distinct 
from the villous cytotrophoblast, as they have been shown to express different angiogenic 
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factors in tissue culture experiments (Lash et 01., 2010). The lacunae fill with blood, and will 
subsequently be known as 'blood lakes'. The utero-placental circulation is thus established. 
Prior to implantation, decidualisation occurs. The endometrial cells surrounding the embryo 
become loaded with glycogen and lipids, and polyhedral in shape. The intercellular space 
becomes filled with extravasate and the tissue is therefore oedematous. The endometrium in 
these circumstances is called the decidua, and is composed of three parts. The decidua basalis 
is the part closest to the embryonic pole, and forms a compact layer of cells which is called the 
decidual plate. This plate is the part of the maternal tissue which is connected to the chorion 
frondosum (the part of the chorion at the embryonic pole, which is bushy in appearance, and in 
which the villous structures will form). The decidua capsularis is instead located over the 
abembryonic pole, and as the embryo grows this part becomes stretched and then degenerates. 
Finally, the decidua parietalis is on the opposite side of the uterus and as the fetus grows fuses 
with the chorion laeve (the abembryonic part of the chorion, which is devoid of villi from the 
third month, and is smooth in appearance). 
The chorionic villi begin to be formed on the 13th day p.c. as the cells of the cytotrophoblast 
invade the local endometrium, forming cellular columns covered with syncytia (Boyd and 
Hamilton, 1970). These are referred to as primary villi, and initially they completely surround 
the embryo around the circumference of the chorion (Pijnenborg et 01., 1981). The secondary 
villi begin to be formed at 15 days p.c, when mesodermal cells invade the core of the primary 
villi, from the chorion in the direction of the decidua. Only one layer of cytotrophoblast cells 
are present between the surface covering of the syncytiotrophoblast and the inner mesodermic 
core. The secondary villi are formed before the start of villous vasculogenesis (Demir et al., 
2006). Finally, the tertiary or definitive placental villi are formed by the end of the third week 
p.c. when the mesodermal cells begin to differentiate into blood cells and blood vessels (Boyd 
and Hamilton, 1970). This process of vasculogenesis and development from secondary to 
tertiary villi is influenced by the trophoblast (Kingdom et al., 2000). That the trophoblast is an 
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essential factor in the development of the chorionic villous tree was demonstrated in knockout 
experiments, where the absence of trophoblastic transcription factor glial cell missing-l, a 
protein which regulates syncytiotrophoblast differentiation in mice, resulted not only in failure 
of syncytiotrophoblast formation but also in the decreased formation of blood vessels in the 
feto-maternal unit (Anson-Cartwright et 01., 2000). In the following months, the tertiary villi 
then sprout to create a villous tree, comprised of stem villi, intermediate villi and terminal villi. 
As the embryo grows and becomes a fetus (at 8-10 weeks gestation), more nutrient and gas 
exchange is required to maintain growth of the fetus at the appropriate rate. In order to 
achieve this, the composition of the terminal villi, and to a certain extent the intermediary and 
stem villi, changes. The cytotrophoblastic layer in the villi and some of the connecting tissue 
starts to disappear, leaving only the syncytium and the endothelial layer of the blood vessels to 
separate the two circulations, therefore allowing a more intimate connection, and a greater 
exchange of molecules, as there are only two layers instead of four separating the maternal and 
fetal circulations. Furthermore, the syncytium becomes very thin, facilitating the exchange. 
This latter process begins in the fourth month, and at birth no cytotrophoblast is found in the 
terminal villi, although some is found in the stem villi (Benirschke and Kaufmann, 2000). 
During the fourth/fifth month, another morphological change occurs in the placenta: 10-40 
cotyledons are formed, which persist until birth. They are formed by a core of maternal tissue, 
covered in syncytial cells to disallow direct contact between the two circulations, called the 
decidual septa, projecting into the intervillous spaces. It is very important that the two 
circulations remain separated at all times, as even a minor bleed can lead to haemolytic disease 
due to Rh-incompatibility (if the embryo is Rh-positive and the mother Rh-negative, the mother 
will produce antibodies against the fetus' blood cells, which penetrate the placental barrier and 
cause a breakdown of the fetal red blood cells). The septa penetrate the intervillous space, 
however they do not reach the chorionic plate, allowing contact between the various 
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intervillous spaces in the different cotyledons to be maintained (Benirschke and Kaufmann, 
2000). 
The cotyledons receive blood from spiral arteries which perforate the decidual plate and enter 
the intervillous space. The extravillous trophoblast invaded the muscle wall (interstitial 
extravillous cytotrophoblast) and the endothelium (endovascular extravillous cytotrophoblast) 
of the spiral arteries, amd might be replacing these cell layers with trophoblast (Brosens et 01., 
1967; Kaufmann et 01., 2003). However, recent views dispute this endothelial replacement 
(Bulmer et al., 2012). The result of this invasion is the loss of maternal muscular and vascular 
control, vasomotor control and vessel elasticity, in order to create a high flow but low 
resistance environment which maximises gentle but high blood flow into the intervillous space 
with exposure of the chorionic villi to minimal shear. If this remodelling is in part or fully absent, 
the narrow lumen of the spiral artery and intact muscular wall may restrict and perturb blood 
flow to the placenta, and the physical influence of the high shear stress on the chorionic villi can 
induce the villi to secrete vasoactive substances into the intervillous space, possibly leading to 
maternal hypertension and pre-eclampsia later in the pregnancy (Brosens et al., 1972; 
Pijnenborg et 01., 2006). The intervillous spaces hold about 150ml of blood, which is 
replenished 3-4 times per minute. The surface area of the villi is around 13m2 (Luckhardt et 01., 
1996), although it is mostly the terminal villi which contribute to the placental exchange 
(Benirschke and Kaufmann, 2000). 
By the end of the pregnancy, terminal villi contain dilated and highly coiled capillaries, and the 
endothelium of these capillaries is only separated from the maternal circulation by a thin layer 
of syncytiotrophoblast, minimising the distance between maternal and fetal circulation and 
thus maximising exchange capabilities without compromising the barrier function of the 
placenta (Demir et 01., 1989; Kingdom et al., 2000). 
The placenta throughout the pregnancy increases in parallel to the developing fetus, and it 
covers approximately 15-30% of the internal surface of the uterus. The increase in thickness of 
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the placenta during the pregnancy is not due to the further penetration of the maternal tissue; 
rather, it is due to the further arborisation of the villous trees (Benirschke and Kaufmann, 2000). 
1.1.4 Placental vasculogenesis and angiogenesis and its control 
Vasculogenesis in the placenta occurs in three steps (Figure 1.5). The first step starts in the 
third week, and comprises the formation of haemangiogenic cords from angioblastic progenitor 
cells, which form aggregates arranged in strings. These cells can then differentiate into two cell 
types: cells in cords located peripherally will become angioblasts, which will go on to become 
the lining of the blood vessels (the endothelium), whilst the cells in centrally located cords will 
become haematopoietic cells, which will go on to form blood cells (Demir et 01., 2004). They 
contain desmosomes and primitive tight junctions but have few organelles and no cellular 
extensions at this stage (Kaufmann et 01., 2004). This first step is controlled by the villous 
cytotrophoblast and Hofbauer cells, as they begin to produce the angiogenic molecules vascular 
endothelial growth factor (VEGF) and placental growth factor (PIGF) (Seval et 01., 2007). These 
two growth factors, via a paracrine mechanism, initiate the differentiation, migration and 
proliferation of pluripotent mesenchymal cells, which in turn differentiate to haemangiogenic 
progenitor cells. 
The second step of vasculogenesis involves the formation of a lumen by the enlargement of 
centrally located intercellular clefts, and the presence of cytoplasmic protrusions and 
outgrowths, as well as pericytes surrounding these primitive vessels (Demir et 01., 1989). This 
step is regulated by the cytotrophoblast, Hofbauer cells and fibroblasts cords, which produce 
VEGF, PIGF and fibroblast growth factor (FGF) and activate the cords formed in the first step, 
which then respond by differentiation into endothelial precursor cells (Kaufmann et 01., 2004). 
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Figure 1.5: Vasculogenesis and angiogenesis in the human placenta. Angioblastic progenitor cells are 
arranged in haemangiogenic cords in the first step, which then form endothelial tubes in the second step, 
and vessels grow by branching and non-branching angiogenesis in the third step. On the right, the 
mediators for these steps are annotated. FGF: fibroblast growth factor, NO: nitric oxide, ECM: 
extracellular matrix. Adapted and redrawn from Charnock-Jones et 01. (2004) . 
The endothelial tubes remain isolated until they join up with the fetal circulation, which at this 
point has not begun yet. Vasculogenesis starts at the same time in both the placenta and the 
extraembryonic allantois, which then connects to the placenta and embryo allowing the feto -
placental circulation to start. At the same time as the developing vasculature, haematopoietic 
stem cells start to develop from primitive vessel wall into lumen (Downs et 01., 1998). 
The third stage is formally referred to as angiogenesis, and consists of the remodelling of the 
vessels. This stage is mediated by extracellular matrix (ECM) components, perivascular cells, 
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and the environment through molecules such as VEGF, PIGF, nitric oxide (NO), and vascular 
endothelial cadherin (VE-cadherin) (Kaufmann et 01., 2004). Low oxygen concentrations also 
stimulate the formation of blood vessels, as the oxygen concentration before 10 weeks p.c. is 1-
2%, whilst this level rises to 6-8% after maternal blood flow to the placenta is established 
(Yedwab et 01., 1976; Jauniaux et 01., 2000; Lash et al., 2002). There are two types of 
angiogenesis in the placenta, branching and non-branching angiogenesis, the former being 
predominant in early pregnancy (32 days p.c. to 25 weeks p.c.), and the latter being 
predominant in late pregnancy (25 weeks p.c. to term) (Kaufmann et al., 2004). The blood 
vessels are formed by continual sprouting of the endothelial celis, and fusion of the vessels 
when they reach one another. To establish contact with the intra-embryonic vessels, the extra-
embryonic blood vessels then continue budding until there is contact between the two. Thus, 
when the heart begins beating at the beginning of the 4th week, this primitive cardiovascular 
system is able to bring nutrients and essential gases to all parts of the developing fetus. 
We have seen than VEGF is a key molecule for the control of vasculogenesis and angiogenesis 
(Figure 1.5). Furthermore, it is also a key growth factor for the control of vascular integrity. 
This topic will be explored in the next section. 
1.2 Control of endothelial Integrity 
1.2.1 VEGF-A 
Vascular endothelial growth factor (VEGF) is one of the most important growth factors involved 
in angiogenesis and permeabiility. It is 40,000 more times effective than histamine, in a molar 
ratio, in inducing an increase in permeability (Senger et 0/., 1993). Therefore, any molecules 
which either inhibit or potentiate the action of VEGF are important players, especially in the 
placentation research area, as the placenta requires tight regulation of angiogenesis and 
permeability. 
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1.2.1.1 Molecular biology 
VEGF is a family of growth factors which includes 7 members: VEGF-A, -B, -C, -0, -E and -F, and 
PIGF. VEGF-E and -F were discovered from non-human sources (VEGF-E from a virus (Lyttle et 
01., 1994), VEGF-F from viper venom (Suto et 01., 2005)), but they are not endogenous to the 
placenta, and thus shall not be discussed further. Three members for which limited information 
in the placental context is available, and which do not seem to be the major members for VEGF 
action, are VEGF-B,-C, and -D. VEGF-B can only bind VEGFR-1 (for more detail about VEGF 
receptors, see section 1.2.1.2); however, VEGF-B can form heterodimers with VEGF-A, and may 
influence VEGF receptor signalling in this way (Nash et 01., 2006). VEGF-B is present in two 
isoforms in humans, VEGF-B167 and 186. VEGF-C and -0 can bind VEGFR-2, but not VEGFR-1, and 
although VEGF-C is expressed in the placenta, it is mainly a Iymphangiogenic agent (Karkkainen 
et 01., 2004), and thus it is not the subject of this thesis. VEGF-O is not present in the placenta. 
The member of the VEGF family we are interested in for this thesis is VEGF-A. 
The VEGF-A gene has 8 exons divided by 7 introns, and it gives rise to six isoforms arising 
through alternative splicing: VEGF-A l2l, 145, 165, 183, 189 and 206 (Figure 1.6), the most abundant of 
which are VEGF-Al2l and 165, while other isoforms are expressed only in certain tissues 
(interestingly, VEGF-A145 and 206 are found only in embryonic and placental tissue) (Pages and 
Pouyssegur, 2005). The heparin binding isoforms bind heparin in the homodimeric 45kOa 
protein form (Ferrara and Henzel, 1989) (exons 6-7 in Figure 1.6), and each isoform is 
differentially regulated (Pages and Pouyssegur, 2005). 
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Figure 1.6: VEGF-A gene and pre-mRNA splicing pattern and sequence. The six 'conventional ' isoforms of 
VEGF and VEGF165b are shown. PSS: proximal splicing site, DSS: distal splicing site, UTR: untranslated 
region. Adapted and redrawn from Woolard et 01. (2004) . 
VEGF-A isoforms have different characteristics which allow them to have different properties in 
the extracellular space. VEGF-Al2l is an acidic polypeptide (lacking exons 6-7, Figure 1.6), and 
therefore does not bind heparin or heparan sulphate (a component ECM). It is therefore freely 
diffusible in the extracellular space, which makes it a very potent but short acting VEGF isoform. 
VEGF-A183, 189 and 206, in contrast, are highly basic (as they include exons 6-7, Figure 1.6) and 
therefore bind to the ECM with high affinity, and are almost completely sequestered in the ECM. 
When the heparin-binding domain is cleaved by plasmin, 110 amino acid active fragments are 
released, and they are free to bind to the VEGF receptors, and in this way, they are more 
biologically available than VEGF-Al2l . VEGF-A16S has intermediate properties (as it lacks exon 6 
but includes exon 7, Figure 1.6), which give it optimal characteristics for both biological 
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availability and potency: a significant proportion stays bound to the ECM, but the rest is freely 
diffusible (Houck et 01., 1992). It is the isoform of VEGF-A which most closely corresponds to 
the native properties of VEGF (Houck et 01., 1992), and is the main molecule responsible for 
VEGF-A action. 
As expected for a vascular growth factor, VEGF-A shows a ubiquitous distribution in the body, 
and is the member that is most often simply called 'VEGF'. Taking this convention a step 
further, for the purposes of this thesis, any mention of 'VEGF', unless otherwise specified, will 
be referring to VEGF-A16S• Similarly, VEGF16Sb (see Figure 1.6) will hereafter be referred to as 
simply VEGFb. 
VEGF exerts its effects on the vasculature through the VEGF receptors, which will be discussed 
in the following section. 
1.2.1.2 Receptors 
The VEGF receptor family consists of three members: VEGFR-1 (also called fms-related tyrosine 
kinase-1, or Flt-1), VEGFR-2 (also called kinase domain region, or KOR), and VEGFR-3 (Flt-4) 
(Figure 1.7). All three receptors are members of the tyrosine kinase family of transmembrane 
receptors. VEGFR-3 only binds with VEGF-C and -0, and as such will not be discussed further. 
VEGFR-1 is a negative regulator for VEGF, whilst the primary receptor for VEGF signalling is 
VEGFR-2 (Mukherjee et 01., 2006). The Neuropilins (Nrp), receptors of the semaphorin-collapsin 
family (Chen et 01., 1997), also bind VEGF, VEGF-B, and PIGF, even though they are not tyrosine 
kinase receptors. 
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Figure 1.7: VEGF receptors and their ligands, showing which VEGF family member binds to each VEGF 
receptor (VEGFR). In addition, the structural details of these and the neuropilin receptors (Nrp) are 
shown. Red, blue and yellow horizontal ovals: immunoglobulin domains, green reclangles: tyrosine kinase 
domains, horizontal purple and green ovals: complement-like (CUB) domains, purple and green diamonds: 
homologous to factors V and VIII (FV/VIII) domains, vertical purple and green ovals: meprin, AS, mu (MAM) 
domains. Adapted and redrawn from Hicklin and Ellis (2005) . 
The structure of both VEGFR-l and VEGFR-2 is composed of seven extracellular immunoglobulin 
domains, each of which have a specific function, a single transmembrane domain, and a 
consensus tyrosine kinase sequence which is interrupted by a kinase-insert domain (Shibuya et 
01.,1990) (Figure 1.7). However, slight differences in the immunoglobulin domains result in the 
VEGF binding with VEGFR-2 to cause strong tyrosine autophosphorylation leading to VEGF 
signalling activation, whilst VEGF binding to VEG FR-l causes only weak tyrosine 
autophosphorylation leading to negative regulation of VEGF signalling. 
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VEGFR-2 is located in endothelial cells (ECs) and in circulating endothelial progenitor cells in the 
placenta. In comparison, VEGFR-1 is expressed on vascular ECs (Barleon et al., 1994), smooth 
muscle cells (Ishida et 01., 2001) and trophoblasts (Ahmed et 01., 2000) in the placenta. As the 
main regulator of the effects of VEGF, VEGFR-2 mediates the major effects of VEGF action: 
angiogenesis, permeability, cell migration, vasodilation, and proliferation. Also, it can form a 
complex with integrin aVP3 to regulate integrin-dependent cell migration, tube formation and 
survival (Somanath et 01., 2009). 
There are two neuropilin (Nrp) receptors: Nrp-1 and -2. Both can bind VEGF (but have slightly 
different affinities for it); however, they have different specificities for the other isoforms and 
for the other members of the family. The binding occurs in a heparin-dependent manner 
(Migdal et 01., 1998). 
The structure of the Nrp is composed of two complement-like (CUB) domains, two domains 
homologous to coagulation factors V and VIII (FV!FVIII) and one meprin, AS, mu (MAM) domain 
(Chen et 0/.,1997) (Figure 1.7). 
Both Nrps are expressed in human umbilical vein endothelial cells (HUVECs), while only Nrp-l 
can be found in capillaries (Soker et al., 1998). They are expressed in development in the 
endothelium of all blood vessels and mesenchymal cells surrounding the blood vessels, 
amongst others. 
Nrps are co-receptors for many members of the semaphorin/collapsin family. It is thought that 
they affect VEGF's signalling by binding VEGF with high affinity, but acting as co-receptors and 
therefore not directly transducing a signal (Soker et al., 1998). In support of this theory, VEGF 
has a different binding site on Nrp-1/2 than VEGFR-2, and therefore does not affect VEGF's 
binding affinity to VEGFR-2, but greatly potentiates its effects (probably through higher order 
clustering) (Whitaker et 01., 2001). However, Nrps do not seem to influence endothelial cell 
proliferation in vitro (Neufeld et 01., 2002). 
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The signalling pathways mediating the effects of VEGF are discussed in the following section. 
1.2.1.3 Signalling 
There are several signalling pathways that VEGF is thought to activate via VEGFR-2, to mediate 
its various effects. When VEGF binds to VEGFR-2, the receptor dimerises and auto-
phosphorylates on several tyrosines, which then acts on the different pathways to affect cell 
behaviour. 
VEGF is a survival factor in both vascular endothelium (Baffert et al., 2006) and non-vascular 
tissues such as neuronal cells and neuronal stem cells (Kilic et 01., 2006; Schanzer et 01., 2004), 
lymphocytes (Farahani et al., 2005) and haematopoietic stem cells (Gerber et al., 2002). In 
order to accomplish this role, VEGF mediates the VEGFR-2-dependent phosphorylation of the 
phosphatidylinositol-3-kinase (PI3K) pathway which induces 8cl-2 and A1 expression, which 
then leads to EC survival (Fujio and Walsh, 1999; Gerber et 01., 1998). Tyr1175 on VEGFR-2 
seems to be especially important for pro-survival signalling (Holmqvist et 01., 2004). This effect 
can be seen in vitro, as when ECs are starved of serum, there is Pl3K-dependent inhibition of 
apoptosis by VEGF (Abid et 01., 2004). When basal VEGF is inhibited in the vasculature, 
endothelial cell apoptosis is preceded by local thrombosis and a decrease in vascular perfusion 
(Inai et 01., 2004). Hence, small amounts of VEGF are essential for endothelial cell survival. 
In addition to PI3K, the related proteins phospholipase Cy (PLCy), rat sarcoma (Ras) GTPase-
activating protein and the Src family are also phosphorylated, leading to mitogenic, chemotactic 
and prosurvival signals (Guo et al., 1995). VEGF also mediates endothelial cell growth through 
activation of the Raf-Mek-Erk mitogen-activated protein kinase (MAPK) pathway; however, this 
VEGF-induced activation is protein kinase C {PKC)-dependent but Ras-independent, which is an 
unusual situation (Takahashi et al., 1999). 
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The production of NO by endothelial nitric oxide synthase (eNOS) (see section 1.3.3.1 for more 
details on NO synthesis) can be induced independently by both VEGFR-1 (via PI3K) and by 
VEGFR-2 (via PlCy1) (Ahmad et 01., 2006). This creates an increase in EC-derived NO, which 
then increases vasodilation (Hood et 01.,1998; Kroll and Waltenberger, 1999). In a related, NO-
dependent pathway, VEGFR-2 activates guanylyl cyclase, which then produces cyclic guanosine 
monophosphate (cGMP), which leads to an increase in vesico-vacuolar organelles, fenestrations 
and transcellular gaps, thereby increasing permeability. This has been shown to occur in vitro 
(Dvorak and Feng, 2001). Calcium influx is another mechanism for VEGF-induced permeability, 
as it has been shown that VEGF causes an increase in microvessels' hydraulic conductivity 
(Bates and Curry, 1997). 
The effects mediated by these signalling pathways are discussed next. 
1.2.1.4 Effects and role 
VEGF is the driving force behind neo-vascularisation: both during embryonic and placental 
development and during solid tumour vascularisation (Pages and Pouyssegur, 2005). VEGF is 
produced under hypoxic conditions, which then drives the growth of vessels towards the 
hypoxic areas. As well as vascularisation, the main member of the VEGF family is responsible 
for proliferation, sprouting, migration, survival, changes in permeability and tube formation of 
ECs, and induces angiogenesis in embryogenesis and corpus luteum formation amongst other 
processes (Ferrara and Davis-Smyth, 1997; Dvorak et 01., 1995; Hippenstiel et 01., 1998). 
Isoforms of VEGF which bind heparin are essential stimulatory cues for the initiation of the 
formation of vascular branches. This further role is possible because VEGF is regulated by 
plasmin, which cleaves the heparin-binding domain of ECM-bound forms when more 
bioavailable VEGF is needed (Carmeliet et 01., 1999). 
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VEGF promotes vascular inflammation (Detmar et 01., 1998), and adhesion molecule expression 
might be stimulated by VEGF, and angiopoietin-l (Ang-l) has been shown to suppress this, 
leading to inhibition of leucocyte adhesion in vitro (Kim et 01., 2001). VEGF is also able to 
regulate its inhibitor, Ang-l, as Ang-l's inhibitor angiopoietin-2 (Ang-2) mRNA expression and 
release is strongly upregulated by VEGF (Oh et 01., 1999). 
VEGF studies have led to insights into its importance in the body. VEGF was the only known 
example of haploinsufficiency that led to lethality; Vegtl - mutants died between days 11 and 12 
(Ferrara et 01., 1996), due to severe vascular abnormalities. This means that VEGF must be 
carefully regulated both spatially and temporally (Ferrara and Davis-Smyth, 1997). 
VEGF overexpression studies by Bhardwaj et 01. (2003) in rabbit showed a strong angiogenic 
effect in carotid arteries, and several groups have also shown a similar effect on various animal 
tissues (as reviewed by Rissanen et 01. (2004)). However, this often produced large, dilated and 
leaky vessels. Excessive VEGF has been shown to be dangerous, as recombinant VEGF in 
pregnant mice led to an increase in resorption frequency, placental haemorrhage, and a 
decrease in embryo weight. Therefore, bioactive VEGF levels appear to be critical in the 
regulation of the growth and function of vessels, both during placental and embryonic 
development (Charnock-Jones, 2002). 
In studies by Lim et 01. (2004, 2005) in Type 2 diabetic patients, plasma VEGF was found to 
correlate to glycated haemoglobin (HbA1c), a marker for high blood glucose, both in patients 
with and without cardiovascular disease. Additionally, VEGF levels associated more strongly to 
HbA1c levels than to which group the sample belonged in (whether the sample was from 
controls or from diabetic patients with or without cardiovascular disease). The increased VEGF 
levels showed a correlation with hyperglycaemia in the entire subject group and also in the 
patients alone (however, the correlation between Ang-2 and hyperglycaemia was only 
significant in the entire group). Ang-1 expression, in contrast to Ang-2, was affected only in a 
limited way by VEGF, and this effect might be specific to the cell type. Blood pressure, body 
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mass index (BMI), smoking and sex did not correlate significantly with VEGF. Therefore, the 
studies showed that plasma levels of VEGF (and those of Ang-2) correlate with endothelial 
damage/dysfunction indexes, but not inflammation indexes. They also indicated a link between 
glycaemic control, endothelial abnormalities, and angiogenesis. 
These are the effects of VEGF on the vasculature, but how is VEGF itself regulated and affected 
by its environment? These aspects are discussed in the following section. 
1.2.1.5 Regulation 
Hypoxia is one of the most important VEGF regulators, as VEGF gradients attract and guide the 
new sprouting vessels to the cells which need oxygen most urgently. Hypoxia inducible factor 
(HIF)1a binds to hypoxia responsive elements on the VEGF gene, increasing transcription (as 
reviewed by Pages and Pouyssegur (2005)). 
As discussed in section 1.2.1.3, VEGF is a survival factor in vivo. This is developmentally 
regulated, as inhibition of VEGF causes apoptotic changes in the vasculature of newborn but 
not adult mice (Gerber et 01., 1999). Coverage of vessels by pericytes might be one of the key 
changes that cause the loss of dependence on VEGF in human cancer cells (Benjamin et 01., 
1999). 
Heparan sulphate proteoglycans are important for VEGF regulation. They are negatively 
charged cell-surface associated heparin-like molecules that bind basic VEGF molecules, thereby 
limiting their diffusion. However, both VEGF (Figure 1.6) and VEGFR-2 have heparin-binding 
sites. Low concentrations of heparin (O.1-1OJ.lg/ml) potentiate the effects of VEGF as they allow 
crosslinking between the molecules and therefore increasing local VEGF concentration at the 
VEGF receptor (Gitay-Goren et 01., 1992; Tessler et 01., 1994; Wijelath et 01., 2010); however, 
higher concentrations inhibit the effects of VEGF, as heparin saturates the VEGF and VEGFR-2 
binding sites (Gitay-Goren et 01., 1992; Robinson and Stringer, 2001; Tessler et 01., 1994). Pre-
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treatment with heparinase also inhibits VEGF effects (Pages and Pouyssegur, 2005). However, 
the VEGF l2l isoform, which does not bind heparin, is unaffected by heparin or heparinase. 
In the earlier mentioned studies by Lim et al. (2004, 2005) looking at human plasma levels of 
VEGF in Type 2 diabetic patients compared to healthy controls, the authors found increased 
levels of VEGF in diabetic patients, and a significant positive correlation between these and 
glycosylated haemoglobin (HbA1c) levels. It is thought that raised blood glucose leads to an 
increase in substrate flux through the sorbitol pathway, and this causes a hyperglycaemic 
pseudo-hypoxic state, which then induces VEGF production, in a mechanism shown in rat 
studies (Tilton et 01., 1997). With this mechanism, hyperglycaemia leads to an induction of 
VEGF expression. 
Since the effects of glucose on two splice variants of VEGF-A (VEGFa and VEGFb) in the 
placental vasculature are a main focus of this thesis, it is useful to provide a description of the 
general spicing mechanisms involved. This is provided next in section 1.2.1.6. 
1.2.1.6 General splicing mechanisms 
Splicing is the process which removes intronic sequences from pre-mRNA to form mRNA. 
Splicing occurs at splice sites on pre-mRNA; each intron to be removed has a 5' splice site at its 
upstream end, and a 3' splice site at its downstream end. It is here that the splicing machinery 
(spliceosome) binds and initiates splicing. The spliceosome is made up of a large 
ribonucleoprotein (RNP) complex (comprised of 5 small nuclear (sn) RNP), and catalyses both 
intron excision and the subsequent exon ligation. The splicing process is thus a two step 
process (Figure 1.8). 
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Figure 1.8: Two step splicing mechanism. After assembly of the spliceosome in the C complex, splicing 
occurs in two esterification steps. Both 'intron definition' (left), seen in splicing of short introns, and 
'exon definition' (right), seen in both alternative splicing and splicing of long introns, complexes are 
shown. 5'SS: 5' splicing site, BPS: branching point site, 3'SS: 3' splice site, SR: SR proteins, dotted arrows: 
poorly understood processes, orange sequence: exonic splicing enchancer (ESE). Adapted by permission 
from Macmillan Publishers ltd: [Nature Chemical Biology] (Schneider-Poetsch et al., 2010), copyright 
(2010). 
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The traditional view of the splicing process for introns less than :::::200-250bp begins with the 
binding ofthe U1 snRNP at the 5' splicing site (between exon 1 and the intron), and U2 auxiliary 
factor (U2AF) and splicing factors at the branching site. This causes the formation of the early 
(E) complex, where bridging of the intron allows the juxtaposition of the two exons to be joined. 
U2AF then recruits U2 in an ATP-dependent process, which base pairs with the branch point. 
The pre-spliceosomal branch point A complex is now formed. The spliceosome (complex B) 
forms with the binding of the U5/U4/U6 trimer to the site of cleavage, where US binds exon 1. 
RNA: RNA rearrangements, including U6 replacing U1 at the 5' splice site and U6 binding ta U2, 
leading to the disassociation of U1 and U4 from the spliceosome, then occur, to form the 
catalytic spliceosome (complex C), comprising U2, US, and U6. Complex C then catalyses the 
first cleavage step through transesterification, with the 5' of the intron binding to the branching 
site and forming the lariat. Exon 1 is now free from the lariat, and bound to US. The latter is 
also now bound to exon 2, aligning the two exons and hence facilitating subsequent ligation. 
The 3' splice site is then cleaved, the lariat separates from the exons, and exon 1 and 2 can then 
be ligated (Figure 1.8) (for a review on splicing and the spliceosome, see Will and Luhrmann 
(2010). 
For the splicing of pre-mRNA with large introns (more than :::::200-250bp), due to the relatively 
small size of the exon (:::::120bp) (Hawkins, 1988), and for alternative splicing, the exon to be 
included needs to be identified, and this occurs in a process called t exon definition' (Berget, 
1995). In this process, serine/arginine-rich (SR) proteins which have the correct 
phosphorylation status recruit U1 snRNA to the 5' splice site and U2AF and U2 snRNP to the 3' 
splice site (Bourgeois et 01., 1999; Feng et 01., 2008). The switch from an texon defined' 
complex requires the cross-exon interactions to be disrupted, before cross-intron interactions 
can be formed in 'intron definition' complex A or complex B (Smith and Valcarcel, 2000) (see 
Figure 1.8). The mechanisms behind the switch from 'exan definition' to 'intron definition' are 
currently poorly understood (shown in dotted arrows in Figure 1.8). 
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In order for RNA-binding proteins to localise to the right sequences to initiate splicing, the 
presence of exonic and intronic splicing enhancers (ESEs and ISEs, respectively) and silencers 
(ESS and ISS, respectively) is essential. These then recruit the SR proteins and heterogeneous 
RNPs necessary for alternative splicing to the site, which then further recruit the spliceosome. 
The binding of specific proteins to precise sequences on pre-mRNA found at splicing sites is the 
best understood process regulating alternative splicing, by increasing or decreasing binding of 
the spliceosome at a particular splice site (other less well understood processes regulating 
alternative splicing include elongation rates of the transcript and pre-mRNA secondary 
structure). Alternative splicing affects 30-50% of genes (Modrek and Lee, 2002; Roberts and 
Smith, 2002), greatly increasing the number of proteins arising from single genes, and therefore 
giving rise to greater diversity of proteins. 
As discussed above, the VEGF-A gene is one of the genes that can be alternatively spliced. The 
alternative splicing of the VEGF-A gene results in proteins with different functional 
characteristics: VEGF splice variants containing exons 6 and 7 are capable of heparin binding 
(the extent of which is determined by having both exons or only one), neuropilin binding 
requires both exons 7 and 8a (Appleton et 01., 2007; Soker et 01., 1998), and the presence of 
exon 8a or 8b results in VEGFa (for VEGFa naming convention, see section 4.1.2) or VEGFb, 
respectively (see Figure 1.6). The splicing factors required for the exon 8a/8b selection are 
discussed below. 
1.2.1.6.1 VEGF-A splicing 
VEGF-A mRNA is produced through activity at two promoters of the VEGF gene: the classical 
expression of increased VEGF mRNA following different stimuli is produced through a promoter 
without a TATA-box, whilst the constitutive low levels of VEGF found ubiquitously are produced 
by mRNA formed through a second internal promoter. 
32 
It is the alternative splicing of this 8-exon VEGF-A pre-mRNA that results in differing protein 
products which are differentially expressed (Figure 1.6); they have strikingly different properties 
which confer different roles to these important proteins. 
Splicing is a co-transcriptional process, which as stated above occurs when the sequences at the 
5' and 3' of the intron (the splicing sites) of the pre-mRNA are recognised by the splicing 
machinery. The spliceosome is formed by splicing proteins, and the whole process is regulated 
by splicing regulatory factors. The distal region of the VEGF pre-mRNA (close to the splice 
region for exon 8) is predicted to contain a number of ESEs (Screaton et al., 1995), to which 
different splicing factors can bind and thus favouring the production of either the pro-
angiogenic or the anti-angiogenic splice variant. 
To obtain the splicing product VEGFa requires alternative splicing factor/splicing factor 2 
(ASF/SF2) and SRp40 splicing factors. Bioinformatics show that these cluster adjacently to the 
proximal splice site (Nowak et 01., 2008). ASF/SF2 has been shown in several studies (Ge and 
Manley, 1990; Ge et 01., 1991; Krainer et al., 1990) to favour proximal site selection in 
alternative splicing, and this applies also to VEGF. In order for ASF/SF2 to localise exclusively to 
the nucleus and be released from its nuclear storage site, it needs to be phosphorylated by SR 
protein kinases 1 and 2 (SRPKl-2) (Kuroyanagi et al., 1998; Wang et al., 1998; Yun et al., 2003), 
as inhibition of these then inhibits proximal splicing to produce VEGFa in favour of distal splicing 
to produce VEGFb in human epithelial cells and mouse models (Nowak et 01., 2010). SRPKs are 
thus important for VEGF spliCing decisions. 
In contrast, to obtain the splicing product VEGFb requires the SRp5S splicing factor. 
Bioinformatics show that this splicing factor clusters to 35 nucleotides immediately 
downstream of the distal splice site stop codon (Nowak et al., 2008). Activation of MAPK p38 
seems to correlate to increased phosphorylation and activity of SRpSS, which then results in 
increased levels of VEGFb (Nowak et al., 2008), whilst SRp55 is silenced by small hairpin RNAs 
and is relocated or degraded as a result of phosphorylation by kinase elk/Sty (Lai et 01.,2003). 
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Treatment of human epithelial cells and podocytes with transforming growth factor (11 ( T G F r ~ - l ) )
was found to increase expression of VEGFb through the mechanism described above, whilst 
treatment with insulin-like growth factor-l (IGF-1) and tumour necrosis factor a (TNF-a) 
showed an overall increase in VEGF-A but a decrease in VEGFb through activation of PKC which 
in turn activates SRPKl and localises it to the nucleus, which ultimately results in the activation 
of ASF/SF2 and splicing in favour of VEGFa (Nowak 2008, 2010). 
Although no studies have as yet been performed investigating the effect of glucose on VEGF 
spliCing, a recent study shows the importance of the splicing factors in diabetic disease, as an 
SRp55 polymorphism significantly correlates with proliferative diabetic retinopathy (Carter et 
01., 2011), a diabetic complication characterised by pathogenic angiogenesis. This diabetic 
complication is also associated with a switch from VEGFa to VEGFb (Perrin et 01., 2005), 
indicating that the polymorphism decreases SRp55's affinity to the VEGF mRNA. 
1.2.1.7 VEGFb 
A novel splice variant of VEGF-A, VEGFb was discovered in 2002 in renal cortex (Bates et 01., 
2002). This splice variant was found to be identical to the various isoforms of VEGF (VEGF165, 
VEGF121 etc.) except for the last 6 amino acids at the C-terminus, with a sequence of Ser-Leu-
Thr-Arg-Lys-Asp in VEGFb instead of Cys-Asp-Lys-Pro-Arg-Arg in VEGFa (Bates et 01., 2002). 
These amino acid differences were predicted to confer a different configuration to the entire 
molecule, altering its effects; in particular, the two charged arginine residues are replaced with 
neutral lysine-aspartic acid residues and the proline residue is replaced by an arginine residue 
(Cebe Suarez et 01., 2006). 
After it was discovered, VEGFb was shown to be present in many tissues, both human and 
animal, including colon, islets, vitreous fluid, Circulating plasma, urine, prostate, smooth muscle, 
and, crucially, the placenta. In the first three tissues, it is thought to account for more than 50% 
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of total VEGF protein, whilst in the other tissues it is thought to represent a significant portion 
of total VEGF protein, except in the placenta, where it is reported to make up only a small 
proportion (Bates et 01., 2006; Bevan et 01., 2008; Konopatskaya et 01., 2006; Perrin et 01., 2005; 
Varey et 01., 2008). 
When it was discovered in the renal cortex, it was shown to be down regulated in tumour tissue 
compared to normal tissue. This led to the hypothesis that this splice variant of VEGFa is an 
anti-angiogenic molecule. VEGFb has subsequently been shown to be downregulated in a 
variety of tissues in pathologies where angiogenesis takes place, such as various cancers - colon 
(Varey et 01., 2008), prostate (Woolard et 01., 2004), and renal-cell carcinomas (Bates et 01., 
2002), and in malignant melanoma (Pritchard-Jones et 01., 2007) - as well as diabetic 
retinopathy (Perrin et 01., 2005), pre-eclampsia (Bates et 01., 2006), and Denys-Drash syndrome 
(Schumacher et 01., 2007). It is thought that the ratio of angiogenic/anti-angiogenic splice 
variants might be important in initiating the angiogenesis seen in these pathologies: in normal 
colon tissue and vitreous fluid, for example, VEGFb comprises about 90% and 65% respectively 
of total VEGF, however in colon carcinomas and diabetic retinopathy these percentages drop to 
between 5 and 50% for the former (Varey et 01., 2008) and 13% for the latter (Perrin et 01., 
2005). 
VEGFb exerts its effect by being a weak agonist of the VEGFR-2 receptor, but instead of 
phosphorylating the same Tyrosine residues as VEGFa (Tyr1054, 1075 and 1215), it phosphorylates 
Tyr951 and might phosphorylate other tyrosine residues (Kawamura et 01., 2008). In human 
microvascular endothelial cells, but not in HUVECs, VEGFb activates MAPK and protein kinase B 
(PKB) phosphorylation (Woolard et 01., 2004); however, this signalling is attenuated when 
compared to VEGFa signalling through this pathway (Cebe Suarez et 01., 2006). Activation of 
the MAPK pathway by TGF-13 has also been shown to upregulate expression of VEGFb, by 
downstream activation of ClK/sty kinases, which leads to the phosphorylation of SRp55 (see 
section 1.2.1.6.1), leading to the up-regulation of VEGFb expression (Nowak et 01., 2008). 
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VEGFb can instead be down regulated by IGF-1, TNFa (Nowak et 01.,2008), and by activation of 
PKC (Nowak et 01., 2010), which then phosphorylates alternative splicing factor/splicing factor 2 
(ASF/SF2) (Sanford et 0/., 2005), which can then translocate to the nucleus, leading to an 
increase in VEGFa (Amin et ai, unpublished). 
Studies in rodents have led to the theory that VEGFb is important in the reproductive system, 
where it is tightly regulated. Overexpression of VEGFb in various reproductive systems causes 
abnormalities: in the ovaries it causes defective follicle development, reduced litter size and 
inhibits the formation of the cumulus oocyte complex (Qiu et 01., 2009a; Qiu et 01., 2009b), 
whilst in the mammary, it inhibits alveolar development during lactation causing a reduction in 
milk production (Qiu et 01., 2008). Inhibition of the VEGFb splice variant replicates the effects 
seen with overexpression of VEGFa: in the ovary, it resulted in follicle progression (Artac et 01., 
2009) whilst in males, it stimulated testicular vascular development and caused a perturbation 
in testicular cord formation (Cupp et 0/., 2008). All these studies suggest that the balance 
between the two splice variants may be involved in fertility control. 
Another tissue where VEGFb is thought to be important is the kidney, where it is expressed in 
the human glomeruli (Bevan et 0/., 2008). Overexpression of the anti-angiogenic splice variant 
causes a gene-dose dependent decrease in murine glomerular permeability (Ferguson et 01., 
2007), and has been shown to ameliorate the increased permeability to proteins and water due 
to diabetic nephropathy in streptozotocin-induced diabetic mice (Ferguson et 01., 2009). 
Recombinant VEGFb has also been shown to decrease water permeability in wild type mouse 
glomerulus (Ferguson et 01., 2009) and to inhibit the increased permeability induced by VEGFa 
in human kidneys (Bevan et 01., 2008). Therefore, it seems as though VEGFb also acts as an 
anti-permeability molecule, at least in the kidneys. 
The paracellular cleft of the endothelium, which has a key role in the maintenance of vascular 
integrity by providing a physical barrier, is discussed in section 1.2.2. 
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1.2.2 The endothelial paracellular cleft and its role in endothelial permeability 
The endothelium is the lining of the vasculature, and provides a barrier to plasma proteins, 
which would otherwise move freely in and out of vessels. There is great heterogeneity and 
diversity in the degree of this barrier function between different tissues, which is dependent on 
the type of endothelial arrangement: in the renal glomeruli and intestinal mucosa, fenestrated 
endothelium is comprised of large pores through which proteins can pass, contributing to the 
exchange functions of these tissues, whilst in the blood brain barrier, a tight continuous 
endothelium prevents the passage of proteins and harmful pathogens to the delicate brain 
(Kumar et 01., 1987; Garlanda and Dejana, 1997; Simionescu et al., 2000). 
In the placenta, the vessel wall comprises of a single continuous layer of endothelium and the 
secreted basement membrane (Firth and Leach, 1996). One of the characteristics of this barrier 
is the paracellular cleft, where two endothelial cells come closest to each other (Figure 1.9). 
This 18nm space between the two cells is filled with a layer of glycoprotein, which creates a net 
of fibrous molecules, therefore limiting permeability by acting as a 'molecular sieve' (Luft, 1966; 
Curry and Michel, 1980). Two features of the paracellular cleft in the placenta are adherens 
and tight junctions, which further restrict permeability. 
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Figure 1.9: Stable (A) and open (B) endothelial junctions in the paracellular cleft. In A, the junction is 
stable, with VE-cadherin in its complex with p-catenin, plakoglobin, a -catenin and actin, and VE-cadherin 
homophilic binding with another VE-cadherin on an adjacent cell. In B, in response to VEGF binding to its 
receptor VEGFR-2 (for more detail, see section 1.2.1.2 on VEGF receptors), VE-cadherin has dissociated 
from both its intracellular complex with a-catenin and actin, allowing contraction of the cell by actin, and 
from its partner on the adjacent cell, allowing opening of the junction and paracellular permeability, and 
allowing VE-cadherin internalisation . Also of note is the tight junction in A, but its opening and 
disappearance from the paracellular cleft in B. Junctional adhesion molecule (JAM) is thought to have a 
role in monocyte infiltration in inflammation. Adapted and redrawn from Leach etal. (2009) . 
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1.2.2.1 Adherens junctions 
Adherens junctions represent the majority of junctional cell-cell contacts, and are present in the 
epithelium and the endothelium. They are formed by intercellular components (the 
extracellular domain of cadherin), and an intracellular anchor providing stability and aiding 
adherens junction formation, comprised of the cytoplasmic tail of cad herin, p-catenin, p120 
catenin (p120), u-catenin, and actin (Dejana et al., 1995) (see Figure 1.9A). The extracellular 
domain of VE-cadherin creates a homophilic interaction with the neighbouring cell's cadherin 
(yellow structures in Figure 1.9A), hence connecting the two cells (Lampugnani et 01., 1995; 
Hordijk et 01., 1999; Vandenbroucke et 01., 2008). This dimerisation is partly dependent on the 
binding of calcium to the extracellular domains, as in its absence the extracellular domains of 
VE-cadherin are disorganised and not capable of participating in adhesion, but this is not 
sufficient for complete cell dispersal in a hamster cell culture model (Takeichi, 1977). VE-
cadherin, the endothelial-specific cadherin version, will be dealt with in more detail in section 
1.2.2.1.1. 
The association between cadherins and p-catenin begins in the endoplasmic reticulum and is 
essential for the transport of this complex to the cell surface through the biosynthetic pathway 
(Chen et 01., 1999). After this step, u-catenin is recruited rapidly. Whether p-catenin is 
essential for the stability of the cadherin-u-catenin complex is a matter of controversy, as some 
researchers have found that a cadherin-u-catenin fusion protein is able to function normally in 
the absence of DE-cadherin (the VE-cadherin homologue in D. melanogaster) and Armadillo 
(the p-catenin homologue in D. melanogaster) in the common fruit fly oogenesis (Pacquelet and 
Rorth, 2005), whilst others have found that this fusion protein cannot totally compensate for 
the lack of p-catenin during the dorsal closure in the development of the fruit fly (Gorfinkiel and 
Arias, 2007). Some researchers, as well as work performed in our lab (Wright et 01., 2002), on 
mammalian tissue, have shown that p-catenin plays a role in the dissociation of the cad herin-
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catenin complex, resulting in cadherin endocytosis (Lilien and Balsamo, 2005; Delva and 
Kowalczyk, 2009) (yellow structure in blue oval, Figure 1.9B). 
The function of p120 is less controversial, and is thought to be a positive regulator for the 
function of cadherin. When p120 is bound to the juxta membrane domain of cadherins, it 
renders this domain unavailable for binding to the endocytic machinery and covers sites for 
cadherin ubiquination, thus inhibiting endocytosis (Davis et 01., 2003b; Ishiyama et 01., 2010). 
However, p120 has been shown to be not essential for the development of D. melanogaster, 
and a DE-cadherin mutant that cannot bind p120 can fully compensate for the lack of 
endogenous DE-cadherin (Pacquelet et al., 2003). The fact that both p120 and p-catenin are 
redundant for the function of the oogenesis in the fruit fly suggests that, at least in this 
particular tissue in this organism, the morphogenesis actions of cadherins can be accomplished 
with cadherin-a-catenin alone. 
The presence of a-catenin is necessary for the formation of adherens junctions, as reviewed by 
Kobielak (Kobielak and Fuchs, 2004). a-catenin acts between the cadherin-p-catenin complex 
and the actin cytoskeleton. Until recently, it was thought that the ability of a-catenin to bind 
both p-catenin and actin indicated that a-catenin existed in a complex with both of these 
molecules to keep the cadherin in place in the junctional space. However, recent evidence 
suggests that such a-catenin cannot bind p-catenin and actin simultaneously: a-catenin binds 
p-catenin in a monomeric configuration and actin in a dimer configuration, and furthermore, 
the binding site for p-catenin overlaps the dimerization domain, so whilst bound to p-catenin, 
a-catenin cannot form dimers (Pokutta and Weis, 2000). This evidence is supported by the fact 
that cadherin, p-catenin, a-catenin and actin have not been found in a complex together 
through a variety of approaches (Yamada et 01., 2005). A new model has emerged: binding to 
p-catenin, a-catenin's concentration near the junctional space increases, and on detachment 
from the former, a-catenin dimerises and competes with actin-related protein 2/3 complex 
(ARP2/3, a nucleator of branched actin) for binding to actin. This process would help to convert 
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actin networks from those found in lamellipodia to those seen associated with adherens 
junctions (Yamada et 01., 2005). How adherens junctions couple with actin and how these are 
able to withstand strong pulling forces is, however, not explained by this model, and remains to 
be investigated. 
Interestingly, a-catenin, as well as binding to actin, p-catenin and plakoglobin (another 
molecule that binds to cadherins), binds to zonula occludens-1 (ZO-l), a key molecule for tight 
junctional formation and stability (Kobielak and Fuchs, 2004). Hence, it is thought that 
adherens junctions and tight junctions are somehow related, although the mechanisms behind 
this association are not well understood (and hence not shown in Figure 1.9A). This 
relationship could be essential for the coordinated opening of adherens and tight junctions (as 
if adherens junctions are open and tight junctions are not, permeability would not necessarily 
be increased, as another barrier would still be in place). 
Studies on Madin Darby canine kidney cells have illustrated how adherens junctions are formed. 
First, lamellipodia (mediated by several molecules including ARP2/3) from adjacent cells probe 
a neighbouring cell. Cadherin-catenin complexes cluster at the site of cell-cell contact, a-
catenin concentrations rise, and eventually the adherens junction matures (anchored by actin) 
as a-catenin replaces ARP2/3 in the actin strands, and the junction expands. Cadherin-catenin 
complexes aggregate and connect with actin, and subsequently actin promotes adherens 
junctional growth through its remodelling (McNeill et 01., 1993; Adams et 01., 1996; Vasioukhin 
and Fuchs, 2001). 
Adherens junctional disassembly (Figure 1.9B) occurs when, for example, vessels undergo 
remodelling or wound healing. Cadherins are normally removed from the cell membrane by 
endocytosis, although some other mechanisms occasionally occur. The site where p120 binds is 
also the clathrin binding site (Ishiyama et 01., 2010). When cadherins are tyrosine 
phosphorylated at their intracellular domain, p-arrestin, a clathrin adaptor, is able to interact to 
41 
them, and hakai (an E3 ubiquitin ligase) is able to ubiquitylate the cadherin at the site of p120 
binding, promoting endocytosis (Gavard and Gutkind, 2006). Indeed, cadherin turnover and 
endocytosis is increased in the absence of p120 (Ishiyama et al., 2010). The mechanism of how 
the cadherin-catenin complex disassociates from the actin cytoskeleton is not known. The 
internalisation of VE-cadherin in the endothelium has of course the effect of increasing vascular 
permeability, as explained below. 
1.2.2.1.1 VE-cadherin 
VE-cadherin, also known as C0144 or cadherin-5, is the endothelial-specific cadherin, and, as 
other cadherins, it has three LORE domains, three OXNONXP sequences for the maintenance of 
cadherin conformation, and four cysteine residues near the transmembrane region (Figure 
1.10). VE-cadherin has 5 extracellular domains which, when bound to calcium ions, contribute 
to the binding between VE-cadherin molecules from adjacent cells, in a Zipper-like fashion 
(Figure 1.10). ci+ gives rigidity to these extracellular domains, which are otherwise 
disorganised and cannot bind to each other or provide adhesion (Lampugnani et al., 1995; 
Hordijk et al., 1999; Vandenbroucke et al., 2008). 
The junctional complex of VE-cadherin, f3-catenin, plakoglobin and p120 is important for the 
strength of the junction, more so than its formation: a VE-cadherin mutant which lacks the 
domain responsible for p-catenin and plakoglobin binding still forms functional zipper-like 
structures, but the resulting junctions showed decreased strength (Navarro et al., 1995). Other 
studies have shown that blocking VE-cadherin homophilic association with antibodies in the 
adult mouse led to vast increases in permeability, haemorrhages and overall vascular fragility 
(Corada et al., 1999). 
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Figure 1.10: VE-cadherin structure showing important components and domains. A VE-cadherin dimer on 
one cell is shown binding to another VE-cadherin dimer on an adjacent cell through extracellular domains 
1-2, whilst structural rigidity is being allowed by calcium binding to the extracellular domains. For 
simplicity, VE-cadherin binding to its intracellular complex with p-catenin, plakoglobin and p120 is not 
shown here. EC: extracellular domain, blue circles: Ca 2' ions, bold black lines: cell membrane. Adapted 
with permission, Journal of Cell Science, Dejana et 0/. (2008) . 
It has been shown that several agents which increase permeability (including tumour necrosis 
factor, histamine, and, importantly, VEGF) mediate tyrosine or serine phosphorylation of VE-
cadherin's intracellular C-tail, and subsequently f3 -catenin, plakoglobin and p120 disassociate 
from the VE-cadherin complex (Andriopoulou et 01., 1999; Esser et 01., 1998), thereby increasing 
permeability. f3-catenin, plakoglobin and p120 can also be phosphorylated by some of the same 
agents (notably VEGF) that phosphorylate VE-cadherin, and it is known that f3-catenin tyrosine 
phosphorylation can reduce f3 -catenin/VE-cadherin affinity and increase cadherin turnover at 
the adherens junctions (Lampugnani et 01., 1997; Esser et 01., 1998), again increasing 
permeability (see Figure 1.9B). 
Interestingly, VE-cadherin can interact with VEGF's receptor VEGFR-2 (see section 1.2.1.2). 
Activation of both the PLCy and MAPK are reduced in VE-cadherin-VEGFR-2 associations 
(Miaczynska et 01., 2004). VE-cadherin also inhibits the internalisation of the receptor via 
density-enhanced phosphatase-1 (DEP-1) and this contact-inhibition has the overall effect of 
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inhibiting proliferation (Lampugnani et 01., 2006; Lampugnani et 01., 2003). VE-cadherin 
mutants that cannot bind to ~ - c a t e n i n n (but can bind to p120) cannot bind to VEGFR-2, 
indicating that the former is important in this interaction (Lampugnani et 01., 2003). The 
VEGFR-2/VE-cadherin interaction might also assist the tyrosine-protein kinase Src-mediated 
phosphorylation of the adherens junction constituents, impairing barrier function (Weis and 
Nelson, 2006). Interestingly, Src is not required in angiogenesis (Eliceiri et 01., 1999), which 
allows a differentiation between VEGF's effects on endothelial proliferation and increased 
endothelial permeability. 
1.2.2.1.2 Vascular adherens junctions and VE-cadherin in the control of vascular permeability 
In the endothelium, permeability is mediated by transcellular and paracellular transport. The 
transcellular pathway is outside the scope of this thesis, as it occurs sparsely, if at all, in 
placental tissue, and shall not be discussed further. 
Permeability involving paracellular junctions was first shown by Majno and Palade (1961) and 
with tracer studies by Williams and Wissig (1975) and involves adherens and tight junctions 
opening to allow passage. The openings of these junctions are tightly regulated, as to avoid 
exposing the subendothelial matrix (a highly thrombogenic layer) to blood, and to retain 
vascular integrity, but to allow passage of small hydrophilic solutes and to open up to allow cell 
trafficking to occur (Bazzoni and Dejana, 2004; Aird, 2007). When there is permanent vascular 
damage, requiring wound healing, endothelial cells retract, with accompanying haemorrhages, 
leucocyte adhesion, and small thrombi formation. In contrast, molecules able to increase 
permeability reversibly, such as VEGF and histamine, do not affect functional responses or 
endothelial cell viability, instead mediating the accumulation of fibrin and fibrinogen outside 
vessels, leucocyte transfer to inflamed tissue, or simply an increase in oxygen and nutrient 
access to the surrounding tissues (Dejana et 01., 2009). 
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1.2.2.2 Tight junctions 
Tight junctions represent about 20% of cell-cell junctional complexes. As the spacing between 
cells at tight junctions, also called zonula occludens, is only 4nm, it is the most selective barrier 
of intercellular transport (Mehta and Malik, 2006). 
Tight junctions are comprised of strands of claudin and occludin which are integral to the 
plasma membrane that run alongside the tight junction and that form the basis for the 
adhesion to the neighbouring cell (Furuse et 01., 1993; Furuse et 01., 1998a), and intracellular 
plaque proteins which anchor the tight junction to the cytoskeleton (Figure 1.9A). 
The claud in family of membrane proteins are the key molecules in tight junctions. Their 
structure of claud ins consists of two extracellular loops, the first loop being a selectivity filter 
for claudin pores and the second loop being involved in cell-cell adhesion, four transmembrane 
domains and cytoplasmic NH 2- and C-termini. Most claudins have a conserved sequence of 
GLWxxC in their first extracellular domain, which might assist in the homotypical binding of 
claud ins on the adjacent cell, and a PDZ domain-binding motif at the C-terminus of the 
molecule, to associate with zonula occludens proteins 1-3 (Z01-3) (Itoh et 01., 1999) (Figure 
1.11). They interact with other claudin molecules in the adjacent cell to cause adhesion, and 
interact with other claudin molecules in the plasma membrane to create tight junctional 
strands (Tsukita et 01., 2001; Furuse et 01., 1999). The interaction between the two claudins' 
first extracellular loop creates a pore which is selective for charge and size: solutes under 4A in 
size and with a charge opposite that of the loop can diffuse through the pore without the tight 
junction opening, whilst bigger solutes cannot. 
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Figure 1.11: Claudin structure showing important components and domains. A claudin molecule is shown, 
annotated with conserved sequences (black circles) and important domains. In particular, the lOl-3 
binding site, the PDl domain, is shown, and the conserved GLWxxC domain, which is thought to aid 
homotypic binding on the adjacent cell. Black circles: conserved residues, blue circles:non-conserved 
residues. Taken and adapted (permission not required) from Van Itallie et 01. (2004) . 
Occludin has been shown by overexpression studies to playa role in tight junction formation 
and adhesion, although to a lesser extent than claud in: without the latter, cell-cell contacts 
form, but they are only observed as dots in immunofluorescence micrographs, short occluding 
strands are formed, and weak cell-cell adhesion occurs (Furuse et 01., 1998b; van Itallie and 
Anderson, 1997). However, occludin knockout mice and murine embryonic stem cell mutants 
negative for occludin could still form morphologically and physiologically normal tight junctions, 
and the knockout mice are viable (Saitou et 01., 1998; Saitou et 01.,2000). 
ZOl-3 are cytoplasmic plaque proteins which contain three POl domains, the first of which can 
directly bind to the cytosolic C-terminal domain of claudins (Itoh et 01.,1999) (Figure 1.11); ZO-l 
can also bind to occludin (Fanning et 01., 1998). ZOl-3 can bind to the actin cytoskeleton of the 
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cell, therefore anchoring the tight junction, and can also recruit other structural and signalling 
proteins to facilitate this process (Wittchen et 01., 1999). 
1.2.2.3 Other junctional molecules 
There are other integral membrane proteins found at the paracellular cleft but that are not 
located at the junctional space. Here, we will discuss PECAM-l. 
1.2.2.3.1 PECAM-1 
Platelet-endothelial cell adhesion molecule-1 (PECAM-l, or CD31) is an integral membrane 
protein which functions as an adhesion molecule for inflammatory agents to aid 
transendothelial migration in inflammation (Albelda et 01., 1991). PECAM-1 contains six 
immunoglobulin-like domains in its extracellular domain, and it is through homophilic binding 
of these with the corresponding CD31 on the leucocyte that PECAM-l mediates leucocyte 
extravasation through the paracellular cleft of the endothelium (Sun et 01., 1996). In its 
intracellular domain, PECAM-1 can also associate with p-catenin, through which it may 
influence the barrier integrity of the endothelium (llan et 01., 2000). 
Vascular integrity dysfunction is one of the characteristics of diabetes. In the next section, we 
will introduce and discuss this disease, which also affects the vasculature of the placenta, an 
aspect which is of course of particular interest to this thesis. 
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1.3 Diabetes mellitus 
1.3.1 History of diabetes 
The term 'diabetes mellitus' means 'to pass through sweet urine' in Greek. The term 'diabetes' 
was introduced into the medical field by Aretaeus of Cappadocia, the first person to extensively 
describe diabetes mellitus (hereafter referred to simply as diabetes). He wrote in his book 
Therapeutics of chronic diseases (taken from Henschen (1969)): 
'Diabetes is a wonderful affliction, not very frequent among men, being a melting down of the 
flesh and limbs into urine .... The course is the common one, namely, the kidneys and bladder; 
for the patients never stop making water, but the flow is incessant, as if from the opening of 
aqueducts. The nature of the disease, then, is chronic, and it takes a long period to form; but 
the patient is short-lived, if the constitution of the disease be completely established; for the 
melting is rapid, the death speedy. Moreover, life is disgusting and painful; thirst, 
unquenchable; excessive drinking, which, however, is disproportionate to the large quantity of 
urine, for more urine is passed; and one cannot stop them either from drinking or making 
water. Or if for a time they abstain from drinking, their mouth becomes parched and their 
body dry; the viscera seem as if scorched up; they are affected with nausea, restlessness, and a 
burning thirst; and at no distant term they expire. Thirst, as if scorched up with fire ... But if it 
increase still more, the heat is small indeed, but pungent, and seated in the intestines; the 
abdomen shrivelled, veins protuberant, general emaciation, when the quantity of urine and 
the thirst have already increased; and when, at the same time, the sensation appears at the 
extremity of the member, the patients immediately make water. Hence, the disease appears 
to me to have got the name of diabetes, as if from the Greek word 6laBr'rrnc; (which signifies a 
siphon), because the fluid does not remain in the body, but uses the man's body as a ladder 
(6laBa8pn), whereby to leave it. They stand out for a certain time, though not very long, for 
they pass urine with pain, and the emaciation is dreadful; nor does any great portion of the 
drink get into the system, and many parts of the flesh pass out along with the urine.' 
The first instance of what Aretaeus called the 'wonderful affliction' was found in the Egyptian 
Ebers papyrus, dating from about lSS0BC, which described various diseases including a disease 
characterised by polyuria which resembled diabetes mellitus. The Indian phYSicians Susruta and 
Charuka in the 5th_6th century made the link between polyuria and sugary urine, and 
differentiated between diabetes which affects the old and fat, and diabetes which affects the 
thin and young whose survival wasn't for long, giving the first account of what we now call Type 
2 and Type 1 diabetes, respectively. The next significant advancement was the recognition of 
gangrene and impotence as two complications of diabetes by the Arabic Avicenna in the 10th 
century. Other observations of the disease were made in the 1ih_19th centuries, such as the 
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identification of the pancreas as vital for the disease, but the real breakthrough for treatment 
was made in 1921 with the discovery of insulin, which has been used ever since to treat 
diabetes. 
Even though it has been known since antiquity, diabetes today still presents patient and 
physician with difficulties, providing only a treatment but not a cure. This highlights the 
challenging nature of tackling the diabetic milieu. 
1.3.2 Types of diabetes 
As all the diabetic work in this thesis has been performed on tissue from Type 1 diabetic 
patients, greater emphasis will be placed on this Type of diabetes. 
1.3.2.1 Type 1 diabetes 
Type 1 diabetes currently affects around 15% of diabetic patients in the UK (around 623,500 
people) (Diabetes UK, 2010), and its incidence is increasing (EURODIAB ACE Study Group, 2000). 
Type 1 diabetes is sub-classified into two subgroups: in Type lA there is the immune mediated 
destruction of the f3-cells in the pancreas, whilst in type IB there is a non-immune mediated 
severe insulin deficiency (Expert Committee on the Diagnosis and Classification of Diabetes 
Mellitus, 1997). 
Type lA (hereafter referred to as simply Type 1) diabetes is characterised by the destruction of 
the pancreatic f3 cells by autoimmune mechanisms (Expert Committee on the Diagnosis and 
Classification of Diabetes Mellitus, 1997). This destruction subsequently leads to the 
insufficient production of insulin which is characteristic of this type of diabetes mellitus. 
Therefore, the symptoms of diabetes are dependent on the lack of insulin present, which 
explains its previous name of insulin dependent diabetes mellitus (IDDM). 
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The symptoms of the disease are often preceded by an autoimmune response, whereby 
autoantibodies against Type 1 diabetes-specific antigens (the three major antigens being insulin, 
glutamic acid decarboxylase, and insulin autoantigen 2) are present. The detection of two or 
more of these autoantibodies has a predictive value of over 90% for the development of Type 1 
diabetes within the next 7 years (Verge et 01., 1996). These antigens act as markers for the T-
lymphocytes, dendritic cells and macrophages which subsequently infiltrate the islets of 
Langerhans (Imagawa et 01., 1999). The ~ ~ cells (which produce insulin) are uniquely targeted in 
this destructive infiltration, which does not affect a cells (producing glucagon) or () cells 
(producing somatostatin) (Miao et 01., 2007). 
Overt Type 1 diabetes progression from insulinitis is controlled by an alteration in the T helper 
cells Th1 to Th2 balance, with the subsequent attack and destruction of ~ - c e l l s s (Csorba et 0/., 
2010). By the time symptoms appear, most of the ~ - c e l l s s responsible for the production of 
insulin have been destroyed, leaving the body unable to produce insulin. 
Both genetic and environmental factors contribute to the development of Type 1 diabetes. The 
genetic component involves several genes, the most important of which is the human leucocyte 
antigen (HLA) class II gene on chromosome 6p21 (Singal and Blajchman, 1973; Cudworth and 
Woodrow, 1974; Nerup et 0/., 1974) and the insulin gene on chromosome llp15 (Bennett and 
Todd, 1996; Bell et 0/., 1984). HLA class II molecules are present on antigen-presenting cells 
such as dendritic cells, B lymphocytes, macrophages, and the thymus epithelium, and are 
responsible for presenting antigens to T cells. The defect around the insulin gene which 
predisposes to diabetes is in a variable number of tandem repeats (VNTR) found 596 base pairs 
upstream of the insulin gene. A short version of this VNTR predisposes to Type 1 diabetes in 
Caucasians, whilst longer versions offer protection from the disease (Bell et 0/., 1984). It is 
thought that these polymorphisms act by regulating the transcription of the insulin gene in cis. 
The longer polymorphism is associated with a 20% lower insulin mRNA in the pancreas but a 
two- to three-fold increase in the thymus. It is thought that the higher thymic levels seen with 
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the protective variant facilitate the induction of immune tolerance (Vafiadis et 01., 1997; 
Pugliese et 01., 1997). Therefore, it is not surprising that Type 1 diabetes is associated most 
commonly with thyroid disease, along with other autoimmune conditions (Devendra and 
Eisenbarth, 2003). 
There are two theories to explain the environmental factor of Type 1 diabetes, both arising to 
try to explain the rise in the incidence of the disease. The first theory hypothesises that there 
could be certain viruses or environmental triggers for the disease. Possible viruses implicated 
are congenital rubella syndrome (Ginsberg-Fellner et 01., 1984) and enteroviruses (reviewed by 
Tracy et 01. (2010)). The second theory is the so called 'hygiene hypothesis', which states that 
our environment for infants and children is too clean, which inhibits the proper development of 
the immune system, leading to a predisposition to immune diseases such as diabetes and 
asthma (Bach, 2002; Wen et 01., 2008). 
1.3.2.2 Type 2 diabetes 
Type 2 diabetes was previously called non-insulin dependent diabetes, as it is a type which is 
characterised by insulin resistance, not total insulin deficiency (Expert Committee on the 
Diagnosis and Classification of Diabetes Mellitus, 1997). It affects around 85% of diabetic 
patients (Diabetes UK, 2010). This insulin resistance therefore leads to a relative insulin 
deficiency. Whilst ~ - c e l l s s in the pancreas are functional and insulin production seems normal or 
even elevated, insulin resistance and higher blood glucose levels result in the demand for 
insulin being greater than the supply. There is usually no autoimmune cause to this type. Most 
Type 2 patients are obese, which is a risk factor for it, as obesity itself is known to cause a 
limited insulin resistance (Turner et 01., 1979; Olefsky et 01., 1982; Reaven et 01., 1976). 
In individuals with Type 2 diabetes, the development of hyperglycaemia is gradual, and the 
patient may at first not notice the classic symptoms of diabetes (Zimmet, 1992). Therefore, it 
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may be several years before the disease is diagnosed and treated, and as such they are at 
greater risk of developing macro- and microvascular complications. 
Unlike Type 1 diabetes, Type 2 diabetes can potentially be completely ameliorated with lifestyle 
changes, as insulin resistance may improve with weight loss and exercise (Zanuso et 01., 2010). 
If this fails, treatment includes pharmacological intervention, most often with metformin, to 
control hyperglycaemia (Ripsin et 01., 2009). However, seldom does insulin resistance disappear 
completely. 
Type 2 diabetes has a strong genetic association (Barnett et 01., 1981); it is therefore not 
surprising that it is more common in certain populations. However, unlike Type 1, the genetic 
association is very complex. 
1.3.2.2.1 Developmental origins of Type 2 Diabetes 
Both macrosomia and growth restriction have been associated with a predisposition to 
developing Type 2 diabetes. Both of these might have a genetic basis, but the fetus' 
environment is also crucial. 
The evidence for macrosomia, an example of fuel-mediated teratogenesis predisposing the 
fetus to future type 2 diabetes, was initially shown in diabetic Pima Indians (McCance et 01., 
1994), but later studies have subsequently found it in other populations as well (Dyck et 01., 
2001; Wei et 01., 2003). It is thought that the main cause of this predisposition to Type 2 
diabetes is the fetal exposure to hyperglycaemia and hyperinsulinaemia in utero. 
That growth restriction, an example of nutrient-mediated teratogenesis, predisposes to Type 2 
diabetes is explained by the 'thrifty phenotype hypothesis' (Hales and Barker, 1992), also 
known as Barker's hypothesis, after the author of the theory. In this hypothesis, the fetus 
makes adaptations in utero and in early post-natal life for its survival, based on the nutrient 
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deficient environment during gestation. If, in later life, this environment becomes more 
plentiful, the individual is prone to becoming obese and experience relative insulin deficiency. 
1.3.2.3 Gestational diabetes 
Gestational diabetes (GDM) is the development of diabetes during pregnancy. Gestational 
diabetes affects up to 5% of all pregnancies (Diabetes UK, 2010), but the frequency varies 
depending on which populations are studied. GDM represents around 80-90% of diabetic 
pregnancies (Osborn, 2005). 
Gestational diabetes develops in the second and third trimester of pregnancy (Diabetes UK, 
2010), and as such it does not affect the early development of the placenta, as do Type 1 and 
Type 2 diabetes mellitus. Insulin resistance due to pregnancy hormones tends to develop in 
pregnancy, possibly arising downstream of the insulin receptor; however, the l3-cells in women 
who develop GDM are unable to increase insulin production sufficiently to keep glycaemic 
levels under control (Catalano et 01., 1993). GDM usually resolves within 6 weeks post-partum; 
however, women who develop GDM have a predisposition to developing Type 2 diabetes later 
on in life (Girling and Dornhorst, 2003). 
Newborns to GDM mothers are often macrosomic and are prone to experience hypoglycaemia 
immediately after birth, as they have been exposed to high glucose levels in utero, and may 
therefore be producing too much insulin after birth without the corresponding high glucose 
from the mother (Barnes-Powell, 2007). 
1.3.3 The diabetic milieu 
Diabetes is essentially a disease of relative insulin deficiency, whether by insulin deficiency 
(Type 1) or insulin resistance (Type 2). 
53 
Insulin is found in the bloodstream at a constitutive level which regulates basal metabolism 
when blood glucose levels do not exceed 4mM; a higher level of insulin is released at glucose 
concentrations of >4mM (Henquin et 01., 2006) in a mechanism illustrated in Figure 1.12. 
>4mM glucose 
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Cell 
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Figure 1.12: Insulin secretion mechanism. When extracellular glucose concentrations exceed 4mM, 
GLUT2 glucose transporters on ~ - c e l l s s in the islets of Langerhans transport glucose inside the cells, which 
then undergoes glycolysis. This increases the ATP:ADP ratio, closing ATP-sensitive potassium channels 
(KATP channel), causing the ions to accumulate intracellularly. This causes cell depolarisation, which begins 
at -40mV and peaks at 10mV, thereby opening L-Type Ca2+ channels. Ca l> then accumulates inside the cell 
which mediates the release of insulin (green Circles) from insulin granules to the bloodstream. The cell 
depolarisation then causes the activation of voltage dependent K+ channels (Kv channels), which then 
inhibit further insulin release until the next depolarisation event. The effect of these 
depolarisation/repolarisation events lead to pulsatile insulin secretion. Blue arrows: pathways leading to 
insulin release, grey arrows: pathways leading to insulin release inhibition, arrow with + sign: activation of 
channel, arrows with red - sign: inhibition of channel. Figure is based on the reviews by Dunne (2000) and 
MacDonald and Wheeler (2003). 
After its release into the circulation, insulin acts through the insulin receptor in the liver, 
skeletal muscle and adipose tissue. The insulin receptor autophosphorylates when bound to 
insulin, and subsequently phosphorylates insulin receptor substrates (IRSs). IRS-l and IRS-2 
then activate PI3K, MAPK, and CAP/cbl. PI3K then activates the PKC pathway, mammalian 
target of rapamycin (mTOR) and PKB. The MAPK pathway and mTOR signalling lead to 
increased protein synthesis, while increased cell survival, proliferation and differentiation are 
mediated by both the MAPK pathway and PKB. Increased glucose uptake through GLUT4 
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translocation to the cell membrane is mediated by CAP/cbl, PKC and PKB signalling. The 
metabolic effects of insulin are instead mediated by the PKB and PKC pathways (as reviewed by 
Leclercq et al. (2007)). A list of the metabolic effects of insulin in peripheral tissues is shown in 
Table 1.1. 
Insulin effects 
Liver Skeletal muscle Adipose tissue 
Insulin increases 
Glycogenesis Glucose transport Glucose transport 
Fatty acid synthesis Glycolysis Glycolysis 
Lipogenesis Glycogenesis Glycogenesis 
Low-density lipoprotein Fatty acid uptake Fatty acid synthesis 
synthesis 
Cholesterol synthesis Amino acid transport Lipoprotein lipase 
Amino acid transport Protein synthesis Amino acid transport 
Protein synthesis Protein synthesis 
Insulin decreases 
Glycogenolysis Glycogenolysis Lypolysis 
Gluconeogenesis Protein degradation Protein degradation 
Protein degradation 
Table 1.1: The main effects of insulin on peripheral tissues. Data based on information found in book by 
Watkins (2003). 
At basal insulin levels, the insulin receptor signals to inhibit the actions of the opposing 
hormone glucagon, thus inhibiting lipolysis and gluconeogenesis and upregulating protein 
uptake. When glucose is present at high levels, the insulin receptor and IRS-2 activate the 
translocation of the GLUT4 glucose transporter to the cell membrane, thus upregulating glucose 
transport into the cell, as first hypothesized in 1980 (Cushman and Wardzala, 1980; Suzuki and 
Kono, 1980). 
When considering the diabetic milieu, there are four important factors to consider: 
hyperglycaemia, which results from the defective glucose uptake, hyperinsulinaemia, as a result 
of fetal hyperglycaemia (in the fetus of a diabetic pregnancy) or due to insulin resistance (in the 
case of Type 2 diabetes), hypoglycaemia, as a result of hyperinsulinaemia in the Type 1 diabetic 
patient, and insulin resistance, the presenting feature in Type 2 diabetic patients. 
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As this thesis is mostly concerned with hyperglycaemia, this will be the focus in this section, 
although the mechanisms for and consequences of hyperinsulinaemia, hypoglycaemia and 
insulin resistance will also be discussed. 
1.3.3.1 Hyperglycaemia: effects of high glucose on the vasculature 
The diabetic condition is comprised of many characteristics, and one of the most widely known 
is hyperglycaemia, which can have both chronic and acute effects. This rise in blood glucose 
has several effects on the surrounding vasculature through various inter-connected 
mechanisms. Through these, hyperglycaemia acts as a pro-constrictor (Singh et 01., 2008; 
Fujimoto et 01., 2006; Boden et 01., 2007), pro-coagulatory (Kwaan, 1992; Boden et 01., 2007; 
Karia et 01., 1995), pro-inflammatory (Yang et 01., 2009; Sweet et 01., 2009), pro-angiogenic 
(Ettelaie et 01., 2008; Ejaz et 01., 2008; liu et 01., 2007) and pro-permeability (Chiarelli et 01., 
2000a; Sung et 01., 2006) agent. The pathways affected by hyperglycaemia are described here 
(Figure 1.13). 
One of the classical mechanisms affected by high glucose is the PKC pathway. High glucose has 
been shown to cause de novo synthesis of diacylglycerol (DAG) in various tissues in the rat 
(Craven et 01., 1990; Derubertis and Craven, 1994; Shiba et 01., 1993; Inoguchi et 01., 1992), 
which in turn caused an increase in the production of PKC (Vasko et 01., 2009). This leads to an 
increase in the release of several growth factors, amongst which VEGF (Xia et 01., 2007; Kelly et 
01., 2007). The PKC pathway has been the subject of various inhibition studies, and it has been 
shown that the diabetic changes to VEGF levels (Kelly et 01., 2007; Xia et 01., 2007) could be 
reversed by inhibiting this pathway. 
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Figure 1.13: The five pathways altered as a consequence of high glucose. Abbreviations used: NADP(H): 
Nicotinamide adenine dinucleotide phosphate, NAD(H): Nicotinamide adenine dinucleotide, GFAT: 
glutamine:fructose-6-phosphate amidotransferase, Gln:glutamine, Glu: glutamate, UDP-GlcNAc: UDP-N-
acetylglucosamine, DHAP: dihydroxyacetone phosphate, DAG: diacylglycerol, GAPDH: glyceraldehydes-3· 
phosphate dehydrogenase. Adapted by permission from Macmillan Publishers Ltd: [Nature] (Brownlee, 
2001), copyright (2001). 
Interestingly, the production of a key vasodilator, NO, is decreased in hyperglycaemic rats 
(Bohlen and Nase, 2001) and diabetic humans (Shiekh et 01., 2011). NO is normally produced by 
nitric oxide synthases (NOS), of which there are three members: eNOS and neuronal NOS 
(nNOS), which provide constitutive production of NO, and inducible NOS (iNOS), which when 
induced produces large quantities of NO. NOSs catalyse the oxidation of L-arginine to L-
citrulline and NO. However, this reaction requires NADPH, and this molecule is decreased by 
the increased levels of NAD(P)H oxidase that are seen in hyperglycaemia and diabetes (see 
figure 1.14) (Guzik et 01., 2002) (Figure 1.14). Inhibitors of the PKC pathway can ameliorate this 
decrease in NO. 
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Figure 1.14: NO synthesis and effects of hyperglycaemia. NO (in rectangle) is produced along with 
citrulline from arginine, with the oxidation of co-enzyme NADPH to NADP+ being a concurrent required 
step. Under hyperglycaemic conditions (in blue) the following are increased: the polyol pathway (leading 
to a decrease in the NADPH: NADP+) (Bravi et 0/., 1997), the PKC pathway (leading to phosphorylation and 
inactivation of eNOS) (Matsubara et 0/., 2003), and advanced glycation end-products {leading to increased 
glycated low-density lipoproteins (LDls), which results in decreased L-arginine cell uptake) (Posch et 0/., 
1999). All these changes lead to decreased NO production in response to hyperglycaemia. 
The polyol pathway is also increased under conditions of hyperglycaemia (Figures 1.13 and 
1.14). Too much glucose overwhelms the glycolytic pathway, and this causes an 
overproduction of fructose and sorbitol by aldose reductase and sorbitol dehydrogenase, 
respectively (Gabbay, 1973). The increase in these two sugars creates a pseudohypoxic 
environment, where there is an increase in the NADH/NAD+ ratio (Ido et 01., 2004; Ido and 
Williamson, 1997). In this state, the endothelium increases its production of prostaglandins 
which act as vasoconstrictors, and decreases the production and availability of NO (Pugliese et 
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01., 1991). NO is an inhibitor of VEGF production, so this leads to more VEGF being produced. 
Therefore, the outcome of high glucose on the polyol pathway reinforces the effects due to the 
increased PKC production described above. An alteration in the NADH/NAD+ ratio also directly 
stimulates the PKC pathway -- a double-edged sword for the production of VEGF. 
Hyperglycaemia also causes an increased flux through the hexosamine pathways (Figure 1.13). 
Through this pathway, hyperglycaemia increases the transcription of TGF-/31 (Kolm-Litty et 01., 
1998). Another consequence of increased flux to this pathway is endothelial eNOS inhibition 
(Musicki et 01., 2005), which together with the decreased NO availability (Pugliese et 01., 1991) 
discussed above, contributes to the dysfunction in this important pathway in diabetes. 
NO and the PKC pathway also playa part in another glucose-induced pathological cellular 
response, oxidative stress (Figure 1.13). Glucose autooxidates to form free radicals hydroxilic 
anions (Dominguez et 01., 1998; Thornalley et 01., 1984), and together with a decrease in the 
endogenous antioxidant activities of the cell that is caused by other characteristics of diabetes, 
this autooxidation overwhelms the antioxidant cellular responses. This leads to the 
endothelium being more sensitive to free radicals, which react with NO to form peroxynitrates, 
one of the most damaging free radicals (Vareniuk et 01., 2008; Nishikawa et 01., 2000). The 
sensitivity to free radicals also directly switches on the PKC pathways (Xia et 01., 2007), and 
leads to sorbitol accumulation, as in the polyol pathway, and also leads to the production of 
nuclear factor ICB (NFKB) (a pro-inflammatory transcription factor) (Nishikawa et 01., 2000). 
All these changes can be seen under relatively short-duration hyperglycaemia (Lee et 01., 2009; 
Yang et 01., 2009). If however high glucose is sustained, the formation of advanced glycation 
end products (AGEs) occurs (Brownlee et 01., 1988a) (Figure 1.13). These are formed as glucose 
binds nonenzymatically and irreversibly to free amino acids and lipids (Brownlee et 01., 1988b). 
The functions of the proteins that contain AGEs can be altered, and as AGE formation is 
irreversible, they accumulate in cells. AGEs can form naturally as a person gets older, but it has 
been shown that this formation is greatly accelerated in diabetes mellitus, and that this is 
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directly proportional to glycaemic status (Stitt et 01., 1998). AGEs can increase the production 
of free radicals, therefore feeding into the oxidative stress mechanism detailed above. AGEs 
also can react with various intracellular proteins (Giardino et al., 1994), which may alter their 
function, and the extracellular matrix (Brownlee et 01., 1986; Haitoglou et al., 1992), which then 
leads to abnormalities in the structure of the affected vessels (Vlassara et 01., 2002; Brownlee, 
1995a; Brownlee, 1995b; Zieman et 01.,2005; King and Brownlee, 1996). Also, AGEs can bind to 
their receptors (AGEs receptors), which then stimulate the production of NFKB and various 
cytokines (Schiekofer et 01., 2003; Yan et 01., 1994), leading to inflammation (Ettelaie et 01., 
2008), and also inhibit the production of NO (Chakravarthy et 01., 1998; Bucala et aI., 1991). 
These alterations working together have a powerful effect on the vasculature. The vasculature 
is prone to vasoconstriction and inhibition of vasodilation, as the endothelins, the major 
endothelial vasoconstrictors, are negatively regulated by NO. It has been shown that NO-
dependent vasodilation, but not NO-independent vasodilation, is inhibited in hyperglycaemia 
(Williams et 01., 1998). NO is also part of the anti-coagulation cellular mechanisms, together 
with prostacyclin, thrombomodulin, and tissue plasminogen activator amongst others, and 
these mechanisms are decreased in diabetes, leading to a pro-coagulant state which increases 
the risk of stroke, amputation and myocardial infarction. In one study, a decrease in blood 
glucose to euglycaemia showed a decrease in tissue factor, which is a main initiator of 
coagulation (Boden and Rao, 2007). The risk of myocardial infarction has been shown to be 
increased after acute (30 minutes) hyperglycaemia in rats (Yang et al., 2009). This fast acting 
effect of hyperglycaemia might be due to the fact that NO has a very short half-life, therefore 
high glucose can have rapid results that are seen in the immediate vicinity of the endothelium. 
Atherosclerosis is a chronic inflammation of the arterial walls, and hyperglycaemia creates the 
conditions for this to occur by producing NFKB under oxidative stress, as described above. 
AGEs also seem to have a part in this inflammation, as studies in rats have shown that both AGE 
formation inhibitors and cross-link breakers reduce plaque area by 40% and 30% respectively 
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(Forbes et 01., 2004; Candido et 01., 2002). Atherosclerosis is the main cause of diabetic 
mortality and morbidity, and glucose seems to have a big role in it. Interestingly, it seems that 
long duration hyperglycaemia in rats predisposes the vasculature to increased inflammation, as 
bone marrow derived endothelial progenitor cells had a pro-inflammatory phenotype (Loomans 
et 01., 2009). 
As for the pro-angiogenic and pro-permeability aspects of hyperglycaemia, VEGF and NO seem 
to be the main players. In a normal endothelial cell, if VEGF is produced at a basal rate it 
increases the production of NO by eNOS, and NO then feedbacks to inhibit further VEGF 
production (Ferrara, 2002; Kroll and Waltenberger, 1998; Ghiso et 01., 1999; Parenti et 01., 1998; 
Ferrara, 2004; Ziche et 01., 1997). However, in diabetes, this balance is lost. VEGF leads to a 
direct increase in permeability (Ferrara and Henzel, 1989), while inducible NOS produces large 
quantities of NO which also leads to increased permeability (Kroll and Waltenberger, 1999). 
As some of the effects of glucose, especially on NO, which has a short life and is therefore short 
acting, are mechanisms to which cells respond rapidly, a short burst of hyperglycaemia might 
be enough to have a pathological effect on them. Several studies (Gerich, 2003; Fujimoto et 01., 
2006) have been conducted on postprandial hyperglycaemia, and the effects of glucose are 
seen as quickly as 30 minutes after insult. It is therefore important to remember that it is not 
only the fasting glucose level that is important, but also the postprandial hyperglycaemic peaks. 
The alteration of these mechanisms in hyperglycaemia is a main contributor to the diabetic 
phenotype, and in tissues that are insulin-independent for glucose uptake (such as the eye, 
kidney and nervous tissues), high glucose causes a range of pathologies. In the eye, 
hyperglycaemia can lead to retinopathy (Chakravarthy et 01., 1998; Ido et 01., 2004; Ido and 
Williamson, 1997), where excessive angiogenesis and permeability of newly-formed vessels 
causes visual problems. In the kidney, diabetic patients might experience nephropathy 
(Chiarelli et 01., 2000a; Derubertis and Craven, 1994; Kelly et 01., 2007; Xia et 01., 2007), where 
the kidneys become leaky to blood proteins and where there is an association with high blood 
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pressure due to the vasoconstriction described above (Balakumar et 0/., 2009; Leehey et 0/., 
2000). In nerve endings, neuropathy might develop (Vareniuk et 01., 2008), where the blood 
supply is decreased due to the vasoconstriction caused by decreased NO (Cotter et 0/., 2003), 
and sorbitol accumulation from the polyol pathway in the pericytes surrounding the cell cause 
osmotic stress (Sussman et 0/., 1988). Therefore, hyperglycaemia is a key characteristic of 
diabetes, causing serious pathologies for the diabetic patient. 
1.3.3.2 Hyperinsulinaemia 
Hyperinsulinaemia is seen in two circumstances in diabetes: in Type 2 diabetes, where the 
aetiology of disease is insulin resistance, and thus greater and greater amounts of insulin are 
produced without effect (see section 1.3.3.4), and in GDM, where after 20 weeks gestation, the 
fetal pancreas responds to the maternal hyperglycaemia with fetal hyperinsulinaemia in order 
to try to restore an euglycaemic environment. 
1.3.3.3 Hypoglycaemia 
Hypoglycaemia is the main obstacle to tight glycaemic control (The Diabetes Control and 
Complications Trial Research Group, 1993; UK Prospective Diabetes Study (UKPDS) Group, 
1998), as when it arises, it is a medical emergency. Hypoglycaemia is seen in Type 1 diabetics 
when incorrect insulin treatment delivers more insulin than the physiological needs of the body, 
and results in a blood glucose concentration which is too low to sustain the body, especially the 
brain, which needs a constant supply of glucose to function. A low level «2.2mM) of glucose 
can lead to diabetic unawareness and diabetic coma, and can be reversed by taking a small 
quantity of carbohydrate or sugar. 
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The body's response to hypoglycaemia involves the release of glucagon and adrenaline, 
normally inhibited by insulin, to signal the liver to produce glucose (Schwartz et a/., 1987; Rizza 
et a/., 1979). Also, there is activation of the central sympathetic nervous system, which is 
manifested in a variety of symptoms including a pounding heart, hunger, sweating, anxiety and 
tremor (McAulay et a/., 2001). These symptoms are helpful in alerting the patient of their low 
glycaemic status. Whilst in poorly controlled diabetes featuring hyperglycaemia the threshold 
for these body's responses to hypoglycaemia is higher than normal, in patients with tight 
glycaemic control or frequent exposures to hypoglycaemia this threshold drops, leading to 
impaired awareness of the impending hypoglycaemia (White et a/., 1983). 
In the occurrence of hypoglycaemia, blood is diverted away from 'non-essential' systems (such 
as the eyes and kidneys), and towards the brain and the liver (for production of glucose). It is 
thought that haemodynamic and haematological changes seen in response to hypoglycaemic 
episodes may be an aggravating factor in diabetic complications, by causing acute stress to the 
fragile diabetic microcirculation. Thus, hypoglycaemic episodes can result in capillary closure 
and micro-haemorrhages in the retina, as well as the rupturing of newly-formed vessels formed 
in response to retinal hypoxia (Frier and Hilsted, 1985; Frier et a/., 1987). All these factors 
contribute to advancing diabetic retinopathy. 
1.3.3.4 Insulin resistance 
In type 2 diabetes, relative insulin deficiency is caused by insulin resistance. Here, the insulin 
receptors are down-regulated (Tiwari et a/., 2007), usually through receptor degradation and its 
kinase activity decreasing, possibly due to serine/threonine phosphorylation. Thus, even 
though the f3-cells of the pancreas of Type 2 patients are producing insulin, they are unable to 
compensate for this insulin resistance, and diabetes develops. 
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1.3.4 Microvascular complications - diabetic angiopathy 
Tissues which are independent of insulin for glucose uptake show glucose toxicity under 
hyperglycaemia. Such tissues include endothelial cells and the pericytes that surround them. 
Over a prolonged time, pericytes are lost from around blood vessels, resulting in a loss of vessel 
integrity (the consequences of which (for the eye) are reviewed by Ejaz et 01. (2008)), and 
vasoconstriction due to decreased NO production is seen. Another consequence of prolonged 
hyperglycaemia is an abnormal vessel wall, which displays an increased thickness due to 
overproduction of fibronectin and collagen type IV (Bollineni and Reddi, 1993; Koya et 01., 1997), 
and increased permeability and impaired architecture due to the effects of AGE receptors 
(RAGES) signalling and oxidative stress (Brownlee et 01., 1984; Haitoglou et 01., 1992). 
Here following are the main effects of this altered vasculature in the diabetic patient, and their 
pathophysiology. 
1.3.4.1 The vasculature in diabetic retinopathy 
Retinopathy is a leading cause of blindness in the UK, and most Type 1 diabetic patients will 
develop it within 20 years of diabetes onset (Fong et 01., 2003). Diabetic retinopathy affects 
mostly the vasculature of the retina in the eye, and hyperglycaemia seems to be the main 
causative player, as the severity and duration of high glucose are directly associated with the 
pathologic changes that cause retinopathy (Yanko et 01., 1983; Klein et 01., 1994). Retinopathy 
is characterised by an initial increase in permeability and blood flow to the retina together with 
altered composition and thickening of the basement membrane and loss of pericytes from the 
vessel walls. As well as these changes, microaneurysms are formed by retinal endothelial cell 
proliferation in vessels where pericytes have been lost. This environment results in retinal 
hypoxia, activating the expression of angiogenic factors such as VEGF that initiate 
neovascularisation. The main pathways that are disrupted in retinopathy in response to 
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hyperglycaemia are the PKC pathway and the formation of free radicals and AGEs, as reviewed 
by Cai and Boulton (2002). 
1.3.4.2 The vasculature in diabetic nephropathy 
Diabetic nephropathy is the most common cause of end stage renal failure. As with retinopathy, 
the changes seen in this disease seem to be directly related to glycaemic status (Mogensen, 
1971). 
Diabetic nephropathy is characterised by glomerular basement membrane thickening and 
mesangial expansion, as well as hyalinosis of both afferent and efferent arterioles, although it is 
the thickening and accumulation of extracellular matrix that is the central abnormality in the 
disease (Tervaert et al., 2010). There is also evidence of podocyte damage and detachment 
(Petermann et al., 2004). These changes result in a decrease in barrier function of the kidneys, 
leading to proteinuria and eventually may lead to end stage renal failure. 
The main pathways that lead to these characteristics of diabetic nephropathy are accumulation 
of AGEs, increased oxidative stress and PKC activation, and increased production and 
expression of vasoactive growth factors in the glomerulus, as reviewed by He and King (2004). 
Indeed, suppression of these mechanisms has been shown to be protective against the 
development of diabetic nephropathy (Nakagawa et al., 2006; Schrijvers et al., 2006). 
1.3.5 Diabetes management 
In Type 1 diabetes, management of glycaemic levels with insulin or insulin analogues is 
currently the only method available to stabilise hyperglycaemic excursions. It has been shown 
in the DCCT trial (1993) that microvascular complications are reduced with strict control, 
although the incidence of hypoglycaemia then increases. In the last ten years, great advances 
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have been made in the field, with long- and fast-acting insulin analogues (Rys et 01., 2011), 
insulin pumps, and continuous glucose monitoring systems (Hoeks et 01., 2011) all helping to 
reduce incidences of hypoglycaemia whilst maintaining tight control. 
Long- and rapid-acting insulin analogues are used to replicate the non-diabetic basal and post-
prandial production of insulin. Long-acting insulin analogues are injected at regular intervals 
(usually once or twice daily) into the subcutaneous tissue. This insulin is then slowly absorbed 
into the bloodstream throughout the next 12-24h, therefore providing an insulin profile similar 
to basal insulin production in non-diabetics. Rapid-acting insulin analogues are instead used 
immediately prior to a meal, simulating the post-prandial rise in insulin release seen in non-
diabetics. 
Insulin pumps use fast-acting insulin, but they deliver it continuously to the body in smaller 
units, replicating the basal insulin profile. They then deliver a higher dose bolus immediately 
before a meal, replicating the post-prandial insulin peak. The advent of smaller and tubing-free 
'patch' insulin pumps, the programming of different insulin delivering profiles matching 
differing schedules, and alarms sounding when hypo- or hyperglycaemia are detected, are all 
recent useful advances that aid convenience and safety in diabetes management (Selam, 2010). 
Real-time continuous glucose monitoring systems are relatively new, but they could potentially 
provide an important and effective tool for improving glycaemic control, as the patient can see 
and immediately correct any hyperglycaemic excursion. However, studies still need to be 
performed to show the benefits of continuous glucose monitoring in certain patient groups 
(such as in pregnancy and with a history of severe hypoglycaemia) (Hoeks et 01., 2011). 
Together with insulin pumps, continuous glucose monitoring is leading to the development of 
closed-loop insulin delivering, or artificial pancreas, which will ultimately lead to optimal tight 
glucose control with reduced hypoglycaemia risk (Elleri et 01., 2011). 
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Recently, metformin (an oral drug which reduces hepatic gluconeogenesis and lipogenesis) 
treatment alongside insulin has increased, as studies have shown a potential benefit to Type 1 
patients who are receiving large amounts of insulin, are overweight, or have an HbA lc of over 
64mmol/mol (Meyer et 01.,2002; Meyer and Guerci, 2003). 
In Type 2 diabetes, often the first route of management is through an altered diet and exercise 
regime which aids weight loss in overweight Type 2 diabetic patients, helps regulate glycaemic 
levels, and decreases risk factors associated with cardiovascular disease (Sibal and Home, 2009), 
combined with metformin. However, if HbAlc levels are above 56mmol/mol or microvascular 
symptoms are being exhibited, other oral drugs are then prescribed (such as insulin, 
sulphonylureas and thiazolidinediones) (Nathan et 01., 2006). 
Tight glycaemic control in diabetes is important for managing macro and microvascular 
complications. There is a significant association between higher HbAlc levels and increased 
macrovascular complications such as coronary artery disease (Selvin et al., 200Sa), peripheral 
arterial disease (Selvin et al., 2006) and stroke (Selvin et al., 200Sb), and a Ummol/mol 
decrease in HbA1c also resulted in a 37% reduction in microvascular complications (Stratton et 
af., 2000). However, glycaemic control is not the only avenue for macrovascular complications 
management, as hypertension and dyslipidaemia have also been shown to be associated with 
development of macro and microvascular disease in diabetic patients: the risk of myocardial 
infarctions increases 12% for every 10mmHg increase in systolic blood pressure (Adler et af., 
2000), and use of statins to decrease cholesterol significantly decrease the risk of cardiovascular 
disease (Ginsberg et 01., 2010). Thus, tight glycaemic, blood pressure, and lipid control are all 
important tools for management of diabetes. 
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1.4 Diabetic pregnancy and the placenta 
1.4.1 Diabetes in pregnancy 
Diabetes is a major complication of pregnancy, and constitutes a major morbidity risk factor for 
the fetus, with mortality rates for neonates four times those of normal pregnancies (Macintosh 
et 0/., 2006). The mortality in this study was shown to result from an increased risk of 
congenital cardiac abnormalities and neural tube anomalies. Other complications in diabetic 
pregnancies include other congenital abnormalities, spontaneous abortion, stillbirth, neonatal 
hypoglycaemia, intra-uterine growth restriction (IUGR), respiratory distress, and, importantly 
for the purposes of this thesis, macrosomia (Sosenko et 0/., 1979; Gale and Amiel, 2002). 
Further, recently a link was found between diabetes in pregnancy and metabolic syndrome in 
the offspring later in life (Dabelea, 2007). 
Intensive management prior to conception and during pregnancy can reduce the risk of 
spontaneous abortion and congenital malformations (The Diabetes Control Complications Trial 
Research Group, 1996); however, even with tight control, some incidence of macrosomia 
remains (Evers et 0/., 2002). 
All types of diabetes (whether Type 1, Type 2 or gestational) require further interventions 
during pregnancy, as during gestation glycaemic homeostasis changes, and patients require 
more insulin (see section 4.1.3.) to achieve euglycaemia. 
The diabetic pregnancy can be divided into two parts as far as complications are concerned: 
before 20 weeks and afterwards. The first 20 weeks post-conception are characterised by 
hyperglycaemia in the fetus, as insulin is not yet being produced by the fetal pancreas and 
maternal insulin only crosses the placenta in small amounts (Challier et 0/., 1986), if at all (Keller 
and Krohmer, 1968). Therefore, the fetus is exposed to hyperglycaemia due to the 
transplacental glucose flux down the glucose concentration gradient. It is this early fetal 
hyperglycaemia that is thought to be responsible for the increase in congenital abnormalities 
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and spontaneous abortions seen in diabetic pregnancies (Hanson et al., 1990), as glucose is 
thought to act as a teratogen here (Eriksson, 2009). Excessive glucose also acts as a growth 
inhibitor, and thus during the first trimester the pregnancy might be affected by IUGR. 
In contrast, insulin is a growth promoting hormone. When the fetal pancreas begins production 
of insulin at 20 weeks gestation, hyperinsulinaemia might occur to try to achieve an 
euglycaemic environment. This theory is called the Pedersen hypothesis after the person 
behind it (Pedersen, 1954). The ~ - c e l l s s in the pancreas become hypertrophic to meet the 
demand of the hyperglycaemic environment (Jaffe, 1991), and the high insulin concentration 
causes the excessive deposit of fat, cellular glucose utilisation, and protein production in the 
fetus, which then leads to organomegaly (Langer, 2000), resulting in a macrosomic fetu s. 
Macrosomia then often complicates the delivery of the infant by resulting in shoulder dystocia, 
operative delivery and brachial plexus injury (American College of Obstetricians and 
Gynecologists Committee, 1992). Macrosomia is present in 48.8-62.5% of diabetic pregnancies 
(Evers et al., 2002). 
Figure LiS, below, is a flow chart illustrating the effects of maternal hyperglycaemia in 
pregnancy. 
Materna l hyperglycaemia 
Fetal hyperglycaemia 
/ / 1 Hyperinsul 
. . (Ollcelton 20 wrkS 
Tlmellne 
Congenital 
abnormalities 
Decreased 
fetal growth 
Fetal 
macrosomia 
Figure 1.15: Temporal effects of maternal Type 1 diabetes on the pregnancy. 
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The fetus of the diabetic pregnancy might also be exposed to hypoxic conditions due to the 
maternal hyperglycaemia and fetal hyperinsulinaemia. Evidence for this comes from high 
erythropoietin (EPO) levels at birth, which correlate closely with both maternal HbA1c levels in 
the month prior to delivery and fetal plasma insulin levels (Widness et 01., 1990). EPO is 
involved in the regulation of production of red blood cells, and normally it is produced only in 
the fetal kidneys (Zanjani et 01., 1981), but under hypoxic conditions it is produced in other 
tissues (Dame et 01., 2000; Davis et 01., 2003a). It is thought that this more ubiquitous (and 
hence higher) synthesis of EPO is an adaptation of the fetus to lower oxygen-carrying capacity 
of fetal blood. 
We have seen here the effects a diabetic pregnancy may have on the fetus. In the next section, 
we shall detail the phenotype of the placenta of diabetic pregnancies. 
1.4.2 The diabetic placenta 
Type 1 placentae are the most studied placentae from diabetic pregnancies. This in itself makes 
it an ideal subject of study, as results can be compared to a well defined "diabetic phenotype". 
In contrast, placentae from Type 2 diabetic women have until recently not been thoroughly 
characterised, and therefore any results would not be as comparable to the current literature 
as Type 1; furthermore, any conclusions drawn from Type 2 placentae would not be as definite. 
From a gross anatomy perspective, the type 1 placenta is not significantly heavier than a normal 
placenta (average of 470g) (Teasdale, 1981; Benirschke and Kaufmann, 2000; Mayhew, 2002; 
Jones and Fox, 1976), although there is a correlation between placental and fetal size, i.e., 
larger placentae are present combined with a macrosomic fetus (Taricco et 01., 2003). 
The placenta of a diabetic pregnancy shows increased vascularisation within the placental 
tissue (72% increase in combined lengths of placental vessels (Leach et 01., 2004)). In addition, 
it has been found that more than 50% of Type 1 placental chorionic villous vessels are 
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significantly leakier to large macromolecules (76KDa) than normal placental chorionic villous 
vessels and show increased levels of endogenous VEGF (Leach et 01., 2004). The latter was 
linked to an increased proliferation index in the diabetic placenta. 
The increase in vascularisation has been shown to be due to branching angiogenesis in GDM. 
This increase in this type of angiogenesis results in the vascular bed being less efficient, as it is 
structurally more complicated, with increased redundant connections between vessels in 
diabetic placentae compared to normal placentae (Jirkovska et 01., 2002). It is thought that this 
decreased efficiency of the placental vascular network might playa role in the fetal hypoxia 
seen in diabetic pregnancies. 
In diabetic placentae, there is an increase in DNA content, which indicates more cellular 
material in the parenchymal tissue (Winick and Noble, 1967), and higher numbers of stromal 
fibroblasts and villous macrophages (Younes et 01., 1996). The trophoblast basement 
membrane has also been shown to be thicker in diabetic pregnancies compared to normal 
pregnancies, perhaps because of increased amounts of collagen type IV (Younes et 01., 1996). 
The phenotype of the diabetic placenta depends partly on glycaemic control, which plays a 
large role in the abnormalities seen in the diabetic placenta. In tightly controlled pregnancies, 
for example, there are no significant differences in the number of abnormal villi recorded 
compared to non-diabetic pregnancies, whilst placentae from poorly controlled pregnant 
women contained a higher percentage of abnormal villi (Bjork and Persson, 1982). 
Thus the human placenta in a diabetic environment undergoes structural and functional 
changes that may affect the fetus. 
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1.5 Hypothesis and aims 
Hyperglycaemia is a main complication of diabetes, and in animal studies it has been shown to 
cause increased permeability of vascular beds. The placenta is a very sensitive organ to 
angiogenic and permeability stimuli, so that an increase in leakage of the endothelial lining of 
the placenta might adversely affect the fetus. It is known that one of the main complications of 
a pregnancy involving a diabetic mother is macrosomia of the baby. 
Our working hypothesis was that hyperglycaemia causes an increased permeability in the 
vascular beds of the human placenta. To answer this research question, we developed aims: 
To establish an explant culture methodology as a suitable model to enable us to 
evaluate the effects of glucose on VEGF and VE-cadherin, two key molecules for 
assessing the permeability of the vascular beds. 
To analyse the effects of high glucose (15mM) on VEGF splice variants and VE-cadherin 
expression in the endothelium of normal and diabetic placental vessels by using the 
validated explant culture. 
To assess the effects of high glucose (15mM) on vascular leakage to a tetramethyl 
rhodamine isothiocyanate (TRITC) tracer in a dual perfusion model. 
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Chapter 2 
Validation of chorionic villous explants 
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2.1 Introduction 
2.1.1 General principles of chorionic villous explants culture 
Chorionic villous explants provide a balance between whole-organ and cell culture experiments, 
providing the 3D architecture and in vivo environment of the former combined with the ease of 
use and flexibility of the latter. Use of chorionic villous explants provide an ideal methodology 
to study the placental architecture with short and long-term cultures, as explants remain viable 
for up to 12 days. There are a variety of explants culture methodologies used in the literature, 
each suited to each experimental set-up and experimental question. An explant culture which 
is suitable for trophoblast proliferation studies, for example, might not be suitable for VEGF 
studies in the endothelium. However, there are some principles that all explants cultures 
should aspire to fulfil. In a review of explant culture methodologies (Miller et 01., 2005), the 
authors elegantly summarised the four main requirements for judging whether an explants 
culture methodology is appropriate for a certain experimental question. These are: 
applicability, where the explants culture mimics an in vivo situation; validity, where the culture 
behaves like a 'living' system; consistency, where the explants culture gives consistent results; 
and generalisation, where we can compare results with other experimental systems and clinical 
situations. Miller et 01. (2005) state in their review that the complete fulfilment of each 
criterion might not be possible, but that the culture method should be chosen to maximise the 
compliance to these criteria in light of the research question being asked. 
Chorionic villous explants are most often taken from first and third trimester pregnancies. First 
trimester explants are used for the study of differentiation and invasion of extravillous 
trophoblast, whilst term placenta can be used for mature placental studies. Both allow the 
study of villous trophoblast proliferation and turnover. Third trimester explants can be 
incubated on a mesh support just below the gas-liquid boundary (Siman et 01., 2001), on the 
bottom of the well (Black et 01., 2004), or suspended from polystyrene blocks into the medium 
(Huppertz, unpublished). To allow first trimester trophoblast migration and differentiation, a 
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matrix (matrigel or collagen I) is added to the bottom of the well (Genbacev et 01., 1992), as 
trophoblast outgrowth grown on plastic are often contaminated with fibroblasts. 
2.1.2 Trophoblast and hypoxia in explant cultures 
The main focus of chorionic villous explant cultures until now has been trophoblast study. It is 
possible to isolate cytotrophoblast cells from the placenta; however, several investigators have 
shown that once the cytotrophoblast cells are put in cell culture, they quickly differentiate and 
fuse into a giant cell, which degenerates after 5 days (Morrish et 01., 1997; Handwerger and 
Aronow, 2003; Kliman et 01., 1986), therefore not allowing long-term study of trophoblast 
migration and differentiation. The duration of these cultures can be extended by addition of 
epidermal growth factor to the media (Johnstone et 01.,2005), but even this is not ideal, as it is 
exposing the cytotrophoblast to an external stimulus. Therefore, chorionic villous explants 
provide the ideal methodology for the study of trophoblast function. 
One of the most studied variables when studying the trophoblast in placental explants is oxygen 
concentration. In the first trimester of gestation (up to -11 weeks), the maternal blood does 
not yet bathe the blood lakes of the placenta, and therefore there is a hypoxic environment 
(estimated to be around 2-3% oxygen) (Foidart et 01., 1992; Jauniaux et 01., 2003). In both early 
and late gestation, hypoxia is thought to contribute to a variety of pathologies, including pre-
eclampsia (Soleymanlou et 01., 2005). Therefore, hypoxia is a highly important factor in both 
physiologic and pathologic placental development, leading several groups to try to simulate it in 
in vitro placental explants. In some of these hypoxic studies, hyperoxic conditions (20% oxygen) 
were also compared to normoxic (8% oxygen) and hypoxic (1% oxygen) conditions (Royle et 01., 
2009). As 20% oxygen is the level commonly seen in culture incubators, this gives an indication 
as to whether certain studies can be performed at this level, or if the molecule(s) or system 
studied is adversely affected by this hyperoxic environment. In the next section, we will discuss 
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how these previous placental explant cultures helped shape our two versions of chorionic 
villous explants. 
2.1.3 Chorionic explant models in this study 
2.1.3.1 Oxygen 
The explant methodology needs to be carefully developed depending on what the experimental 
aims are. Explant cultures have been extensively used for studies focusing on the trophoblast 
layer. However, it has been shown that this layer undergoes significant changes in the initial 
period of culture, and then degenerates after a few days in culture (Siman et 0/., 2001; Di Santo 
et 01., 2003). Therefore, explant cultures used for these experiments have been specially 
developed to preserve the trophoblast and allow its proliferation. We, however, wished to 
study the endothelium of the explants, a use of this methodology which has not been published 
before, and therefore a different explant culture might be more suited for our experiments. 
Our aim was to study VEGF and VE-cadherin expression in the endothelium. Therefore, we 
needed an explant culture which minimised VEGF production. The normal oxygen 
concentration in the intervillous space in utero is around 8% (45-50mmHg) (Fujikura and 
Yoshida, 1996). Studies on hypoxia in placental explants have repeatedly shown that VEGF 
expression is lowest in conditions of hyperoxia (20% oxygen), whether as excreted VEGF in the 
media of first trimester (Munaut et 01., 2008) and third trimester explants (Padavala et 01., 
2006), or in the placental tissue of third trimester placental explants itself at Oh (before culture) 
(Sokolov et 01., 2008). Of course, the study by Munaut et 01. (2008), which shows very low 
levels of VEGF both at Oh (before culture) and at 48h, uses first trimester placentae, which have 
very different angiogenic and permeability characteristics than full term placenta and a very 
different oxygen environment (2-4% oxygen). The study by Sokolov et 01. (2008) shows an 
expression area for VEGF levels in syncytiotrophoblast and vascular endothelial cells to be 3.11% 
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in the tissue. These decreases in VEGF would be advantageous for our studies, as it would 
lower the baseline VEGF and therefore make any increase due to glucose more noticeable. 
Therefore, our explants were incubated in 20% oxygen. 
2.1.3.2 Excision artefacts 
A possible complication is that VEGF might be expressed on excision of the explants from the 
placenta, as this process technically creates a wound, and VEGF is expressed in wound healing. 
However, a study of hypoxia on the expression of inflammation and wound healing molecule 
TNFa and anti-angiogenic soluble VEGF receptor sVEGFR-1 found that 20% oxygen minimised 
expression of these wound healing molecules (Royle et 01., 2009), and so in theory the wound 
healing effect might not be relevant. 
2.1.3.3 Flow and shear stress 
One of the methodologies tested, hereafter called the 'free-floating methodology', involves the 
explants being submerged in media in a universal tube, and agitated on a roller. The explants in 
this methodology are free-floating in the media (hence the name), and this simulates the 
condition in vivo where the chorionic villi are floating in the maternal blood lakes, with blood 
flowing over the explants as it enters the intervillous space from the spiral arteries and is 
drained from this space by maternal veins. 
In vivo, the endothelium adapts remarkably well to changes in flow and shear stress. In 
response to a change in flow, endothelial cells produce powerful vasoactive molecules (such as 
prostacyclin and nitric oxide), resulting in vascular relaxation due to inhibition of smooth muscle 
cell contraction (as when the endothelium is in steady state). If the flow then returns to normal, 
this process is reversible, due to the short half life of these Signalling molecules and the nearby 
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presence of other signalling molecules that allow the switching off of these second messengers. 
If, however, the altered flow and shear stress persist, transcription factors that regulate flow-
responsive gene transcription are activated, which leads to changes in the phenotype of the cell 
and more permanent adaptation to the altered environment (Davies, 1997). We hypothesise 
that these mechanisms will allow our free-floating explants to adapt to the flow in the agitated 
tube, allowing the replication of in vivo flow in our experimental set-up. 
In the case that the adaptation of the endothelium to the shear stress created by agitation were 
not appropriate, we also chose to validate another technique, the stationary methodology, 
where the explants are floating in a well of a twelve-well culture plate, with a metallic mesh 
(with 7 0 0 ~ m m pores) underneath to avoid the trophoblast cells migrating to the well's bottom 
wall. 
2.2 Aims and objectives 
The aim of this chapter was to validate a placental chorionic villous explants methodology to 
study its vasculature, in respect to two important molecules for blood vessels, VE-cadherin and 
VEGF. In order to achieve this aim, we performed two protocols, one with (free-floating 
methodology) and one without (stationary methodology) simulation of blood flow. 
2.3 Methods 
2.3.1 Materials 
The source and catalogue number for all materials mentioned in this chapter are listed in 
Appendix 1. 
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2.3.2 Placenta selection 
Consent for use of the placentae in our study was sought if the donors met the following 
criteria: healthy pregnancy with no complications, non-smoker, 18-35 years of age, BMI 20-25, 
no medications, gestational age ~ 3 7 7 weeks. Women gave informed consent as they came in for 
their scheduled term elective Caesarean sections. Any pregnancy (for example, diabetes, pre-
eclampsia, pregnancy hypertension) and/or placental complication (for example, placenta 
praevia, placental abruption, twins) was excluded from the study. Each placenta was 
transported to the laboratory for excision of explants as soon it was delivered. 
2.3.3 Explant excision 
The placentae were cooled on ice during the excision of explants. Explants (l1mg) (n=5 per 
experiment, 6 explants per placenta) were excised from different cotyledons, taking care not to 
include maternal and fetal tissue and cutting from the central part of the cotyledon. Villous 
tissue taken was free of calcification and infarcts. Explants were washed in ice-cooled PBS to 
remove blood. The explants were processed within 30 minutes of delivery. Half the explants 
were used for the free-floating methodology, and half for the stationary methodology. 
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Figure 2.1: Micrograph of a chorionic villous explant floating in PBS. Visible are the branches of chorionic 
villous trees, and in one villous, some remaining blood is visible (arrow). Magnification: x40, scale bar: 
SOOllm. 
2.3.4 Free-floating methodology 
Explants (n=5, 3 explants per placenta) were incubated in Sml M199 medium (which had been 
briefly oxygenated) containing 5% (v/v) Fetal Calf Serum, 100U/ml penicillin, 100mg/ml 
streptomycin, 2 ~ g / m l l Fungizone with continual agitation (45 rpm) to simulate blood flow, for 
either Oh, 1h, 4h or 24h. After this period of incubation, the explants were removed and fixed 
in 1% (w/v) paraformaldehyde (PFA, pH7.2) for 30 minutes to allow cross-linking to occur, 
before being quickly washed in cold PBS and inserted in a drop of optimum cutting temperature 
compound (OCT) and snap frozen with liquid nitrogen cooled isopentane to minimise freeze 
damage. 
2.3.5 Stationary methodology 
Explants (n=5, 3 explants per placenta) were incubated in 2ml M199 medium (which had been 
briefly oxygenated) containing 5% (v/v) Fetal Calf Serum, 100U/ml penicillin, 100mg/ml 
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streptomycin, 2 ~ / m l l Fungizome with a net support (pore size 700\lm) in a twelve-well plate, to 
avoid the explants to adhere to the bottom of the well, for either Oh, 1h, 4h or 24h. After this 
period of incubation, the explants were removed and fixed in 1% (w/v) PFA for 30 minutes to 
allow cross-linking to occur, before being quickly washed in cold PBS and inserted in a drop of 
OCT and snap frozen with liquid nitrogen cooled isopentane. 
2.3.6 Fixation before excision control 
In order to evaluate whether the phenotype seen in the t=Oh control was due to the excision 
and washing process, control cotyledons from placenta (n=l) were subjected to a fixation 
before excision protocol, and then the phenotype of the resulting tissue analysed compared to 
the Oh control. 
Whole placentae cotyledons were excised from the organ alongside the decidual septa, so as 
not to disrupt the structure of the lobule. The cotyledons were quickly washed in cold PBS to 
remove most blood, and then fixed with 1% (w/v) parafolmaldehyde at 4°C for 4h. The 
cotyledons were then excised into explants as described in section 2.3.3, and the explants were 
then washed in PBS to remove further blood, and then fixed in 1% PFA for a further 30 minutes, 
washed in PBS, and then inserted in a drop of OCT and snap frozen with liquid nitrogen cooled 
isopentane. 
2.3.7 Immunofluorescence protocol 
Frozen sections were cut to 7\lm-thick slices with a cryostat (CM151O, Leica) and positioned on 
microscope slides, which were removed from the cryosectioning machine and allowed to airdry. 
An ImmEdge pen (hydrophobic pen) was then used to draw around each section, to keep the 
liquids on the section. A 20Il' drop of 0.1% (w/v) PFA in PBS was added to each section for 5 
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minutes, to fix the section, and then removed. A 20111 drop of 0.1% (v/v) Triton, 0.1% (w/v) BSA 
in PBS was then added and left for ten minutes at room temperature in a covered humidity tray, 
to permeabilise cell membranes so the antibodies would be able to enter cells, and then 
removed. A 20111 drop of blocking solution (1:20 dilution of normal human serum in PBS) was 
then added for 30 minutes at room temperature in a covered humidity tray. After removal, 
20111 of the primary antibody (mouse anti-human VE-cadherin (555661, BD Biosciences): 5 ~ / m l , ,
mouse anti-human VEGF (MAB293, R&D Systems): 5Ilg/ml, negative control: 0.1% (w/v) BSA in 
PBS) was added, and the slides placed in a covered humidity tray for an overnight incubation at 
4°(, After the overnight incubation, two quick washes with PBS with standard pipette were 
performed, followed by three 15 minute washes with 0.1% (w/v) BSA in PBS. A 20111 drop of 
goat anti-mouse IgG fluorescein isothiocyanate (FITe) secondary antibody (F-0257, Sigma-
Aldrich, 20Ilg/ml) was added and kept at room temperature for 2 hours in darkness. The same 
washes as after the primary antibody were then repeated in aluminium foil covered Coplin jars. 
One ten minute wash with PBS only was then performed, followed by one 2-5 minute wash 
with distilled water. The slides were then carefully dried, mounted with vectorstain and sealed 
with nail varnish. The slides were then allowed to settle overnight before analysis. 
2.3.7.1 Vessel identification verification 
In order to confirm that the counting of vessels was performed in an accurate fashion, some 
separate slides were incubated with endothelial marker PECAM-1 (5Ilg/ml, SC-1505-R, Santa 
Cruz) primary antibody and goat anti-rabbit tetra methyl rhodamine isothiocyanate (TRITe) 
secondary antibody (T-6778, Sigma-Aldrich). This allows the endothelium to be shown in the 
TRITC but not FITC channel. Micrographs of both channels were taken, but only the 
micrographs in the FITC channel were initially analysed. After vessels were identified in the 
FITC channel, the accuracy of the identification was checked in the TRiTe micrographs. 
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2.3.8 Freeze damage and morphology evaluation 
One slide (containing one section) of each explant was exposed to 0.1% (w/v) toluidine blue in 
water for 30 seconds before being thoroughly washed with water. The slide was then 
immediately analysed under the microscope (Nikon LaboPhot-2 fluorescence microscope, Nikon 
Instruments) to check the gross morphology of the explants. Toluidine blue stains nudeic acids 
and all proteins a blue-purple colour, and allows detection of freeze damage to the tissue. 
Haematoxylin and Eosin (H&E) staining was also performed to allow structural detail to be 
evaluated. Slides were rehydrated in tap water, submerged for 5 minutes in Harris 
haematoxylin, and washed in a bath of running tap water until the water cleared. They were 
then dipped in acid alcohol for 10 seconds, washed until there were no streaks on the slides, 
and dipped in Lithium Carbonate/Scott's Tap Water. Slides were then submerged in 1% Eosin 
for 5 minutes, and washed again in tap water. A series of dehydration steps were then 
performed, by dipping the slides in 50%, 70%, 90% and 100% alcohol for 10 seconds each. 
Finally, slides were dipped in fresh and finishing xylene for 2 minutes each, and mounted with 
di-n-butyle phthalate in xylene (DPX). 
2.3.9 Microscopy and analysis of slides 
A Nikon fluorescence microscope (Nikon LaboPhot-2 fluorescence microscope, Nikon 
Instruments) was used to visualise the immunoreactivity of the placental tissue. Micrographs 
were obtained with a Nikon Coolpix 995 digital camera. Using Adobe Photoshop 6.0, each 
micrograph was analysed by using selective random sampling (adapted from systematic 
random sampling (Mayhew, 1991), by superimposing a grid onto each picture and then 
assessing the immunoreactivity in every 5th square (see Figure 2.2). To calculate the percentage 
of vessels showing immunoreactivity to VEGF or VE-cadherin, vessels were counted using the 
83 
unbiased forbidden line counting technique; for each time point between 150-200 vessels were 
counted to avoid over-sampling. 
Figure 2.2: Selective random sampling. A grid was superimposed on the micrograph, and counting was 
started from the start pOint square (S), chosen as the upper left area of tissue. Every 5th square on the 
grid was counted (e) after the start pOint. When the square at the limit of the tissue (square 4 in this 
example) was reached, the counting continued in the square immediately below it. To avoid counting 
vessels twice, the forbidden lines (in red in this diagram) method was used, where vessels on the 
forbidden line were not counted. Selective random sampling was also used when counting under the 
microscope, and to choose which micrographs to take, except instead of squares we used fields of view. 
We attempted to sub-categorise the vessels stained with VEGF and VE-cadherin, by dividing the 
vessels immunopositive to VEGF into three intensity levels, intensity 1 being the weaker 
staining and intensity 3 being the brightest staining, and by dividing VE-cadherin 
immunopositive vessels by differentiating between diffuse cytoplasmic immunoreactivity 
(location 1), partially diffuse cytoplasmic location and partially continuous junctional location 
immunoreactivity (location 2) and continuous junctional location immunoreactivity (location 3) 
(Figure 2.3). 
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Figure 2.3: Micrographs showing sub-categories ofVE-cadherin (A-D) and VEGF (E-H) immunopositive vessels. For VE-cadherin, 
micrograph A shows a VE-cadherin immunonegative vessel, micrograph B shows a vessel with VE-cadherin in location 1 (fully 
cytoplasmic location), micrograph C shows a vessel with VE-cadherin in location 2 (partly cytoplasmic and partly junctional 
locations), and D shows a vessel with location 3 (fully junctional location) VE-cadherin. For VEGF, micrograph E shows a VEGF 
immunonegative vessel, micrograph F shows intensity 1 VEGF immunoreactivity, micrograph G shows intensity 2 VEGF 
immunoreactivity, and micrograph H shows intensity 3 VEGF immunoreactivity. 
2.3.9.1 Statistical testing 
GraphPad Prism version 5.01 statistical software was used to analyse results. Parametric 
testing was not appropriate due to the low n numbers. Kruskal-Wallis non-parametric testing 
was therefore used. However, the only non-parametric post-test to the Kruskal-Wallis available 
in Prism, Dunn's post-test, has inherent low power (Demsar, 2006). More powerful post-tests, 
such as Holm's procedure, were not available. Therefore, in order to avoid a high rate of Type 2 
statistical errors (false negative), whenever the Kruskal-Wallis test detected a significant 
difference between the groups, the Mann-Whitney U test was used to determine significance 
between relevant sub-groups. This could produce Type 1 statistical errors (false positives); 
however, the use of the Mann-Whitney U test was justified by the low power of Dunn's post-
test, and the lack of more suitable tests in the statistical software available to us. 
Although data was analysed using non-parametric testing, the results in this and subsequent 
experimental chapters are presented in histograms showing means ± standard deviation, 
normally used when presenting data analysed in parametric tests; this was for simplicity of 
presentation. 
2.4 Results 
2.4.1 Morphology of the explants 
All explants from both methodologies and at all timepoints were free of ice crystal damage, as 
detected using Toluidine blue staining (Figure 2.4A-B). 
Furthermore, all ex plants from both methodologies and at all timepoints had a normal 
morphology as evaluated by H&E staining. Both the vascular tissue and the trophoblast 
appeared intact with no detachment or appearance of large vacuoles or necrosis (Figure 2.4C-D) 
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Figure 2.4: Toluidine blue and H&E staining of placental chorionic villous explants. A: Toluidine blue 
micrograph of a stem villous showing no freeze damage to the tissue. B: Toluidine blue micrograph 
of intermediate and terminal villi showing no freeze damage to the tissue. C: Micrograph of a 
placental explant slice stained with H&E, showing structural detail of intermediate villi. 0 : 
Micrograph of a placental explant slice stained with H&E, showing intermediate and terminal villi. 
The absence of freeze damage and the normal morphology of the placental chorionic villous 
explants confirms that the chorionic villous explant methodology is suitable for our investigations. 
Magnification : x200. Scale bar: SOum. 
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2.4.2 Vessel identification and negative controls 
PECAM-l immonureactivity aided the identification of the placental vasculature. Confidence in 
identifying immunonegative vessels was obtained by identifying vessels in the FITC channel, and 
then confirming that the observation was indeed a vessel by PECAM-l immunoreactivity in the 
TRITC channel (Figures 2.sA-B). 
Negative controls (without primary antibodies) showed no non-specific immunoreactivity of the 
secondary antibody (Figures 2.sC-D). 
2.4.3 Fixation before excision results 
Toluidine blue and H&E staining of slices of explants derived from whole cotyledons fixed 
before the excision process revealed a large proportion of vessels with blood trapped in them 
(Figure 2.6A-B). These vessels would therefore not be suitable for pseudo-quantitative 
immunofluorescence analysiS, hence this protocol was conducted on only one placenta - an 
extremely low n=1. In addition, due to the high amount of blood remaining in the vasculature, 
counts could not be performed; thus, direct comparison between this tissue and 'fixation after 
excision' explants (Le., t=Oh) could not be conducted. 
However, qualitative immunofluorescence analysis revealed that in 'fixation before excision' 
explants, vessels that did not contain trapped blood showed a normal phenotype of fully 
junctional VE-cadherin immunopositive vessels (Figure 2.6e) and very few vessels 
immunopositive for VEGF (Figure 2.6D). 
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Figure 2.5: Vessel identification with PECAM-l, and negative controls. Assessment of total 
number of vessels was performed by counting all visible vessels (v) in a given field of view in the 
FITC channel (A), and subsequently the presence of vessels in that area was verified by looking in 
the same field of view in the TRITC channel (6) and confirming vessel location with polyclonal 
PECAM-l immunoreactivity. The tissue in A and B was treated exclusively with TRITC-Iabelled 
secondary antibody, and therefore A resembles an immunonegative control. C: Negative control 
for VE-cadherin immunoreactivity, showing no non-specific immunoreactivity. D: Negative 
control for VEGF immunoreactivity, showing no non-specific immunoreactivity. v: vessels. 
Magnification: x200. Scale bar: lOOum. 
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Figure 2.6: Micrographs of tissue fixed before excision. A: Toluidine blue staining of tissue, 
showing no freeze damage but red blood cells (light purple) trapped in the vasculature of a stem 
villus. B: H&E staining of tissue, showing normal morphology of tissue but red blood cells 
(intense red) trapped in the vasculature of stem, intermediate and terminal villi. C: A majority 
of vessels in the fixed before excision tissue showed VE-cadherin immunoreactivity in location 3. 
D: A majority of vessels in the fixed before excision tissue showed no VEGF immunoreactivity. 
whilst there was some trophoblast VEGF immunoreacitivity (t). Black arrows: red blood cells, 
white arrows: VE-cadherin location 3 immunoreactivity, asterisks: VEGF negative vessels, t : VEGF 
immunopositive trophoblast . Scale bar: 50 um. 
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2.4.4 Total number of immunopositive vessels 
2.4.4.1 Percentage staining for VE-cadherin 
Figure 2.7 shows the percentage of vessels immunopositive for VE-cadherin in free-floating 
and stationary methods. 
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Figure 2.7: VE-cadherin immunopositive vessels - free-floating vs. stationary methods . The stat istica l 
testing shown here refers to the Mann-Whitney U test between relevant groups in the data (n=5), wh ich 
were only analysed if the Kruskal-Wallis test had detected a significant difference in the wider groups. 
a: p<O.05 relative to 24h free-floating. 
2.4.4.1.1 Percentage staining for VE-cadherin in free-floating method 
The total number of vessels immunoreactive to VE-cadherin were about 59% at Oh (pre-
incubation), 61% at 1h, 60% at 4h, and 51% at 24h (Figure 2.7, dark grey bars). Kruskal-Wallis 
statistical analysis resulted in no significant difference between any of the groups (p>0.05). 
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2.4.4.1.2 Percentage staining for VE-cadherin in stationary method 
The total number of vessels immunoreactive to VE-cadherin was about 60% at Oh (pre-
incubation), 62% at lh, 60% at 4h, and 64% at 24h (Figure 2.7, light grey bars). Kruskal-Wallis 
statistical test resulted in no significant difference between the groups (p>O.OS). 
2.4.4.1.3 Comparison between free-floating and stationary methods, VE-cadherin 
immunopositive vessels 
Using the Kruskal-Wallis test, there was a significant difference (p<O.OS) between free-floating 
and stationary groups. Mann-Whitney U analysis revealed that the total number of vessels 
immunopositive for VE-cadherin was significantly higher in the stationary methodology than in 
the free-floating methodology (p<O.OS) at the 24h timepoint. However, at all other timepoints, 
there was no significant difference (p>O.OS) (Figure 2.7). 
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2.4.4.2 Percentage staining for VEGF 
Figure 2.8 shows the percentage of vessels immunopositive for VEGF in free-floating and 
stationary methods. 
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Figure 2.8: VEGF immunopositive vessels - free-floating vs. stationary methods. The statistical testing 
shown here refers to the Mann-Whitney U test between relevant groups in the data (n=5), which were 
only analysed ifthe Kruskal-Wallis test had detected a significant difference in the wider groups. 
a: p<O.05 relative to Oh, b: p<O.05 relative to Ih free-floating . 
2.4.4.2.1 Percentage staining for VEGF in free-floating method 
The total number of vessels immunoreactive to VEGF was about 46% at Oh (pre-incubation), 63% 
at lh, 55% at 4h, and 50% at 24h (Figure 2.8, dark grey bars). Kruskal-Wallis statistical test 
resulted in a significant difference between the groups (p<0.05) (Figure 2.8); Mann-Whitney U 
test was used to show that the significant difference was between lh and Oh and between lh 
and 24h. Thus VEGF is highest after lh and then declines (although there is no significant 
difference between lh and 4h, perhaps because of the intra -timepoint variation (error bars) at 
lh and 4h). 
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2.4.4.2.2 Percentage staining for VEGF in stationary method 
The total number of vessels immunoreactive to VEGF was about 44% at Oh (pre-incubation), 50% 
at lh, 43% at 4h, and 43% at 24h (Figure 2.8, light grey bars). Kruskal-Wallis statistical analysis 
resulted in no significant difference between any of the groups (p>O.05). 
2.4.4.2.3 Comparison between free-floating and stationary methods, VEGF immunopositive 
vessels 
The Kruskal-Wallis test showed no significant difference between the free-floating and the 
stationary methods in the total number of vessels immunopositive for VEGF at any timepoint 
(p>O.05) (Figure 2.8). 
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2.4.5 location/intensity of immunopositive vessels 
2.4.5.1 Percentage staining for VE-cadherin 
Figure 2.9 shows the percentage of immunopositive vessels in locations 1 and 3 (wholly 
cytoplasmic and wholly junctional locations, respectively) in free-floating and stationary 
methods. 
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Figure 2.9: location of VE-cadherin in immunopositive vessels - free-floating and stationary methods . 
location 2 data not shown as not physiologically relevant. The statistical testing shown here refers to the 
Mann-Whitney U test between relevant groups in the data (n=5), which were only analysed if the Kruskal -
Wall is test had detected a significant difference in the wider groups. a: p<O.05 relative to Oh, 1h, 4h 
stationary method location 1, b: p<O.OS relative to Oh, 1h, 4h stationary method location 3. 
2.4.5.1.1 Percentage staining for VE-cadherin in free -floating method 
At all timepoints, most (::::40-60%) vessels immunopositive for VE-cadherin were grouped in 
location 1 (diffuse immunoreactivity not localised to the junctional space) (dark grey bars in 
Figure 2.9 and Figure 2.lDA, B, D, F), and the fewest (::::5-25%) vessels were in location 3 (beads-
on-a-string VE-cadherin immunoreactivity localised exclusively to the junctional space) (striped 
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bars in Figure 2.9). There was great variation (standard deviation), but no significant difference 
(p>0.05, n=5) was detected using the Kruskal-Wallis test between the various timepoints (Figure 
2.9, dark grey and striped bars). 
2.4.5.1.2 Percentage staining for VE-cadherin in stationary method 
At Oh and 4h most (::55%) vessels immunopositive for VE-cadherin were at location 1 (light grey 
bars in Figure 2.9, Figure 2. lOA, E), whilst at 1h (Figure 2.1OC) most immunopositive vessels 
were almost equally divided between locations 1 and 2 (location 2 not shown in Figure 2.9). At 
these three timepoints (Oh, 1h, and 4h), only about 10% of immunopositive vessels showed 
location 3 (dotted bars in Figure 2.9) immunoreactivity. The 24h timepoint shows a significantly 
different (p<O.Ol, Kruskal-Wallis test, n=5) distribution, with more location 3 ( ~ 3 5 % ) ) and fewest 
location 1 immunoreactivity ( ~ 2 5 % ) , , see Figure 2.9 and Figure 2.10G. Mann-Whitney U test 
subsequently showed that the 24h location 1 and 3 were both significantly different from all 
other groups (Oh, 1h, 4h, Figure 2.9). The variation (standard deviation) in some groups was 
very small (Figure 2.9, light grey and dotted bars). 
2.4.5.1.3 Comparison between free-floating ond stationary methods, VE-cadherin locations 
There were no significant differences between the two methodologies at any timepoint (p>0.05, 
Kruskal-Wallis test, n=5). However, the error bars for the free-floating methodology were very 
large (5.45%-14.17%) compared to the stationary methodology (0.62%-7.29%), see Figure 2.9. 
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Figure 2.10: Representative micrographs of VE-cadherin immunolocalisation in placental 
explants at different timepoints. A: Oh explants show mostly location 1 (asterisks) 
immunoreactivity. B: lh free-floating explants show mostly wholly non-junctional location 1 
(asterisks) immunoreactivity with few wholly junctional location 3 (arrows) immunoreactivity. C: 
lh stationary explants show a similar VE-cadherin profile as lh free-floating explants: mostly 
location 1 (asterisks), with few location 3 (arrows). D: 4h free-floating explants show mostly 
wholly cytosolic (asterisks) VE-cadherin localisation, with few wholly junctional (arrows) 
localisation. E: 4h stationary explants show a similar pattern as the Oh and lh explants, and 4h 
free-floating explants. F: 24h free-floating explants show more location 3 (arrows) 
immunoreactivity than the other free-floating groups, although the difference was not significant 
(variation not shown). G: 24h stationary explants (high magnification) showing significantly 
fewer vessels with wholly cytosolic VE-cadherin (asterisks) and significantly more vessels with 
wholly junctional (arrows) VE-cadherin. In short, all timepoints exhibit a similar profile, except 
the 24h timepoint, which displays more junctional VE-cadherin (arrows). The variation between 
explants is not shown here, but is shown in Figure 2.9. Arrows: VE-cadherin location 3 
immunoreactivity, asterisks: VEGF negative vessels. Magnification: x200. Scale bar: 100um. 
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2.4.5.2 Percentage staining for VEGF 
Figure 2.11 shows the percentage of immunopositive vessels showing intensity 1, 2 and 3 
immunoreactivity in free-floating and stationary methods. 
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Figure 2.11: Intensity of VEGF immunopositive vessels - free-floating and stationary methods. The 
statistical testing shown here refers to the Mann-Whitney U test between relevant groups in the data 
(n=5), which were only analysed if the Kruskal -Wallis test had detected a significant difference in the 
wider groups. a: p<O.OS relative to Oh intensity 1, b: p<O.OS relative to 4h free-floating intensity 1, c: 
p<O.Ol relative to Oh intensity 3, d: p<O.Ol relative to 4h free-floating intensity 3. 
2.4.5.2.1 Percentage staining (or VEGF in free-floating method 
At Oh, 1h and 24h, most (;::;45-60%) of vessels immunopositive for VEGF were grouped in 
intensity 1 (dark grey bars in Figure 2.11, and Figure 2.12A, B, F), and the fewest (;::;5-15%) 
immunopositive vessels were in intensity 3 (striped bars in Figure 2.11). At 4h, the 
immunopositive vessels were almost evenly distributed among the three intensity levels (Figure 
2.11 and Figure 2.120); there was a significant difference between Oh and 4h at intensities 1 
and 3 (p<O.05 and p<O.Ol, respectively, Mann-Whitney U test, n=5) . There was no significant 
98 
difference (p>0.05, Mann-Whitney U test, n=5) between any other timepoints, perhaps due to 
the great variation (standard deviation) in some groups, especially at the 4h timepoint (Figure 
2.11, dark grey, black and striped bars). 
2.4.5.2.2 Percentage staining for VEGF in stationary method 
At all timepoints, most (::::60-70%) vessels immunopositive for VEGF were grouped in intensity 1 
(light grey bars in Figure 2.11, Figure 2.12A, C, E, G), and the fewest (::::5-10%) vessels were in 
intensity 3 (dotted bars in Figure 2.11). Using the Kruskal-Wallis test, there was no significant 
difference between any of the timepoints (p>0.05, n=5) There was a relatively small variation 
(standard deviation) in all groups (Figure 2.11, light grey, white and dotted bars). 
2.4.5.2.3 Comparison between free-floating and stationary, VEGF intensity levels 
There was a significant difference at the 4h timepoint both in intensity 1 (p<0.05, dark grey and 
light grey bars in Figure 2.11) and intensity 3 (p<0.05, Mann-Whitney U test, n=5; striped and 
dotted bars in Figure 2.11, Figure 2.12D, E). In addition, the error bars for the free-floating 
methodology were very large (1.32%-18.33%, dark grey, black and striped bars in Figure 2.11) 
compared to the stationary methodology (1.89%-5.74%, light grey, white, and dotted bars in 
Figure 2.11). 
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Figure 2.12: Representative micrographs of VEGF immunoreactivity in placental explants at 
different timepoints. A: Oh explants showing intensity 1 and 2 VEGF immunoreactivity. B: 1h 
free-floating explants showing mostly vessels at intensity 1 and 2, with few vessels at intensity 3, 
C: 1h stationary explants showing mostly intensity 1 and 2 VEGF immunoreactivity, D: 4h 
free-floating explants showing an even distribution between intensity 1, 2, and 3 VEGF 
immunopositive vessels, E: 4h stationary explants, showing vessels with mostly intensity 1 and 2 
VEGF, F: 24h free-floating explants showing a similar profile to 1h free-floating explants, G: 24h 
stationary explants showing a similar profile to Oh, 1h, and 4h stationary explants. In short, the 4h 
free-floating group shows a higher intensity of VEGF immunoreactivity than all the other groups, 
which show similar profiles between them. 1: Intensity 1 immunopositive vessels, 2: Intensity 2 
immunopositive vessels, 3: intensity 3 immunopositive vessels. Magnification: x200. Scale bar: 
100um. 
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2.S Discussion 
2.S.1 Summary of results 
In all freshly cut explants (Oh), the junctional integrity marker VE-cadherin was present in about 
60% of vessels (Figure 2.7). In both the free-floating methodology and the stationary 
methodology, there were no significant differences between any groups. 
For VE-cadherin, the variation in the free-floating groups, in both total number of vessels and 
the location of staining, is higher than in the stationary groups. In the localisation of 
immunoreactivity analysis, free-floating and stationary methodologies gave about the same 
number of vessels in each location (Figure 2.9). 
For VEGF, an important molecule for the processes of increased permeability and angiogenesis, 
there are about 45% VEGF immunopositive vessels at Oh (pre-incubation). In the free-floating 
methodology, there was a difference between Oh and 1h, but no further difference between 
any other groups (Figure 2.8). Therefore, the 1h timepoint is unusable for further experiments 
The intensity of staining in the free-floating methodology also showed a big intra-group 
variation, as shown by the standard deviation. Following the stationary methodology, in 
contrast, there was no significant difference between the various groups and the Oh control, 
and the intra-group variation was lower (Figure 2.11). 
Therefore, the best methodology to use for our subsequent glucose studies on explants 
(Chapters 3 and 4) is the stationary methodology. 
2.5.2 Context of our explant culture validation 
In our explant studies, the endothelium was the main and exclusive focus. In contrast, most 
other explants studies currently in the literature focus exclusively on the trophoblast. This 
limited our approach, whereby quantitative techniques currently used in molecular biology, 
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such as Western blotting and enzyme-linked immunosorbent assay (ELISA), which would 
present global data (trophoblast and endothelium) could not be used. As the endothelium 
represents a relatively minor percentage of the total explant, the results from these techniques 
would not be a true representation of the endothelium. The trophoblast, in comparison, 
represents a bigger percentage of the total mass of the explants, and thus, the results from 
quantitative techniques give a better description of the trophoblast. In this thesis we have 
instead used a pseudo-quantitative technique, by counting immunopositive vessels following 
immunofluorescence, to attempt to quantify our results. 
The total number of VEGF immunoreactive vessels is around 45% at Oh (Figure 2.8). Explants 
which were fixed before being cut showed the expected profile of high VE-cadherin and low 
VEGF (Figure 2.6e-D), but their usefulness was hampered by the excessive blood found in the 
vessels (Figure 2.6A-8) as a result of less effective washing of whole cotyledons as opposed to 
individual explants, and therefore more repeats were not performed. These experiments 
revealed that excision prior to fixation might be resulting in increased VEGF; nevertheless, more 
repeats would be necessary to confirm this. 
In the free-floating vessels, the number of vessels VEGF immunopositive increased from 45% at 
Oh to a maximum of around 63% at the Ih timepoint, before dropping to 54% and 50% at 4h 
and 24h (Figure 2.8). This pattern implies that the explant methodology itself is having an 
effect on the levels of VEGF, and therefore the free-floating methodology is completely 
unusable for experiments concerning VEGF production. However, even if the stationary 
methodology is used, the excision artefacts are still present, but seem to be less prevalent and 
more stable, and therefore more suitable for VEGF studies. 
In addition, measuring the intensity of staining has an inherent flaw, as it only shows vessels 
which have already been shown to express VEGF, and not vessels which are affected due to 
duration of culture. Therefore, the results from analysing the intensity levels can only tell us 
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how a test condition affects the excision artefacts of the placental vessels, and not how it would 
affect the vessels in vivo. 
This explant validation should serve as a warning for other laboratories working with explants. 
Anybody using them should always validate the explant methodology, showing how the 
technique itself affects the molecule that is being analysed, for the time point chosen. In 
particular, the effect of the methodology on molecules known to be expressed during wound 
healing, such as cytokines, should be analysed. 
For our experiments, due to the nature of the research question (whether high glucose is able 
to have an effect with acute 4h insults) we expect to have small changes to the vascular 
expression of VEGF-A splice variants and junctional integrity; having a large variation, therefore, 
is not appropriate, even if it may be a more physiological environment. Therefore the free-
floating methodology could not be used for our purpose, and the stationary methodology was 
chosen. 
An unexpected result was the presence of VEGF in the Oh (pre-incubation) explants (Figure 
2.12A). As explained in section 2.1.3.1, Sokolov et 01. (2008) had used Oh explants in their 
methodology, and found only 3.11% of syncytiotrophoblast and endothelium immunopositive 
for VEGF, as compared to our :::::45%. Unfortunately, in their paper, there is not enough detail in 
the Methods section to reproduce their methodology. The authors only state that they fixed 
their explants in formalin and embedded their explants in paraffin prior to their 
immunohistochemical analysis. The difference in VEGF localisation may be due to the authors 
excising their explants after fixation, therefore eliminating the wounding that our tissue 
experienced. Additionally, and more importantly, the paraffin step with high temperatures 
used by Sokolov et 01. (2008) may have induced antigen denaturing, which is not experienced in 
frozen histochemistry protocols (as our experiments used). 
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Although the explant methodology is not perfect, it has several useful characteristics. It allows 
for long duration experiments which would be impossible with a perfusion technique. It is a 
relatively inexpensive methodology, and allows for easy manipulation of the media in which the 
explants are incubated. The stationary method provides a substantial improvement to the free-
floating methodology for our experiments, as it gives the least variation in VE-cadherin 
immunoreactivity and in intensity of staining throughout the experiment for VEGF, and is thus 
the chosen methodology for further experiments. 
With respect to Miller's criteria for acceptable explants cultures (Miller et 01., 2005), the 
stationary methodology fits consistency, as the variation is not too great, and generalisation, as 
this methodology can be compared to others easily. It also partially fits the criteria of validity, 
as the placental explants experience excision artefacts just as any 'living' system would if it 
were excised from its organ. We have also tried to maximise applicability; however, we felt 
that the benefits from having an oxygenated environment (see section 2.1.3.1) and having a 
stationary media instead of replicating flow, thereby deviating somewhat from mimicking the in 
vivo situation, were essential for answering our research question investigating the effects of 
glucose on VEGF expression. 
2.5.3 Shear stress in free-floating explants 
In the free-floating methodology, we tried to simulate the in vivo environment of flow over the 
explants. However, we observed a very high variation in the number of vessels expressing VEGF 
and junctional localisation of VE-cadherin. 
Endothelial cells are reported to adapt very quickly to shear stress and not lose functionality 
(Davies, 1997). However, it has been observed in vitro that individual endothelial cells react 
with a large variation to various stimuli, as there is heterogeneity in shear stress distribution, 
and there are large variations between cells of average cell stress concentration. There is 
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variation in the location of flow sensing structures on endothelial cells, which are involved in 
the sensitivity of the response to flow, and therefore the stress concentration is different in 
different parts of the same cell, leading to different responses to flow in different cells (Davies 
et 01., 1995). The difference in response between endothelial cells has been shown in both 
acute and chronic responses. As an example of the former, some endothelial cells in a 
monolayer and in vivo had a strong intracellular calcium mobilisation, a key cellular mechanism 
for initiating changes in response to flow and to shear stress, whilst others needed a much 
greater increase in flow to achieve the same end result (Falcone et 01., 1993). Chronically, it has 
been shown that gene induction of vascular cell adhesion molecule-l (VCAM-1) protein, an 
inflammatory molecule, is heterogeneous in decreased shear stress in rabbit arteries (Walpola 
et 01., 1995). 
These studies help explain our large variability in the free-floating methodology; there was an 
overall response and adaptation to changes in flow and shear stress, but this adaptation 
showed variability within explants. Also, in our model, the explants were subjected to a 
uniform flow, but whether this was physiologically accurate and recreated the in vivo direction 
offlow is unknown. 
A reason why there is an increase in VEGF at 1h in the free-floating methodology could be that 
following the excision procedure the endothelium is not intact. The adaptability of the 
endothelium to shear stress requires intact endothelium, and therefore the wound healing 
effect that we are observing might worsen the variability and effects to the flow that we have 
observed. 
The variation in the various groups (standard deviation) was very high in the free-floating 
methodology, more than in the stationary methodology, especially regarding the intensity 
levels (Figures 2.9 and 2.11). This might be related to the individual placentae reacting to the 
rolling agitation inherent in the free-floating technique. Whilst this methodology was used to 
simulate flow, an unexpected result of the explants culture (the excision artefacts mentioned in 
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section 2.5.2) meant that the explants were subjected to a non-physiological wounding effect, 
as in vivo the placenta may be less likely to experience severe wound healing in normal 
pregnancies. The resulting wounded explants might therefore be unable to withstand the 
stresses of flow when subjected to it in the free-floating methodology. That the increased VEGF 
was due to the excision process was shown by its absence in the qualitative analysis of the 
'fixation before excision' results (section 2.4.3 and Figure 2.6D). 
Normal placental tissue (non-wounded) from different individuals might respond very similarly 
to physiological and pathological environment (hence the perfusion model being a very suitable 
model for experimentation in the environment of the placenta). However, once a tissue is 
injured in a situation that would not normally occur in vivo, intrinsic differences in individual 
placentae might become more obvious, affecting the results. 
2.5.4 Excision artefacts and 'wound response' 
Although it is better than the free-floating methodology, as it has less variation, the stationary 
methodology still has some problems to consider whilst using it, the main one being the 
explants' high VEGF and low VE-cadherin immunoreactivity. In previous studies, VE-cadherin in 
the endothelium of perfusion-fixed placentae reached about 90% of total vessels (Babawale et 
01., 2000; leach et 01., 2004). In our explant model, this percentage at Oh (pre-incubation) is 
around 60%. This difference can be explained by the initial cutting of the placentae to excise 
the explants, whilst the perfUSion-fixed placentae are not cut prior to fixation. The cutting 
might thus have created an inflammation at the site of the 'wound', which the tissue tries to 
respond to with a wound healing response. VE-cadherin delocalisation from the endothelial 
junctional space is a feature of inflammation in vessel remodelling and wound healing 
(Albuquerque and Flozak, 2002), as is VEGF upregulation in the vessels affected by wounding. 
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The main factor altering 'wound healing' in our explants compared to in vivo wounds is the lack 
of blood in the explants, as all blood is washed off immediately after excision. Therefore, there 
is no coagulation cascade (for a review describing the coagulation cascade and the classic 
wound healing process, see Clark (1993)), as there are no platelets, neutrophils or monocytes in 
placental tissue. Macrophages are present in the villous mesenchyme (Hofbauer cells) and 
recently they have been shown to play a role in trophoblast differentiation, mesenchyme 
development, and importantly, gestational inflammatory responses (Tang et al., 2011); 
however, in our explant model, the mesenchyme did not seem to be involved, and it was the 
endothelium that showed VEGF immunoreactivity. 
If an adapted wound healing process is responsible for the high VEGF seen in our explants, what 
is the mechanism in the endothelium of our explants? Clues to this question are found in 
endothelial cell culture models that test wound healing, as in this model there is no blood 
involved either. 
In cell culture, wounding and subsequent healing is most often replicated by scratching a 
pipette tip on an endothelial monolayer, creating a linear area devoid of any cells. Another 
methodology is to freeze an area of a monolayer, and this again creates an area without any 
cells. The repopulation of endothelial cells into the empty area is then monitored. Using these 
techniques, it was shown that there is an increase in DNA transcription to lead to cell migration; 
this was seen in cells close to the margin of the 'wound' but not those elsewhere. By 10h, 
expression of endothelin-1 (ET-1), an indicator of endothelial proliferation, was already 
prevalent, and therefore VEGF might be present as well. Endothelial cells migrate into the 
wound by 24h, and express molecules such as VEGF and ET-1, indicators of endothelial 
proliferation (Akimoto et al., 2002). Wound healing then continues for days after the wound 
was created. 
In our explant model, we observed endothelial VEGF production early in wound healing, being 
present even at time Oh immediately after the creation of the wound in normal tissue. This is 
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similar to the situation observed in cell culture, and might occur because there are no blood 
constituents which take over the initial wound healing response and inflammation in vivo. 
However, our explant model shows differences from wound healing in endothelial cell culture, 
as the endothelial production of VEGF and VE-cadherin disappearance from the junctions 
(indicative of wound healing processes) seems to decrease in our explants at 24h, instead of the 
continuing wound healing at and after 24h seen in cell culture. We hypothesise that this is 
because in our explants there is the additional 3D chorionic villous architecture which, in the 
absence of the classical wound healing effect seen in vivo involving blood constituents and the 
immune response (macrophages, platelets, fibroblasts etc.), signals to inhibit the wound healing 
response and restore junctional integrity. 
2.5.5 caveats to wounding hypothesis 
Although we hypothesised that wound healing may have caused the higher levels of VEGF seen 
in the explants, other explanations are possible. VEGF is known to be present and be an 
important mediator of endothelial proliferation. Whilst we cannot exclude that this is occurring 
in our explants, we have taken steps in our set-up to try to minimise this risk. We have placed 
the explants in metal nets, allowing the tissue to be freely suspended in the media, without an 
extracellular matrix containing collagen I or fibrin, which introduces an oxygen gradient and 
induces in vitro endothelial cell proliferation (Bocci et 01., 2001; Cenni et 01., 2011). Perhaps the 
best evidence that our explants are unlikely to be undergoing proliferation is the lack of any 
oxygen gradient. Proliferation and angiogenesis are processes that are driven by hypoxia (see 
section 1.1.4), and are inhibited by normoxicjhyperoxic conditions, such as those in which we 
incubated our explants (see section 2.1.3.1). 
Another possibility is that the endothelium is producing VEGF as a survival factor, to prevent 
apoptosis induced by wounding (see section 1.2.1.3). However, VEGF is only a survival factor 
108 
when present at low doses. At higher doses, and in conjunction with TGF-I3, it acts as an 
apoptotic agent in human and bovine cells (Ferrari et al., 2006). Indeed, again in human and 
bovine cells, apoptosis is shown to occur in angiogenesis, where ECs need to be pruned in the 
newly formed vessels (Pollman et al., 1999). We only tested our explants for VEGF, and not 
other cytokines; thus, we are unable to say with certainty whether the VEGF present is acting in 
this instance as a survival factor, or as an inflammatory response. 
Furthermore, both proliferation and anti-apoptosis hypotheses are unable to explain why after 
24h there was a reduction of VEGF present in the endothelium of explants. For proliferation, 
VEGF needs to remain present until the remodelling is completed, and for the pro-survival 
hypothesis, a decrease in VEGF would lead to apoptosis of tissue which was not seen (Figure 
2.4). 
2.5.6 Recovery period 
The temporal pattern of downregulation of VEGF and localisation of VE-cadherin suggest a 24h 
recovery period in the explants in this study. If the 'wound healing' hypothesis is shown to be 
correct, further studies could use the first 24h of culture as a recovery period, and the 
subsequent period for the actual experiments. However, in order for this recovery period to be 
useful, further validation would be needed in order to observe whether there is a plateau in the 
temporal pattern of VEGF and VE-cadherin beyond 24h, to establish whether the recovery 
period is indeed 24h long, or if it is ongoing after this timepoint. 
However, continued incubation beyond 24h was not performed in our study. This, along with 
the caveats to the 'wound healing' hypothesis, negated the usefulness of a recovery period and 
therefore no such period was designed into subsequent chapters. 
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2.6 Summary 
Due to the lower number of VE-cadherin immunopositive vessels at 24h, the intensity of VEGF 
immunopositive vessels at 4h, and the high variation in most of the timepoints, the free-
floating methodology is not suitable for the study of VEGF and VE-cadherin in placental 
explants. 
The stationary methodology is the preferred methodology, but care should be taken to 
consider the excision artefact effect that seems to be a player in this methodology. 
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Chapter 3 
The effect of lSmM glucose on the explant culture: 
analysis of VE-cadherin and VEGF at two different 
timepoints 
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3.1 Introduction 
3.1.1 Effects of glucose on VE-cadherin and VEGF expression 
In Chapter 1, the general effects of hyperglycaemia in the vasculature of the diabetic milieu 
were discussed. This chapter focuses on the effects of high glucose on two molecules 
important for vascular integrity and permeability, namely VEGF and VE-cadherin. 
3.1.1.1 Effects of glucose on VEGF 
Diabetic patients, even those with short duration exposure to the diabetic condition (such as 
children, duration of diabetes 2-4 years), show increased levels of plasma VEGF (Chiarelli et 01., 
2000b). Furthermore, in this study patients who had poor control (defined as an HbA1c level 
higher than 86mmol/mol) had significantly higher VEGF levels than those with lower HbA1c 
levels, indicating that glucose is responsible for this increase. A study by Sorensen et 01. (2005) 
on Type 1 diabetics, comparing 48h of good glycaemic control with poor glucose control, found 
that the good glucose control group (which had a median blood glucose of 6.3mM) had lower 
plasma VEGF concentration than the poor glucose control (median blood glucose: 15.9mM). 
What is remarkable about this paper is that it is a paired study, where each subject examined 
was subjected to both good control and poor control, thereby eliminating individual differences 
between different subjects. 
Possible mechanisms behind this hyperglycaemia-induced VEGF increase have been studied. 
One of the major players in VEGF actions is NO. VEGF action is normally coupled with NO, and 
when acting together, endothelial cell structure and function is maintained. When VEGF 
increases, NO is produced, which then feeds back to decrease VEGF production. However, 
although VEGF is increased in diabetes, NO is decreased. That this uncoupling occurs is shown 
in a study by Nakagawa et 01. (2006), where it was found that 30mM glucose for 24h inhibited 
NO production in response to VEGF in bovine arterial endothelial cells and that proliferation 
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was increased in these cells under these conditions, compared to a SmM glucose control; the 
presence of an exogenous NO donor blocked this proliferation. VEGF's effects on proliferation 
upon uncoupling of VEGF-NO were mediated by the activation of MAPK1/3 by the VEGFR-2 
receptor (Nakagawa et 01., 2006), whilst inhibition of VEGFR-1 signalling can account for the 
decreased NO production (Ahmad et 01., 2006; Bussolati et 01., 2001). Nakagawa (2007) 
explains in his review that there are several mechanisms by which high glucose might impair NO 
production, including inhibition of eNOS activation, scavenging of NO by glucose itself, and 
quenching of NO to form peroxynitrate by oxidative stress mechanisms. 
Another study which links oxidative stress to high glucose production of VEGF was conducted 
by Chen et 01. (2004). In this study, incubation of HUVECs with 2SmM glucose for 24h caused 
the upregulation of haeme oxygenase (HO), a marker of oxidative stress. HO activity then 
increased VEGF mRNA, and this VEGF increase was partly blocked by an HO inhibitor. However, 
this paper found that there is an increase of eNOS activity, as opposed to a decrease. Although 
these studies have different findings regarding NO production, they are in agreement regarding 
glucose increasing VEGF expression. 
TGF-J32 has been shown to have different effects on VEGF production depending on glucose 
concentration: after 5 days euglycaemic (S.5mM glucose) incubation, human retinal pericytes 
exposed to 0.1ng/ml TGF-132 significantly increased VEGF expression, and exposing to 1ng/ml 
and higher concentrations of TGF-J32 decreased VEGF expression compared to no TGFJ32 
exposure, whilst incubation under 18mM glucose indicated no significant difference in VEGF 
expression between no TGF132 and any TGF-132 concentrations (Vidro et 01., 2008). Importantly, 
TGF-132 has been shown to be increased in rat models ofType 1 diabetes (Lamers et al., 2007). 
The renin angiotensin aldosterone system (RAS) also seems to be important in the production 
of VEGF under hyperglycaemia (Feliers and Kasinath, 2010). This is a system that regulates 
blood pressure and blood volume, and that produces angiotensin. However, angiotensin's 
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precursor is produced in the liver and cleaved in the lungs and renin is produced in the kidney. 
Thus, this model is only relevant in whole body systems, and not in in vitro placental explants. 
3.1.1.2 Effects of glucose on VE-cadherin 
Although not as much evidence exists for the direct effects of glucose on VE-cadherin as there is 
for VEGF, a limited number of papers have investigated this topic. 
The presence of advanced glycation end products (AGEs) have been shown to disrupt VE-
cadherin junctions. A 3h incubation with bovine serum albumin modified with AGEs has been 
shown to decrease the junctional integrity of HUVECs, and to decrease VE-cadherin protein 
levels (Otero et 01., 2001). However, AGE formation is a long term process, and therefore the 
effects due to AGEs would only manifest themselves after long duration exposures to glucose. 
Shorter-term effects of glucose have shown that VE-cadherin is initially affected by glucose, but 
in the long-term VE-cadherin localisation to the junctions is restored, possibly as an adaptation 
to the altered environment. Maillard and Leach (2002) found that a 2h exposure to high 
glucose (25mM) resulted in significantly more HUVECs with discontinuous VE-cadherin 
junctions; however, there was no difference in total VE-cadherin expression. The VE-cadherin 
localisation to the junctional space was recovered after 2 days under 2SmM glucose insult, 
when there was no longer a significant difference between the cells incubated under 
euglycaemic and hyperglycaemic conditions. 
That longer duration (days as opposed to hours) has no effect on VE-cadherin localisation was 
also confirmed by both Matsui-Hirai et 01. (2011), who found no difference between HUVECs 
incubated under 22mM glucose and those incubated under S.SmM glucose for three days, and 
by Singh et 01. (2011), who found no difference in VE-cadherin localisation and total protein in 
glomerular endothelial cells incubated in 2S.SmM glucose for 2, 7 and 14 days. However, there 
are also contradictory results: Rangasamy et 01. (2011), found that phosphorylated VE-cadherin 
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(found in non-junctional VE-cadherin) is increased in human retinal endothelial cells incubated 
for 72 hours under 30.5mM glucose compared to those incubated under 5.5mM glucose. 
3.1.2 How is 'wound healing' affected by glucose? 
We saw in Chapter 2 (see sections 2.1.3.2 and 2.5.4) that there are excision artefacts 
(decreased junctional VE-cadherin and increased VEGF) in our explants, which might be 
attributed to a wounding response. Therefore, it is important to consider how glucose affects 
this. 
It is well known that in diabetes wound healing is often impaired, leading to chronic conditions 
such as diabetic foot ulcers. These conditions are thought to be a consequence of high glucose 
levels. It has been shown in a study of 63 diabetic patients that ulcer wound healing times were 
significantly longer for patients with higher HbA1c values than in patients with lower HbA1c 
values (Markuson et 01., 2009). High HbA1c values are of course representative of chronic 
hyperglycaemia. 
Our explant culture, however, does not model chronic effects of glucose. It is an acute model, 
where we are exposing the explants to 15mM glucose for only 4 or 24h, and most studies agree 
that the development of complications is due to the chronic effects of glucose, as reviewed by 
Fowler (2008). McMurry (1984) describes the stages of wound healing affected by glucose in 
diabetes, which can be ameliorated by either insulin administration or the reduction of glucose 
levels as: granulocyte phagocytosis, chemotaxis, and killing of bacteria, synthesis of 
protocollagen and collagen, fibroblast proliferation, and capillary ingrowth. Importantly though, 
one study (Weringer et 01., 1981) suggested that, rather than the hyperglycaemia per se causing 
the dysfunction in vessels ingrowth, it was the decreased insulin availability which caused this 
phenotype. Metalloproteinases that are involved in clearing the way for inflammatory 
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molecules in wound healing have also been shown to be affected by 2SmM glucose (Death et 
al.,2003). 
Our acute glucose insult studies described in this chapter may reveal, rather than confound, 
effects of high glucose on post-wounding events. 
3.1.3 Effects of hyperglycaemia on explant cultures 
Hyperglycaemia is a key characteristic of diabetes, and, as detailed in Section 1.3.3.1, has 
effects on the production of VEGF, and thus, on the permeability of the endothelial layer and 
VE-cadherin localisation. We wished to see if we could observe a change in VEGF and VE-
cadherin localisation within a single insult with a mild hyperglycaemic hit (15mM glucose) of 4h 
and 24h duration. The 15mM glucose was chosen as a blood glucose level that is seen in Type 1 
diabetic pregnancies where the mother is exposed to lSmM postprandial glucose for 4h before 
return to normal (Kerssen et al., 2004; Kyne-Grzebalski et al., 1999) (see section 4.1.3 and 
Figure 4.3 for more detail). 
The 4h timepoint, as analysed in Chapter 2, was an ideal short duration timepoint to use. 
Studies conducted on postprandial hyperglycaemia (Gerich, 2003; Fujimoto et al., 2006) 
revealed that glucose can cause fast-acting responses which can be seen from 30 minutes 
onwards. The 4h we chose would allow data collection of any effects of glucose on the 
production of VEGF and localisation of VE-cadherin. 
The 24h timepoint was chosen to represent a single but long duration insult, to observe 
whether a longer insult worsened the phenotype observed at 4h. Cell culture studies have 
revealed that glucose exposure leads to increased VEGF production and VE-cadherin disruption 
(Chen et al., 2004; Nakagawa et al., 2006; Rangasamy et al., 2011); whether chorionic villous 
explants respond similarly requires elucidation. 
116 
In previous literature of glucose studies with human tissue, there has often been an osmolarity 
control in the form of mannitol. We wished to test this 'negative' control to see if it is an 
effective control. We wanted to test this for two reasons. Firstly, the normal range of blood 
osmolarity is 27S-299mOsm/l, the biggest contributor to this value being sodium levels, which 
contribute around 270mOsm/1. The glucose component contributes the same value as its 
concentration in mM (Le., in a normal adult, around 5mM, so it contributes around 5mOsm/l). 
Therefore, adding 10mM glucose, or indeed mannitol, to the media only increases its 
osmolarity by 10mOsm/L, which is a physiologically insignificant addition. Secondly, mannitol 
has long been used in medicine to increase permeability and open up endothelial junctions, 
which is very relevant to our experiment (Infanti, 2008; Hartwell and Sutton, 1993). The 
concentration of mannitol used in these experiments was extremely high (in the molar values), 
and it is assumed that this has an osmotic effect, thus mannitol being used so often as an 
osmotic control. However, mannitol is also an effective oxygen free radicals scavenger, which 
has been shown to have important vascular effects (Fu and Jiao, 1995; Magovern et 01., 1984; 
Paterson et 01., 1989). Therefore, mannitol may not be a good osmotic control in this situation, 
especially at the concentration we are using it, and may indeed have an effect itself and this will 
be examined. 
3.2 Aims and oblectives 
The first aim was to observe whether a short duration (4h) of lSmM glucose insult in chorionic 
villous explants affected the production of VEGF and localisation of VE-cadherin. 
The second aim was to observe whether lSmM glucose for 24h in chorionic villous explants was 
as effective as the long duration hyperglycaemic studies in cell culture models at increasing 
VEGF expression, and whether VE-cadherin junctional integrity remained stable at this 
timepoint. 
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The third aim was to establish whether mannitol was a good osmolarity control for our explants, 
as it is in cell culture methods. 
The fourth aim was to discern whether the excision artefacts observed in Chapter 2 affected 
our results. 
3.3 Methods 
All the materials and methods were as in section 2.3 (with the same donor demographic 
requirements as those outlined in section 2.3.2 and with the exclusion of the free-floating 
methodology), with the following exceptions: 
3.3.1 Explant culture 
The explant culture was performed for 4h and 24h as specified in Chapter 2's 'Stationary 
methodology' (section 2.3.5) (n=5 placentae, 6 explants per timepoint); these made up our 
euglycaemic group. In parallel to these, 6 explants (n=5 placentae) per timepoint were cultured 
in media containing an added lOmM glucose (bringing the total glucose concentration to 15mM 
glucose), and 6 explants per timepoint were cultured in media containing lOmM mannitol. 
3.3.2 Analysis 
As in Chapter 2, total number of vessels immunoreactive to VE-cadherin and VEGF were 
counted. The vessels showing immunoreactivity were then split into three categories. For VE-
cadherin, location 1 was wholly cytoplasmic VE-cadherin, location 2 was partly junctional and 
partly cytoplasmic VE-cadherin, and location 3 was wholly junctional VE-cadherin. 
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For VEGF, counts were made by qualitative scoring of intensity of fluorescence. All scoring was 
performed by a single researcher (myself); furthermore, analysis of each n number was 
performed in a single sitting. Criteria used: intensity 1 was weak immunofluorescence, intensity 
2 was medium immunofluorescence, and intensity 3 was strong immunofluorescence. 
GraphPad Prism version 5.01 statistical software was used to perform Kruskal-Wallis test with 
Mann-Whitney U test between relevant groups. The reasoning behind these statistical tests 
has been discussed in section 2.3.9.1. Unless otherwise specified, all the statistics shown 
throughout Chapter 3 were performed with the Mann-Whitney U test (n=5). Where statistical 
significance is present, this indicates that a previous Kruskal-Wallis test (n=5) had shown a 
significant difference between the wider groups. 
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3.4 Results 
3.4.1 Total number of VE-cadherin and VEGF immunoreactive vessels 
3.4.1.1 VE-cadherin 
In any given group (euglycaemic, hyperglycaemic and mannitol incubations), there were no 
significant differences between either short duration (4h) or long duration (24h) insult in the 
number of vessels showing VE-cadherin immunoreactivity (Figure 3.1). The mannitol group 
always revealed a significantly lower number (p<O.Ol for euglycaemia and p<O.OS for 
hyperglycaemia) of VE-cadherin immunopositive vessels (Figure 3.1). However, intra-
experimental differences were not found between the glycaemic groups (p>O.OS). 
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Figure 3.1: Percentage of vessels showing VE-cadherin immunoreactivity at 4h and 24h. The statistical 
testing shown here refers to the Mann-Whitney U test between relevant groups in the data (n=5), which 
were only analysed if the Kruskal-Wallis test had detected a significant difference in the wider groups. 
a: p<O.Ol relative to euglycaemia, b: p<O.05 relative to hyperglycaemia. 
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3.4.1.2 VECiF 
The number of vessels showing VECiF immunoreactivity did not differ (p>O.OS, Kruska l-Walli s 
test, n=S) between experimental groups or duration of insult (Figure 3.2) . 
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Figure 3.2: Percentage of vessels showing VEGF immunoreactivity at 4h and 24h. No significant 
differences were detected between any of the groups (p>O.OS, Kruskal-Wallis test, n=S). 
3.4.2 Location of VE-cadherin in immunopositive vessels 
3.4.2.1 4h duration 
At 4h, there were significantly more wholly cytoplasmic (non-junctional) VE-cadherin 
immunoreactive (location 1) vessels in euglycaemic conditions than in hyperglycaemic 
conditions (p<O.OS) (Figure 3.3), whilst the number of vessels showing exclusively junctional VE-
cadherin immunolocalisation (location 3) in the euglycaemic (Figure 3.48) and hyperglycaemic 
(Figure 3.4C) groups was not significantly different (p>O.OS) (Figure 3.3). 
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The number of vessels in the mannitol group (Figure 3.40) showing wholly cytoplasmic 
localisation (location 1) of VE-cadherin was significantly lower than that in the euglycaemic 
group (p<O.01), and there were also significantly more vessels (p<O.05) showing wholly 
junctional (locat"lon 3) VE-cadherin immunoreact"lvity in the mannitol (FIgure 3.40) group 
compared to the euglycaemic (Figure 3.4B) group (Figure 3.3). 
Analysis of hyperglycaemic vs. mannitol groups also revealed that the mannitol group had a 
significantly lower number of vessels (p<O.05) showing immunoreactivity at location 1; however, 
there was no significant difference between the hyperglycaemic and mannitol group in wholly 
junctional VE-cadherin immunolocalisation (location 3) (p>O.05). 
At the 4h timepoint, therefore, the pattern of junctional localisation is as in the following 
schematic: 
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Figure 3.3: Effect of 4h 15mM glucose insult on VE-cadherin immunolocalisation . The statistica l test ing 
shown here refers to the Mann-Whitney U test between relevant groups in the data (n=5), which were 
only analysed if the Kruskal-Wallis test had detected a significant difference in the wider groups. 
a: p<O.05 relative to 5mM glucose location 1, b: p<O.01 relative to 5mM glucose location 1, c: p<O.OS 
relative to 15mM glucose location 1, d: p<O.OS relative to 5mM location 3. 
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Figure 3.4: Representative micrographs of VE-cadherin immunoreactivity after 4h incubation. A: 
negative control showing no non-specific immunoreactivity. B: SmM glucose explants showing more 
vessels with location 1 VE-cadherin immunoreactivity than both other groups (C and 0), and fewer 
location 3 VE-cadherin immunoreactivity than the mannitol group (0). C: lSmM glucose explants 
showing fewer location 1 VE-cadherin immunoreactivity than the euglycaemic group (B) but more 
than the mannitol group (0). 0: mannitol explants showing fewer vessels in location 1 
immunoreactivity than both other groups (8 and C), but more location 3 VE-cadherin 
immunoreactivity than the euglycaemic group (B) . Neg: negative control, Eu : euglycaemia, Hy: 
hyperglycaemia, Man: mannitol, 1: VE-cadherin location 1, 2: VE-cadherin location 2, 3: VE-cadherin 
location 3 immunoreactivity. Magnification: x200. Scale bar: SOum. 
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3.4.2.2 24h duration 
After 24h culture in hyperglycaemia, there were significantly higher numbers of vessels with 
wholly cytoplasmic VE-cadherin immunolocalisation (location 1) compared to the 24h 
euglycaemic group (p<O.05) (Figure 3.5). Junctional expression of VE-cadherin was also 
downregulated in hyperglycaemia; there were significantly more exclusively junctional (location 
3) VE-cadherin immunolocalisation in the euglycaemic (Figure 3.6B) group than in the 
hyperglycaemic (Figure 3.6C) group (p<O.05) (Figure 3.5). 
Mannitol (Figure 3.60) insult resulted in significantly more vessels showing exclusively 
cytoplasmic VE-cadherin immunolocalisation than the euglycaemic group (p<O.01); conversely, 
there were significantly more vessels with wholly junctional (location 3) VE-cadherin 
immunolocalisation in the euglycaemic group compared to the mannitol group (p<O.01). 
Comparison of hyperglycaemia with mannitol revealed no significant difference in the number 
of vessels showing wholly non-junctional (location 1) immunolocalisation (p>O.05); however, 
there was a significant difference in the number of vessels showing wholly junctional (location 3) 
VE-cadherin immunolocalisation, with the hyperglycaemic group having more vessels than the 
mannitol group at this location (p<O.05) (Figures 3.5). 
At the 24h timepoint, therefore, the pattern of junctional localisation is as in the following 
schematic: 
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VE-cadherin ••••••••••••••••••••• p ..... VE-cadherin 
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Figure 3.5: Effect of 24h 1SmM glucose insult on VE-cadherin immunolocalisation . The statistical testing 
shown here refers to the Mann-Whitney U test between relevant groups in the data (n=S ), which were 
only analysed if the Kruskal-Wallis test had detected a significant difference in the wider groups. 
a: p<O.OS relative to SmM glucose location 1, b: p<O.01 relative to SmM glucose location 1, c: p<O.OS 
relative to SmM glucose location 3, d: p<O.01 relative to SmM glucose location 3, e: p<O.OS relative to 
1SmM glucose location 3. 
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Figure 3.6: Representative micrographs of VE-cadherin immunoreactivity after 24h incubation . A: 
negative control showing no non-specific immunoreactivity, B: explants incubated in SmM glucose 
showing location 2 and 3 VE-cadherin, C: explants incubated in lSmM glucose showing more wholly 
non-junctional vessels (location 1) and fewer wholly junctional (location 3) vessels than the 
euglycaemic group (B), but more location 3 VE-cadherin immunoreactivity than the mannitol group. 
0: explants incubated in mannitol, showing more wholly non-junctional (location 1) but fewer wholly 
junctional VE-cadherin immunoreactivity than both other groups (B and C). Neg: negative control, Eu : 
euglycaemia, Hy: hyperglycaemia, Man: mannitol, 1: location 1 immunoreactive vessels, 2: location 
2 immunoreactive vessels, 3: location 3 immunoreactive vessels . Magnification: x200. Scale bar 
100um. 
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3.4.3 Intensity of VEGF immunofluorescence 
3.4.3.1 4h duration 
At 4h, there was no significant difference between the VEGF immunoreactivity of euglycaemic 
and hyperglycaemic groups for any intensity level (p>O.OS) (Figure 3.7). 
There was a difference in VEGF immunoreactivity between the euglycaemic (Figure 3.8B) and 
mannitol (Figure 3.80) groups, where there were fewer vessels grouped in intensity 1 (p<O.OS), 
more vessels in intensity 2 (p<O.OS) but no significant difference in intensity 3 (p>O.OS), in the 
mannitol group compared to the euglycaemic group. 
Comparing the mannitol group with the hyperglycaemic (Figure 3.8C) group also revealed 
differences, with the mannitol group showing significantly fewer vessels grouped in intensity 1 
(p<O.OS) and more vessels in intensity 2 (p<O.OS) immunoreactivity, whilst no significant 
difference was seen between these two groups in intensity 3 (p>O.OS) (Figure 3.7). 
At the 4h timepoint, therefore, the pattern of junctional immunoreactivity is as in the following 
schematic: 
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Figure 3.7: Effect of 4h 1SmM glucose insult on VEGF intensity levels . The statistical testing shown here 
refers to the Mann-Whitney U test between relevant groups in the data (n=5), which were only analysed 
if the Kruskal-Wallis test had detected a significant difference in the wider groups. a: p<O.OS relative to 
SmM glucose and 1SmM glucose intensity 1, b: p<O.OS relative to SmM glucose and 15mM glucose 
intensity 2. 
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Figure 3.8: Representative micrographs of VEGF immunoreactivity following 4h incubation. A: 
negative control showing no non-specific immunoreactivity, 6: explants incubated in SmM glucose 
media showing most VEGF immunopositive vessels with intensity 1 immunoreactivity. C: explants 
incubated in lSmM glucose media showing more vessels with VEGF intensity 1 and fewer with VEGF 
intensity 2 than the mannitol group (0). 0: explants incubated in mannitol media showing fewer 
vessels with intensity 1 and more vessels with intensity 2 than both euglycaemic (6) and 
hyperglycaemic (e) groups. Neg: negative control, Eu: euglycaemia, Hy: hyperglycaemia, Man: 
mannitol, 1: intensity 1 VEGF immunopositive vessels, 2: intensity 2 VEGF immunopositive vessels, 
3: intensity 3 VEGF immunopositive vessels. Magnification: x200. Scale bar: 100um. 
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3.4.3.2 24h duration 
At 24h, there was a significant difference between the euglycaemic and hyperglycaemic groups, 
with the hyperglycaemic group showing a significantly lower percentage of vessels with 
intensity 1 VEGF immunoreactivity (p<O.05) and significantly higher percentage of vessels with 
intensity 3 VEGF immunoreactivity (p<O.Ol) compared to the euglycaemic group, whilst there 
was no significant difference in intensity 2 between these two groups (p>O.05) (Figure 3.9). 
There was a significant difference between the euglycaemic (Figure 3.lOB) and mannitol (Figure 
3.lOD) groups, with significantly fewer vessels showing intensity 1 (p<O.05) VEGF 
immunoreactivity in the mannitol group, but no significant differences in the number of vessels 
showing intensity 2 and intensity 3 (both p>O.05) VEGF immunoreactivity. 
The hyperglycaemic (Figure 3.10C) and mannitol groups showed a significant difference in the 
number of vessels showing intensity 3 VEGF immunoreactivity (p<O.OS), but no significant 
difference in intensities 1 and 2 (both p>O.OS) (Figure 3.9). 
At the 24h timepoint, therefore, the pattern of VEGF immunoreactivity is as in the following 
schematic: 
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Figure 3.9: Effect of 24h lSmM glucose insult on VEGF intensity levels. The statistical testing shown here 
refers to the Mann-Whitney U test between relevant groups in the data (n=S), which were only analysed 
if the Kruskal-Wallis test had detected a significant difference in the wider groups. a: p<O.OS relative to 
SmM glucose intensity 1, b: p<O.01 relative to SmM glucose intensity 3, c: p<O.OS relative to lSmM 
glucose intensity 3. 
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Figure 3.10: Representative micrographs of VEGF immunoreactivity following 24h incubation. A: 
negative control showing no non-specific immunoreactivity, B: explants incubated in SmM glucose 
media showing mostly intensity 1 VEGF immunoreactivity. C: explants incubated in lSmM glucose 
media showing fewer VEGF intensity 1 vessels than the euglycaemic group (6) but more VEGF intensity 
3 vessels than both euglycaemic (B) and mannitol (D) groups. D: explants incubated in mannitol media 
showing fewer VEGF intensity1 and more VEGF intensity 3 vessels than the euglycaemic group (B), and 
fewer VEGF intenSity 3 vessels than the hyperglycaemic group (C) . Neg: negative control, Eu : 
euglycaemia, Hy: hyperglycaemia, Man: mannitol, 1: intensity 1 VEGF immunoreactivity, 2: intensity 2 
VEGF immunoreactivity, 3: intensity 3 VEGF immunoreactivity. Magnification: x200. Scale bar: 100um. 
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3.5 Discussion 
3.5.1 Summary of results 
There was no significant difference (p>O.OS) in the total number of VE-cadherin (Figure 3.1) and 
VEGF (Figure 3.2) immunopositive vessels between 5 and lSmM glucose at 4h. However, the 
mannitol osmolarity 'control' showed significantly fewer vessels immunopositive for VE-
cadherin (p<O.Ol for mannitol vs. euglycaemia and p<O.OS for mannitol vs. hyperglycaemia, 
Figure 3.1), which indicates that mannitol was having a non-osmotic effect, possibly affecting 
the excision artefacts. 
A metabolic effect of mannitol is also seen in the localisation analysis. The location data reveal 
that not only is mannitol affecting the number of vessels immunopositive for VE-cadherin, it is 
also changing the junctional localisation of VE-cadherin, as more vessels have the 'beads on a 
string' pattern of immunolocalisation characteristic of junctional VE-cadherin (location 3) at 4h 
than the euglycaemic control (p<O.OS), but not the hyperglycaemic group (p>O.OS). However, 
when looking at wholly non-junctional VE-cadherin (location 1) there was a significant 
difference (p<O.OS between euglycaemic vs. hyperglycaemic and hyperglycaemic vs. mannitol, 
and p<O.Ol between euglycaemic vs. mannitol) between all groups, revealing the VE-cadherin 
junctional profile of the high glucose group to be intermediate between the euglycaemic group 
and the mannitol group (Figures 3.3-3.4). Mannitol was also having a non-osmotic effect on 
VEGF at 4h, as there were fewer intensity 1 vessels in the mannitol group compared to both 
euglycaemic (p<O.OS) and hyperglycaemic (p<O.OS) groups. There were no significant 
differences (p>O.OS) in the intensity levels between euglycaemic and hyperglycaemic groups at 
4h for VEGF (Figures 3.7-3.8). 
At 24h, there was no significant difference (p>O.OS) in total number of vessels immunoreactive 
to either VE-cadherin (Figure 3.1) or VEGF (Figure 3.2) between SmM glucose and lSmM 
glucose, whilst the mannitol group had significantly fewer (p<O.Ol and p<O.OS respectively) VE-
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cadherin immunopositive vessels, indicative of a non-osmotic effect on wound healing. 
However, there were significantly fewer vessels (p<0.05) showing 'beads on a string' VE-
cadherin immunolocalisation (location 3) in hyperglycaemic compared to euglycaemic 
conditions; the mannitol incubation had significantly fewer vessels (p<O.Ol compared to 
euglycaemia and p<0.05 compared to hyperglycaemia) showing wholly junctional VE-cadherin 
than either of the other groups (Figures 3.5-3.6). VEGF intensity levels revealed that the 
hyperglycaemic group had a significantly higher number of vessels at the highest intensity level 
(intensity 3) than both other groups (p<O.Ol vs. euglycaemia and p<0.05 vs. mannitol), 
indicating a higher expression ofVEGF in hyperglycaemia (Figures 3.9-3.10). 
Not taking into consideration the mannitol 'control', VE-cadherin location in the hyperglycaemic 
group was significantly different from the euglycaemic group at both 4h (p<0.05 for location 1, 
Figures 3.3 and 3.4B-C) and at 24h (p<0.05 for location 1 and p<O.Ol for location 3, Figures 3.5 
and 3.6B-C). The percentage of vessels showing intensity 1 and intensity 3 VEGF 
immunoreactivity was significantly different between euglycaemic and hyperglycaemic groups 
at 24h (p<0.05 for intensity 1 and p<O.Ol for intensity 3, Figures 3.9 and 3.10B-C) but not at 4h 
(p>O.05, Figures 3.7 and 3.8B-C). 
3.5.2 Effect of short duration glycaemic insult 
These studies show that at 4h there was no significant difference in the number of vessels 
showing VEGF immunoreactivity, neither in the total number of vessels nor in the intensity of 
surface expression. One such short duration of hyperglycaemic insult appears not to be 
sufficient to cause disturbances in vascular VEGF expression. This observation agrees well with 
the induced VE-cadherin dynamics seen in these explant studies. Immediately after excision (as 
seen in Chapter 2), 7-8% of vessels showed exclusively junctional VE-cadherin (Figure 2.9). 
After 4h in solution, the percentages remained similar for euglycaemia (9%) but were higher 
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(19%) in the presence of lSmM glucose (Figure 3.3). The lack of VEGF response could go 
somewhat to explain this phenomena; increases here would lead to a reduction in junctional 
occupancy of VE-cadherin (Underwood et 01., 2002; Esser et 01., 1998). The data suggests lSmM 
glucose may even be playing a protective role in the early post-wound stages; however, the 
validity of this hypothesis and the factors involved remain to be investigated. 
In diabetic patients, the usual timecourse of postprandial increases in glucose levels lasts for 3-
4h, which then reverts down to more acceptable levels until the next meal, when the blood 
glucose increases again (see Chapter 4, Figure 4.3). The only case where this would not be true 
would be if there were undiagnosed diabetes without treatment. Therefore any study that 
extends for a longer time period (over 24h) would be relevant to undiagnosed diabetics, who 
might be subject to prolonged periods of hyperglycaemia, but not pregnant women, who are 
tested for gestational diabetes in their pregnancy if at risk. Pregnant women are thought to be 
more diligent in their insulin regime than their non-pregnant counterparts (Kyne-Grzebalski et 
01., 1999), but as their glucose homeostasis changes throughout the pregnancy, there are times 
where their blood glucose may rise above acceptable limits, until they realise this fact and they 
change their insulin regime. 
The 4h timepoint is very important physiologically, and therefore we have continued to use it in 
this thesis, to test other hypotheses. 
3.5.3 Z4h duration 
There is clear evidence in the literature, using bovine and human endothelial cell culture 
methodologies, showing that a 24h exposure to high glucose should have an effect on VEGF 
expression (Nakagawa et 01., 2006; Chen et 01., 2004), whilst 24h or longer incubation in high 
glucose has been shown by some studies not to have any effect on VE-cadherin (Matsui-Hirai et 
01., 2011; Maillard and Leach, 2002; Singh et 01., 2011). The main drawback to these studies is 
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that they use cell culture methodologies, and therefore the physiological reproduction of the 
effects of the surrounding tissue is not analysed. Our studies in chorionic villous explants 
maintain the physiologic 3D architecture of the villi in our setup, therefore adding an essential 
layer of complexity to our experiment. Research with chorionic villous explants similar to ours 
has shown that the trophoblast surrounding the villi degenerates in the first few days in culture 
(Siman et 01., 2001). Whilst this does not directly affect the vessels we are analysing, the 
degenerating trophoblast may be releasing substances into the media that may affect the VEGF 
production in the endothelium of the vessels, as they are subjected to the same media as the 
trophoblast. This might explain the fact that in our explant model, we observe a decrease in 
VE-cadherin localisation to the junctional space in hyperglycaemic insult compared to 
euglycaemic incubation, in contradiction to the cell culture studies mentioned above. 
However, different VEGF splice variants might be affected, which would not be shown with the 
antibody used in this chapter. This is investigated in Chapter 4. 
3.5.4 Effects of mannitol on the explants 
In this chapter, we have tested the efficacy of mannitol as an osmotic control for glucose, as it 
used in cell culture experiments. The significant differences found between the mannitol group 
and both normal and glucose groups suggest otherwise. Our data, although on the surface 
unexpected, confirm recent change in consensus of opinion regarding the role of mannitol. 
Mannitol has been used for years in medicine as a hyperosmotic agent in humans, by perfusing 
the vasculature with high (1.4-1.6M) concentrations to open the blood-brain barrier and relieve 
intra-cranial pressure (lCR) (Hartwell and Sutton, 1993). However, a recent review of four 
papers published in the last -10 years, has shown that mannitol infusion is actually less 
effective at relieving ICR than hypertonic saline (Infanti, 2008). The author of this review does 
not provide hypotheses for why this might be, only the evidence. A possibility could be that 
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mannitol acts as a reactive oxygen species (ROS) scavenger, and therefore aids the integrity of 
the endothelial junctions in the blood-brain barrier, and therefore cannot affect ICR. 
A study by Huo et 0/. (2009) also suggests an effect on the endothelium by mannitol. This study, 
which used a much lower mannitol concentration (100mM), was shown in vitro to block the 
effects of ROS in a rabbit corneal epithelial cell model. This study was also investigating wound 
healing in a pig cornea organ culture model, and indeed mannitol was shown, putatively 
through its ROS scavenger activity, to inhibit wound healing through a decrease in DNA 
synthesis (Huo et 01., 2009), and therefore, our mannitol group might be affecting the wound 
healing, explaining why the mannitol group is not acting as an osmolarity control in our results. 
We see in our explant culture model that exposure to mannitol resulted in a significant 
decrease in endothelial VE-cadherin immunoreactivity in comparison with normal and glucose 
groups at both 4h and 24h timepoints. Mannitol may in this case be inhibiting wound healing, 
as seen in the rabbit corneal model described above. This overall decrease in VE-cadherin 
would have an inhibitory effect on wound healing given the role VE-cadherin plays in 
endothelial barrier function and as a survival factor (Carmeliet et 01., 1999; Lampugnani et 0/., 
1995), thus disruption of this endothelial barrier plays a role in early angiogenic signalling. 
Down-regulation of the molecule would have profound effects on the endothelium, thus 
mannitol even at lOmM levels may be injurious to human placental microvessels. 
As mannitol is putatively affecting the wound healing response, and not acting as an osmotic 
control as wished, it proved unsuitable for this study. 
3.5.5 Excision artefacts 
As discussed in Chapter 2, there might be a 'wound healing' artefact caused by the excision 
process in our explant model. This can be seen in the observed total number of vessels 
expressing VE-cadherin and VEGF, being 60% and 45%, respectively, at Oh (Figures 2.7 and 2.8). 
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This is different from what is seen in vivo or indeed in non-wounded tissue. A study by Leach et 
01. (2004) shows that in a non-wounding methodology (placental perfusion), 92.9% of non-
diabetic vessels show VE-cadherin immunoreactivity, whilst only 5% of non-diabetic vessels 
show VEGF immunoreactivity. 
In our explants about 60% of vessels did not show any VEGF immunoreactivity. This is 
compared to 95% in the intact tissue of Leach et al (2004), and therefore it matches well with a 
profile affected by the excision process. This theory proposes that VEGF is produced when 
explants are cut, and the absence of VEGF in some vessels in euglycaemic explants may indicate 
that these were vessels which had not been cut in the excision process, whilst the VEGF 
immunopositive vessels had been affected by excision artefacts. 
No further decrease can be seen in the total number of vessels immunopositive to VEGF 
between the euglycaemic and hyperglycaemic groups, and VE-cadherin localisation indicates 
that the mannitol group (which as seen above is likely being affected by the wound healing 
process) shows a different profile than the hyperglycaemic group. Therefore, it seems unlikely 
that the 15mM glucose group is being affected by the wound healing response significantly 
more than the euglycaemic group. 
3.5.6 Critique of analytical approaches used 
The data has been analysed in two ways in both this chapter and Chapter 2: (1) the percentage 
of vessels immunopositive for VE-cadherin and VEGF, and (2) the location/intensity of staining 
in immunopositive vessels. The intensity of fluorescence is useful as a semi-quantitative 
measure of how much VEGF is present. The sub-cellular location of VE-cadherin is important 
for understanding the contribution to cell-cell junctional adhesiveness. We believe this method 
to be of use for the VE-cadherin immunoreactivity, as location 1 (wholly cytoplasmic and non-
junctional) VE-cadherin is contributing as little to cell-cell adherence as a cell which is not 
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expressing any VE-cadherin, as neither have the junctional VE-cadherin necessary for cell-cell 
adhesion and regulation of permeability. However, there is less of an argument for the use of 
intensity data for VEGF, as there is no biological basis for the classification of the three intensity 
levels. Furthermore, wound healing may confound the intensity data for VEGF, as in a non-
wounded vessel only very little basal VEGF would be expressed; therefore, the fact that some 
45% of vessels are expressing VEGF may be due to the wound healing. If glucose is having an 
effect on wound healing, the intensity of immunoreactivity would change, but it would not 
affect the non-wounded vessels; if, however, glucose was having an effect independent of 
wound healing, the total number of vessels immunoreactive to VEGF would change, as non-
injured vessels would express VEGF. We see in this chapter that glucose is not having an effect 
on 'wound healing' caused by the excision artefacts, as demonstrated by the lack of change in 
VEGF intensity (Figures 3.7 and 3.9). Nor is glucose having an effect independent of 'wound 
healing', as shown by the unchanged total number of VEGF immunopositive vessels (see Figure 
3.2). 
From this point onwards (Chapters 4 and 5), only the total number of vessels immunopositive 
to VEGF are counted, regardless of their intensity. 
3.5.7 4h VS. 24h 
All groups (euglycaemic, hyperglycaemic and mannitol incubations) showed no significant 
difference between 4h and 24h when analysing the total number of vessels immunopositive 
with VEGF. Any chronic effects of glucose have therefore not yet set in. Glucose is known to 
have effects on the vasculature through increased advanced glycation end-products (AGEs), but 
these are not formed until after weeks of sustained hyperglycaemia, certainly not by 24h 
(Dawnay and Millar, 1997). For technical reasons, our explant culture cannot be continued for 
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the long-term duration it would take to develop AGEs (maximum culture duration 12 days 
(Miller et 01., 2005)), and therefore these chronic effects of glucose cannot be studied. 
As the 4h and 24h glucose timepoints are similar to each other, one can conclude that any 
undergoing mechanism at 4h is still in action at 24h. However, as discussed above, it is the 4h 
timepoint that is physiologically relevant, as glycaemic levels are unlikely to be elevated 
constantly for 24h, whilst 4h periods of lSmM glucose are likely to be present in diabetic 
pregnancies (see introduction of Chapter 4). 
3.5.8 Other glycaemic studies in placental explants 
Other studies involving glucose in placental explants have studied mainly glucose deprivation 
and glucose consumption. 
Interestingly, glucose deprivation seems to have more profound effects than hyperglycaemic 
insult. Studies involving placental growth hormone production, a hormone that has a positive 
correlation with birth weight (which is often increased in diabetic pregnancies) and is produced 
exclusively by the syncytiotrophoblast, have found that glucose deprivation increased 
production of the hormone in 24h explants culture, whilst 25mM glucose had no effect 
(Fuglsang et 01., 2008; Patel et 01., 1995). Another study has found TNF-a to be decreased in 
response to 2SmM, but not lSmM glucose in placental explants (Coughlan et 01., 2001). This 
result is important for our explant culture, as TNF-a is involved in inflammation and is produced 
in endothelial cells, and could thus be affecting the wound healing response we observe in our 
explants. Also, this highlights the importance of choosing the right glucose concentration to 
test, as different concentrations may have different results. We chose lSmM glucose, as this 
represents a mild glycaemic insult which is likely to occur even in well controlled women in 
pregnancy. 
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Importantly, glucose consumption in term explants was studied (Di Santo et 01., 2003). The 
glucose consumption in term placental explants was O.13sllmol/g/min for a 4h incubation and 
0.102Ilmol/g/min for a 24h incubation. This means our llmg explants consumed 0.12mM 
glucose by 4h, and 0.54mM glucose by 24h. This would make a negligible difference from the 
starting concentration of smM and lsmM glucose. 
3.5.9 VEGFb in explants 
The antibody we used in this chapter was a pan-VEGF antibody, which does not distinguish 
between the two splice variants, VEGFa and VEGFb (for naming convention, see section 4.1.2). 
Therefore, even though we see no significant difference in the total number of vessels showing 
VEGF expression between the euglycaemic and hyperglycaemic groups, one cannot discount 
the possibility that the ratio between the two splice variants is changing in response to glucose. 
This topic is explored in more detail in sections 4.5.3 and 4.5.8. 
VEGFb is known to inhibit angiogenic processes such as vasodilation, endothelial proliferation 
and migration (Woolard et 01., 2004). VEGFb has been shown to be downregulated in both 
physiologic and pathologic models of angiogenesis, such as various cancers and diabetic 
retinopathy (Bates et 01., 2002; Pritchard-Jones et 01., 2007; Perrin et 01., 2005). As such, we 
would expect VEGFb to be decreased in our explant culture, as wound healing is undergoing. 
VEGFb was therefore included as a profile to measure in the next two chapters. 
Most studies have observed an effect of glucose on VEGF and VE-cadherin expression at 24h 
and beyond, but to the best of our knowledge there are not any studies that evaluate the 
effects of glucose itself (as opposed to glycation derivatives such as AGEs, as in the study by 
Otero et 01. (2001)), at an earlier timepoint, such as our 4h timepoint. 
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3.6 Summary 
VE-cadherin was shown to be affected by glucose, both at 4h and 24h, affecting endothelial 
cell-cell adherence, and this merits further investigation. Whether this results in increased 
leakage in the placental organ is not known, and it is not possible to investigate this using the 
placental explants methodology. Any differences in vascular leakage were therefore 
investigated using a dual-independent perfusion method in Chapter 5. 
At both 4h and 24h, glucose was not found to affect VEGF production. However, the antibody 
we used was a pan-VEGF antibody, and as such did not differentiate between the two splice 
variants, VEGFa and VEGFb. This question is investigated in Chapter 4. 
We used mannitol as an osmolarity control; however, results showed that it had effects 
independent of osmolarity, making it unusable as a control, and therefore from this point 
forward, its use was discontinued. 
Analysing different locations gave more precise results for VE-cadherin, as location 1 
represented wholly cytoplasmic VE-cadherln whilst location 3 represented wholly junctional 
VE-cadherin, a difference that could not be discerned by simply counting total number of 
vessels expressing VE-cadherin. However, counting intensity levels in VEGF immunoreactivity 
does not have the same benefits, as it Is a pseudo-quantltative analysis, whilst total number 
of vessels immunopositlve provides a more objective observation. Therefore, in the next 
chapters only total number of vessels Immunopositive to VEGF are counted, disregarding 
intensity levels. 
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Chapter 4 
The effect of lSmM glucose on the explant culture: 
analysis of VEGF splice variants in placentae from 
normal and diabetic pregnancies 
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4.1 Introduction 
4.1.1 The diabetic placenta 
As diabetes is a collective term for several types of diabetes with different aetiologies, it is 
unsurprising that different types (Type 1, Type 2, gestational) of diabetes affect pregnancies 
differently. We chose to study the placentae of Type1 diabetic pregnancies only. Here we 
discuss how the placental phenotype of Type 1 made it suitable for this study, and why 
placentae from gestational and Type 2 diabetic pregnancies were not used. 
4.1.1.1 Pre-gestational and Type 1 placenta and pregnancy 
There are two types of pre-gestational diabetes: Type 1 and Type 2. Here, we study the tissue 
response of Type 1 placentae to glucose. 
The first reason behind this choice is the well-studied phenotype of the Type 1 placenta, 
specifically in our laboratory, where it has been studied for many years. Because of this in-
depth knowledge of the Type 1 placenta, we can study the effects of glucose on VEGF isoforms. 
Type 1 diabetes displays a pathological increase in endothelial VEGF production, and junctional 
adhesion molecules are decreased, so that the overall phenotype is one that is leaky to 
macromolecules slightly larger than albumin (67kDa). Therefore, there is an established 
phenotype to compare both the euglycaemic and hyperglycaemic normal placental explants, 
and to observe how the diabetic tissue exposed to high glucose compares to diabetic tissue 
exposed to euglycaemia, i.e. whether the diabetic phenotype of high VEGF is reversible under 
euglycaemia. No such comparison can be made for Type 2 diabetes, as its pathological 
phenotype has not been as widely studied. 
Secondly, Type 1 diabetes is controlled primarily with insulin, and insulin resistance increases 
during pregnancy. In order to maintain euglycaemia, the insulin requirement for non-obese, 
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singleton pregnancies increases from O.7units/kg per day in the first trimester, to 
O.8units/kg/day in gestational week 18, to O.9units/kg/day in gestational week 26, and finally to 
l.Ounits/kg/day in gestational week 36 (Jovanovic et al., 1981). The authors also noted that 
towards the end of the pregnancy, the standard deviation of insulin required increased, so 
more individual monitoring is required at the end of the pregnancy to maintain euglycaemia . 
Obese subjects required very variable amounts of insulin, and therefore the authors did not 
include their values in their figures (see Figure 4.1). Herein lies another problem with Type 2 
diabetes: it is a much less homogeneous disease, with some patients requiring insulin and some 
being treated by diet alone, and obesity complicates a great percentage of Type 2 diabetics. As 
a result, Type 2 diabetic patients have greater exposure to much higher glucose concentrations, 
with 30mM+ levels being reported . Therefore, the variation between subjects makes it difficult 
to make wide-reaching conclusions. 
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Figure 4.1: Insulin requirements of Type 1 diabetic women during pregnancy, with standard deviation 
(shaded area). The data points were taken at gestational weeks 7, 14, 21, 28, 32, 39, 41. Taken from 
Jovanovic et al. (1981) with permission from Elsevier. 
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Placentae from Type 1 diabetic women without any history of microvascular complications 
were therefore chosen for the reliability of results and less variation as compared to placentae 
from Type 2 diabetic women. 
4.1.1.2 Gestational diabetes (GDM) placenta 
Type 1 and Type 2 are pre-gestational diabetes, and therefore the placenta in these diabetic 
women is subjected to hyperglycaemia throughout the entirety of the pregnancy. Diabetes 
present at the start of gestation may alter formation of the placenta for the rest of the 
pregnancy; as the placenta may adopt different mechanisms to counteract the diabetic 
environment, these alterations may be long-lasting. In contrast, in gestational diabetes (GDM), 
which presents in the second or third trimester of the pregnancy (after the formation and 
maturation of the placenta), the placenta is subjected to a shorter duration of the pathological 
milieu, and any placental changes are less pronounced, and mainly affect short-term changes in 
the gene expression of molecules involved in a variety of chronic stress and inflammatory 
functions, such as inflammation pathways, endothelial differentiation, substrate metabolism, 
transport and trafficking, amongst others (Radaelli et 0/., 2003). The GDM phenotype is 
therefore a more flexible phenotype that does not seem to involve any permanent changes to 
the architecture of the placental morphology, in contrast to the more long-lasting glycaemic 
insults that may have caused permanent changes seen in the placentae from Type 1 diabetic 
pregnancies. 
Term placental vasculature from gestational diabetes (GDM) lies on a spectrum between Type 1 
term diabetic placenta and normal term placenta, in both angiogenic response and evidence of 
junctional perturbation (8abawale et of., 2000). 
Placentae from GDM and Type 2 diabetic pregnancies were therefore not used for these studies. 
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4.1.1.3 Effects on the fetus of alterations in term diabetic placentae 
As the main barrier between the maternal and fetal circulations, the placenta is a crucial 
discriminatory interface for nutrient uptake for the fetus. Both the syncytiotrophoblast and the 
fetal endothelium act as resistance in series in regulating materno-fetal transport (leach and 
Firth, 1992). The leaky endothelium in diabetic placentae may therefore represent a reduced 
barrier leading to the "overnutrition" seen in diabetic pregnancies. Glucose readily crosses the 
placenta, both with simple diffusion and utilising glucose transporters 1 and 3, and, to a lesser 
extent, glucose transporter 4. GlUTl was shown to significantly increase in diabetic placentae, 
but only in the basal membrane and not in the microvillous membrane (Gaither et 01., 1999), 
whilst expression of GlUT3 was shown to be significantly lower in diabetic pregnancies, perhaps 
as an adaptation to the diabetic milieu (Sciullo et 01., 1997). Once the syncytiotrophoblast has 
been traversed, as a hydrophilic molecule glucose can be transported through the paracellular 
clefts of the placental fetal endothelium. Disruptions of junctions here would influence rate of 
transfer. To counteract the resultant fetal hyperglycaemia, there is an increased insulin 
production in the fetus {Pedersen, 1954}. According to the Pedersen hypothesis this may be 
behind the increased macrosomia seen in infants born to Type 1 diabetic mothers. Clinically, 
there are immediate neonatal consequences, whereby after parturition, newborns may 
experience hypoglycaemia and need to be given glucose. 
4.1.2 VEGFb in presnancy 
Henceforth, we will be referring to the pro-angiogenic and pro-permeability VEGF splice variant 
as VEGFa, the anti-angiogenic and anti-permeability splice variant as VEGFb, and total VEGF as 
being the sum of VEGFa and VEGFb. Total VEGF in previous chapters was referred to simply as 
VEGF. In the literature, what we are calling VEGFa is sometimes referred to as VEGFxXXl and 
what we are calling VEGFb is sometimes referred to as VEGFxxxb. 
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VEGFb has been principally studied in the kidney (Qiu et 01., 2010) and the eye (Hua et 01., 2010) 
where overexpression studies have shown it to be both an anti-angiogenic and an anti-
permeability isoform. 
In the only study (to the best of our knowledge) looking at VEGFb in the human placenta, both 
VEGFb mRNA and protein were found (Bates et 01., 2006). These authors found about 22% of 
placental samples (including amnion, chorionic villi and stratum basal e) containing VEGFb only, 
about 37% of samples to contain both VEGFa and VEGFb, about 17% of samples to contain 
VEGFa only, and about 22% to contain neither (exact figures not given; figures estimated by 
observing figure 1D) (Bates et 01.,2006). In particular, the authors found strong VEGFb staining 
in endothelial cells of blood vessels and syncytiotrophoblast in the chorionic villi but less 
staining in other tissues in the chorionic villi (Bates et 01., 2006). Western blotting showed that 
the majority of VEGF splice variants found in these samples was VEGFa. In pre-eclamptic 
placentae, the authors found significant up-regulation of VEGFa and significant down-regulation 
of the VEGFb splice variants, compared to normal placentae (Bates et 01., 2006). 
Whether this splicing pattern also occurs in the diabetic placenta is not known. Glucose, one of 
the two likely candidates (the other being insulin) for causing any such disturbances in the ratio 
of VEGFa to VEGFb also remains to be shown and is the focus of this chapter. 
4.1.3 Postprandial glucose levels in normal and diabetic pregnancies 
Both in normal pregnancies and pregnancies of diabetic women, glucose homeostasis changes 
throughout gestation, the woman becoming progressively more insulin resistant as gestation 
progresses. A normal woman can adjust by producing more insulin, however, a Type 1 diabetic 
pregnant woman is reliant on external insulin injections, and therefore an increase in insulin 
requirement needs to be detected by the patient before glucose levels can be stabilised. 
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A study with 66 non-diabetic women found that, in the third trimester (34 weeks), a normal 
woman's preprandial glucose levels are around 3.SmM glucose, rising to S.SmM postprandially. 
There is not much variation in these values, and the postprandial peak takes about 3 hours to 
return to preprandial values (Parretti et 01.,2001). The results of this study are summarised in 
Figure 4.2, which is adapted from data in the paper by Parretti et 01. (2001). 
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Figure 4.2: Typical daily glucose profile for a non-diabetic pregnant woman. Time for peak postprandial 
glucose concentration to return to fasted glucose levels is shown. Plotted from data from Parretti et al. 
(2001). 
In a study including 111 pre-gestational diabetic (White class B-RF) pregnancies, at 33-36 weeks 
gestation the mean postprandial glucose concentration was found to be 7.4mM glucose (Combs 
et 01., 1992). However, all these women were extremely closely monitored and given individual 
diet plans. Even with this tight monitoring, 3.2±3.8% of readings were hyperglycaemic 
(>11.2mM glucose). This might seem low, but when considering there were at least 4 readings 
a day, in this four week gestational period there were on average 3-4 periods of hyperglycaemia 
per woman. The variation in these hyperglycaemic periods was also very high so some women 
might have had many more hyperglycaemic periods. 
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Other papers also comment on the high variability between Type 1 women in their 
hyperglycaemic excursions. Kerssen et al. (2004) show that there is a high degree of variability 
in two consecutive days of continuous glucose monitoring, with values as high as 14mM (Figure 
4.3). In this example of a pregnant Type 1 diabetic patient, we can also see that the time it 
takes for the postprandial peak to return to preprandiallevels is around 4h. 
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Figure 4.3: Two day continuous monitoring profile for a Type 1 diabetic pregnant woman. The daily 
variation and time for peak postprandial glucose concentration to return to fasted glucose levels are 
shown. Taken from Kerssen et 01. (2004) with permission from John Wiley and Sons. 
In their case report, Kyne-Grzebalski et al. (1999) also comment that postprandial levels in a 
Type 1 diabetic ranged from 1.5-16.9mM glucose for a woman who was thought to have good 
glucose control, due to a HbA1c level of 41mmol/mol. 
From these studies, one can conclude that even though mean postprandial glucose 
concentrations do not seem very high, in reality the variation of these values is great, and can 
easily reach lSmM glucose. 
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4.1.4 Our normal and diabetic explant cultures 
As seen above, 15mM glucose concentration is often reached postprandially in Type 1 diabetic 
pregnancies, and therefore it is an appropriate concentration to use for our experiments to 
simulate hyperglycaemic insults as they happen in vivo. A timepoint of 4 hours was chosen for 
our experiments, as it correlates well with the postprandial glucose profile in diabetic pregnant 
women (as seen above). In non-diabetic pregnant women, glucose levels return to a fasted 
state within three hours postprandially. However, it is most important to simulate the diabetic 
condition as closely as possible, so four hours was chosen as the optimal timepoint. 
In diabetic women, there is an increase in both the magnitude and the longevity of elevated 
glucose levels; hence glucose levels are higher in the diabetic woman and stay so for longer. By 
two hours postprandially, the diabetic woman will still have elevated glucose levels (hence the 
use of the two-hour post-insult glucose blood test as a tool to diagnose diabetes). In pregnancy, 
there is a state of glucose resistance; therefore a normal pregnant woman will experience short 
periods of very mild hyperglycaemia (to 6mM blood glucose) (Parretti et 01., 2001) which return 
to normal within 3 hours. Of course, the situation is worsened in the diabetic pregnant woman, 
where blood levels might stay high for 4 hours (or indeed even in a normal woman who 
develops gestational diabetes). The 4 hours timepoint is therefore very appropriate for our 
experiments. 
4.2 Aims and oblectives 
The first aim was to observe whether glucose alters the VEGF splice variants in normal and Type 
1 diabetic term placentae, using chorionic villous explants as our model. The experimental 
design again utilises the 4 hr incubation with lSmM glucose given that this correlates well with 
the postprandial glucose profile in diabetic pregnant women (see section 4.1.3). This will reveal 
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whether there is a diabetic phenotype described by the expression of VEGF splice variants that 
can be replicated with glucose insult. 
The second aim was to observe whether there was a reversal in the Type 1 diabetic phenotype 
of high VEGF levels, as observed in perfused placentae from diabetic pregnancies by Leach et 01. 
(2004) when such placentae are exposed to euglycaemic conditions. This was studied by 
comparing Type 1 diabetic chorionic villous explants incubated for 4h in euglycaemia to Type 1 
diabetic chorionic villous explants incubated for 4h with hyperglycaemia (15mM glucose). 
4.3 Methods 
4.3.1 Materials 
The source and catalogue number for all materials mentioned in this chapter are listed in 
Appendix 1. 
4.3.2 Explant culture for 4h 
Normal chorionic villous explants (n=4, 3 explants per placenta, with the same donor 
demographic requirements as those outlined in section 2.3.2) and Type 1 diabetic chorionic 
villous explants (n=4 placentae, 3 explants per placenta, see Appendix 2 for donor information) 
were incubated in oxygenated M199 medium which contained 5% (v/v) Fetal Calf Serum, 
100U/ml penicillin, 100mg/ml streptomycin, 21l8/ml Fungizome, on net supports (pore size 
7001lm) in a twelve-well plate. The support ensured that the explants did not adhere to the 
bottom of the well. After 4h of incubation, in hyperglycaemic media (15mM D-glucose) or 
euglycaemic media (5mM D-glucose), the explants were removed and fixed in 1% (w/v) PFA (pH 
7.2) for 30 minutes, before being washed in PBS, inserted in a drop of OCT and snap frozen with 
liquid nitrogen cooled isopentane. 
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4.3.3 Immunofluorescence protocol 
Both diabetic and normal explants, incubated ± high glucose, were subjected to the 
immunofluorescence protocol as detailed in Chapter 2. The antibodies used were VEGF 
( 5 ~ g / m l , , MAB293, R&D Systems) and VEGF165b ( 5 ~ g / m l , , MAB3045, R&D Systems and gift from 
D. Bates, University of Bristol) monoclonal antibodies. Negative controls did not contain the 
primary antibody. Given that both primary antibodies were monoclonal mouse anti-human IgG 
(no other VEGFb antibodies available), a single labelling technique had to be used on 
consecutive frozen sections. 
4.3.4 Analysis 
Using the selected random sampling method (adapted from systematic random sampling as 
described by Mayhew (2008)) (see Figure 2.2), the percentage of total immunopositive vessels 
were counted for both total VEGF and VEGFb using fluorescence microscopy (Nikon LaboPhot-2 
fluorescence microscope, Nikon Instruments) and images were acquired (Nikon Cool pix 995 
digital camera) in ADOBE Photoshop 6.0 Software. All 9 blocks were sectioned for each 
experimental condition and study group. 
Analysis of data was performed using GraphPad Prism version 5.01 statistical software. To 
discern whether the various groups (normal euglycaemia, normal hyperglycaemia, diabetic 
euglycaemia and diabetic hyperglycaemia) were significantly different from each other, non-
parametric Krustal-Wallis test was performed when comparing all groups, with Mann-Whitney 
U test performed on relevant groups if significant differences were found (see reasoning in 
section 2.3.9.1). Unless otherwise specified, all the statistics shown throughout Chapter 4 were 
performed with the Mann-Whitney U test {n=4 for both normal explants and diabetic explants}. 
Where statistical significance is present, this indicates that a previous Kruskal-Wallis test {n=4 
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for both normal explants and diabetic explants) had shown a significant difference between the 
wider groups. 
In order to ascertain whether the ratio of VEGF splice variants could be a predictor of vascular 
dysfunction in diabetes, the average percentage of immunopositive vessels for total VEGF for 
each placenta was plotted on the x-axis, with the corresponding average percentage of 
immunopositive vessels for VEGFb for the same placenta on the y-axis, giving a single point for 
each placenta analysed. Using GraphPad Prism version 5.01 statistical software, Spearman 
correlation analysis was then performed. 
4.4 Results 
For ease of understanding, the following abbreviations are used hereafter: 
N5: normal chorionic villous explants incubated for 4h in 5mM glucose. 
N15: normal chorionic villous explants incubated for 4h in 15mM glucose. 
05: Type 1 diabetic chorionic villous explants incubated for 4h in 5mM glucose. 
015: Type 1 diabetic chorionic villous explants incubated in 15mM glucose. 
4.4.1 Analyses of total VEGF 
There was a higher number of vessels showing immunoreactivity for total VEGF in the explants 
obtained from diabetic pregnancies compared to those from normal pregnancies. The 
percentage of total number of vessels immunopositive for total VEGF was 43% for N5, 51% for 
N15, 70% for 05 and 74% for 015 (Figure 4.4). 
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Mann-Wh itney U statistical analysis showed that the percentage of total VEG F immunopositive 
vessels in N5 was significantly lower than OS (p<0.05) and 015 (p<O.OS), but not N15 (p>O.OS) . 
The percentage of vessels immunopositive to total VEGF in N15 was significantly different from 
05 (p<0.05) and 015 (p<O.05). There was no significant difference in VEGFa immunoreactivity 
between 05 and 01S (p>0.05, Figure 4.4). 
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Figure 4.4: Percentage of vessels showing total VEGF immunoreactivity in normal and diabetic placentae. 
The statistical testing shown here refers to the Mann-Whitney U test between relevant groups in the data 
(n=4 for normal groups, n=4 (donors A-D) for diabetic groups), which were only analysed if the Kruskal-
Wallis test had detected a significant difference in the wider groups. See Appendix 2 for diabetic donor 
details. a: p<O.05 relative to NS, b: p<O.OS relative to N1S. 
VEGF was immunolocalised mostly to the fetal vessels in the chorionic villi of normal explants. 
Some staining was observed in the trophoblast but none in the perivascular layer in normal 
explants, and glucose did not alter this localisation pattern (Figure 4.5A-B) . In diabetic explants, 
total VEGF was seen predominantly in fetal vessels; there was some trophob last staining and 
minimal perivascular localisation (Figure 4.5C-0). Again, glucose did not disturb this pattern . 
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Figure 4.5: Representative micrographs showing total VEGF immunoreactivity in normal and diabetic 
explants. A: NS group showing limited vascular VEGF immunoreactivity, and some trophoblast VEGF 
immunoreactivity B: N1S group showing a similar total VEGF profile to N5 (A), C: 05 group (from 
donor B) showing increased vascular VEGF immunoreactivity compared to the normal placental 
explants (A and B); similarly to A and B, it displayed some trophoblast immunoreactivity, but in 
addition also showed minimal mesenchymal immunoreactivity, D: D1S group (from donor 0) 
showing a similar profile to OS (C), of increased vascular VEGF immunoreactivity relative to the 
normal groups (A and B), some trophoblast immunoreactivity, and minimal mesenchymal 
immunoreactivity. Thus, the diabetic groups showed more vessels immunopositive for total VEGF; 
however, the glycaemic status (euglycaemic or hyperglycaemic media) did not affect vascular VEGF 
immunoreactivity. All groups showed some trophoblast immunoreactivity, but the diabetic groups 
also showed minimal mesenchymal immunoreactivity. NS, N1S: normal explants incubated with 
SmM and lSmM glucose, respectively, OS, 015: diabetic explants incubated with smM and l5mM 
glucose, v: vessel, t : trophoblast, m: mesenchyme. See Appendix 2 for diabetic donor details. 
Magnification : x200. Scale bar: lOOum. 
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4.4.2 Analyses of VEGFb 
There were significantly fewer vessels immunopositive for VEGFb in the Nls and diabetic 
groups than in Ns (Figure 4.6). The percentage of total number of vessels immunopositive fo r 
VEGFb was 57% for Ns, 42% for Nls, 44% for Ds and 39% for DIS (Figure 4.6) . 
Mann-Whitney U statistical analysis showed that the percentages of VEGFb immunopositive 
vessels were significantly different between Ns and Ds (p<O.Os) and between N5 and Nls 
(p<O.Os), but there were no significant differences between neither Ds and DIS nor Nls and 
the two diabetic groups (Ds and DIS) (Figure 4.6) . 
Unfortunately, t=Oh diabetic tissue was not obtained, so the VEGFb profile at that timepoint 
and comparison of t=Oh with the 4h tissue could not be explored . 
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Figure 4.6: Percentage of vessels showing VEGFb immunoreactivity in normal and diabetic placentae. The 
statistical testing shown here refers to the Mann-Whitney U test between relevant groups in the data 
(n=4 for normal groups, n=4 (donors A-D) for diabetic groups), which were only analysed if the Kruskal-
Wallis test had detected a significant difference in the wider groups. See Appendix 2 for diabetic donor 
details. a: p<O.OS relative to NS. 
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VEGFb was immunolocalised to the fetal vessels in the chorionic villi. Some staining was 
observed in the trophoblast in normal explants, but none in the perivascular area. Glucose did 
not alter this localisation pattern (Figure 4.7A-B). In diabetic explants, VEGFb was seen 
predominantly in fetal vessels. Similarly to normal tissue, there was trophoblast staining but no 
perivascular VEGFb localisation. Again, glucose did not disturb this pattern (Figure 4.7C-D). 
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Figure 4.7: Representative micrographs showing VEGFb immunoreactivity in normal and diabetic 
explants. A: N5 group showing a majority of vessels VEGFb immunopositive, some trophoblast 
immunoreactivity and no mesenchymal immunoreactivity. B: N15 group showing decreased vascular 
VEGFb immunoreactivity relative to N5 (A), some trophoblast VEGFb immunoreactivity and no 
mesenchymal VEGFb immunoreactivity. C: Ds group (from donor C), showing similar VEGFb 
immureactivity to the N15 group (B), and decreased vascular VEGFb immunoreactivity relative to the 
N5 group (A). D: D15 group (from donor A) showing similar VEGFb immunoreactivity to N15 (B) and 
D5 (C). In short, the N5 group (A) shows more VEGFb immunopositive vessels than all other groups 
(B, C, D). All groups showed some trophoblast immunoreactivity but no mesenchymal 
immunoreactivity. Ns, N1s: normal explants incubated with smM and 1smM glucose, respectively, 
D5, D1s: diabetic explants incubated with smM and 1smM glucose, v: vessel, t: trophoblast, m: 
mesenchyme. See Appendix 2 for diabetic donor details. Magnification: x200. Scale bar: 100um. 
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4.4.3 Total VEGF/VEGFb correlation and ratio 
Analysis of data revealed a negative correlation between the percentage of vessels expressing 
VEGFb and total VEGF (Figure 4.8). The graph has a Spearman r value of -0.7412 (R2=0.S494) 
and an alpha value <0.01, indicating a statistically significant negative correlation between total 
VEGF and VEGFb. 
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Figure 4.8: Significant (a<O.OI) negative (r=-O.7412) correlation between total VEGF and VEGFb. Dark 
blue data points: N5 placentae, cyan data paints: N15 placentae, red data points: 05 placentae, yellow 
data points: 015 placentae. 
This significant negative correlation between total VEGF and VEGFb implies that the ratio of 
VEGFa/VEGFb is changing in the diabetic groups compared to NS, since 
total VEGF = VEGFa + VEGFb. 
Therefore, because of the significant correlation, VEGFa must be increasing when total VEGF is 
increasing and VEGFb is decreasing. This is indeed the situation in our diabetic explants 
compared to NS (dark blue data points in Figure 4.8, and Figures 4.4 and 4.6). As the diabetic 
data (red and yellow data points in Figure 4.8) cluster further down the line of best fit than the 
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normal data (dark blue and cyan data points in Figure 4.8), the VEGFa:VEGFb ratio must be 
higher in the diabetic groups compared to the normal groups. 
4.5 Discussion 
4.5.1 Summary of results 
The staining of total VEGF was higher in diabetic (Figure 4.SC-O) than in normal (Figure 4.SA-8) 
vessels, possibly due to intrinsic phenotypic differences (discussed later). The addition of 
glucose did not cause an increase in vessels showing total VEGF in neither normal (Figure 4.5B) 
nor diabetic (Figure 4.50) placentae, indicating 1SmM glucose is not the cause of the increased 
total VEGF expression seen in the diabetic placentae. In concordance with this theory, the total 
VEGF expression in the normal explants exposed to hyperglycaemic insult is not as high as the 
total VEGF expression in both diabetic groups (Figure 4.4). 
In contrast, the number of vessels stained for VEGFb was lower in diabetic (Figure 4.7C-0) than 
in normal (Figure 4.7A-B) vessels. The addition of lSmM glucose to the media caused a 
decrease in the amount of VEGFb present in normal tissue (Figure 4.7B), indicating that glucose 
may be able to down regulate VEGFb production and dampen its anti-angiogenic and anti-
permeability actions, allowing VEGFa to predominate and alter the vascular phenotype of the 
placenta. However, the same was not seen in diabetic tissue (Figure 4.70), indicating a possible 
adaptation of the diabetic placenta to high glucose. VEGFb expression was not significantly 
different between the high glucose normal placentae and both diabetic groups (Figure 4.6). 
This further indicates that high glucose can induce the diabetic phenotype in normal placenta 
via down-regulation of VEGFb. 
These results indicate that glucose affects the two splice variants differently, with down-
regulation of the anti-angiogenic splice variant (VEGFb) being a predominant feature. There 
was also a significant negative correlation between total VEGF and VEGFb (Figure 4.8), 
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indicating a change in the ratio of VEGFa to VEGFb between the groups. This ratio of two VEGF 
splice variants may therefore be an important predictor of vascular dysfunction in diabetes. 
4.5.2 Glucose effects on VEGF splice variants in normal and diabetic explants 
Our results show that under euglycaemic conditions, explants from diabetic pregnancies have a 
lower percentage of vessels expressing the anti-angiogenic splice variant VEGFb (Figure 4.6) and 
a higher number of vessels expressing total VEGF (Figure 4.4), indicating an increase in the pro-
angiogenic VEGFa when compared to the normal explants. After 4h hyperglycaemic insult, we 
observed that exposure to high glucose has very different effects on the normal explants as 
compared to the diabetic explants. Normal explants showed a significant down-regulation of 
VEGFb expression when exposed to 15mM glucose (Figure 4.7B), making N15 comparable to 
that seen in the diabetic explants (either 05 or D15, Figure 4.7C-D). Levels of total VEGF were 
not affected here. Plotting the correlation of total VEGF to VEGFb for the different 
experimental groups also proved enlightening, as this showed a significant negative correlation 
(when total VEGF increased, VEGFb decreased, Figure 4.8), and therefore the proportion of 
VEGFa to VEGFb must be changing, ie. there is a changing VEGFa/VEGFb ratio. This correlation 
is maintained with the inclusion of the diabetic explants in the analysis, and therefore study of 
the VEGFa/VEGFb ratio may be important in the prediction of vascular dysfunction in diabetes. 
4.5.3 Pan-VEGF antibody 
The alteration of the VEGFa/VEGFb ratio has been referred to as a potential therapeutic 
strategy for the amelioration of vascular angiogenenic pathologies (Nowak et 01., 2010; Zhao et 
01., 2011). Ideally, it would be important in these experiments to try to calculate the ratio of 
the two molecules. However, currently there is no commercially available antibody which 
detects exclusively VEGFa and not VEGFb (Varey et 01., 2oo8), and the studies on the ratio of the 
163 
two splice variants is currently being calculated by techniques such as peR (Bates et 01., 2002; 
Diaz et 01., 2008; Pritchard-Jones et 01., 2007; Qiu et 01., 2010; Schumacher et 01., 2007; Woolard 
et 01., 2004), which allows the differences in the amino acid composition to be exploited to 
discern the difference between VEGFa and VEGFb. Thus, we sought to calculate the proportion 
of VEGFb to total VEGF. However, when comparing the two, we observed that in NS (see figure 
4.4 and 4.6), the percentage of vessels immunopositive to total VEGF was lower than the 
percentage of vessels immunopositive to VEGFb, which is theoretically not possible if the two 
values were comparable. 
Personal communications with R&D Systems (the supplier of the VEGF antibody used in this 
thesis, MAB293), revealed that the epitope of VEGF used to create MAB293 included alanine 29 
to arginine 191, and therefore includes most of the VEGF molecule. However, there was a very 
minor possibility that the last 6 amino acids were critical for detection of VEGF. Further 
personal communications with R&D however confirmed that that MAB293 cross reacts with 
VEGFb 100%. This was tested with both direct ELISA and Western blotting (reducing and non-
redUCing conditions). The latter indicates that, even if the last 6 amino acids conferred VEGFa 
and VEGFb different secondary structures, they would both be detected by the antibody. 
Therefore, VEGFb would be detected by this antibody in our immunofluorescence protocol. 
Personal communications with D. Bates (University of Bristol), who has experience of using 
MAB293 and other pan-VEGF antibodies, revealed that a possible reason for the discrepancy of 
immunopositive vessels using MAB293 and MAB304S (the VEGFb antibody used) is the affinity 
of the antibodies to VEGF. Indeed, further communications with R&D confirmed this, as 
MAB293 has a detection limit of Sng/well in ELISA and SOng/lane in Western blotting whilst 
MAB304S has a detection limit of 3ng/well in direct ELISA and 25ng/lane in Western blotting. 
Therefore, given the same amount of protein being present, MAB3045 will show more 
immunoreactivity than MAB293. This can account for the higher VEGFb levels seen in some 
samples compared to the total VEGF. 
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Due to this, we have been unable to perform a ratio analysis of the data, i.e. the proportion of 
VEGFb to total VEGF. In order to do this, we would have to use antibodies which have the same 
detection limits. In order to perform the ratio analysis, we would need an antibody which is 
specific to VEGFa and does not detect VEGFb. D. Bates is currently working on producing a 
polyclonal antibody which detects VEGFa exclusively, and therefore this analysis will be possible 
in the near future. In this chapter, we have instead performed a correlation analysis rather 
than a more direct VEGFb/VEGF (total) proportion analysis. 
4.5.4 Reversal of diabetic phenotype In euglycaemic conditions 
One of our aims was to observe whether a 4h incubation with SmM glucose reversed the 
diabetic phenotype. Ifthis had been the case, there would have been a significant difference in 
the number of vessels immunopositive to the VEGF splice variants between DS and DlS. This 
was not seen in our explants. 
It is known that Type 1 diabetic placental vessels are more prone to excessive angiogenesis 
(Mayhew, 2002). It has also been shown that there is a high variation between Type 1 diabetic 
pregnant women's hyperglycaemic excursions (Kerssen et 01., 2004), and therefore a 
hyperglycaemic episode might be followed by euglycaemic periods. Had the Type 1 diabetic 
phenotype been reversible upon the cessation of glycaemic insult, it would have discarded 
glucose as an important mediator in the pathology of the diabetic placenta, as any changes 
would have been reversible upon better glycaemic control. 
However, there was a significant negative correlation between total VEGF and VEGFb (r=-
0.7412, Figure 4.8) when considering all data (normal and diabetic explants), indicating that the 
ratio of the splice variants is changing in the four groups (NS, N1S, DS, DlS). Furthermore, the 
diabetic groups (Ds and Dls) all lie further down the correlation line than the normal groups 
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(Figure 4.8), indicating a higher VEGFa/VEGFb ratio in diabetic explants compared to normal 
explants. 
If it is the ratio of VEGFa/VEGFb, rather than the total expression of the two splice variants, that 
is an important predictor of vascular dysfunction in the diabetic placenta, then better glycaemic 
control after lsmM glucose exposures might indeed ameliorate the outcome of the pregnancy. 
An analysis of the VEGFa/VEGFb ratio itself is however important to propose possible 
mechanisms: if the ratio of the VEGF splice variants in 05 is significantly different from Ns for 
example, it would suggest that persistent epigenetic changes have occurred, which are known 
to occur in diabetic pregnancies (reviewed by Leach (2011)). This is an important experiment to 
consider once a VEGFa antibody becomes available. 
To test further whether the effects of lsmM glucose are reversible or not, a future experiment 
with the reversal of Nls to Ns again, followed by one or more cycles of glucose insult followed 
by reversals, would be informative. Pol hill et al. (2004) in their study on human cortical 
fibroblasts have shown that 2h repeated short-term hits with hyperglycaemia (lsmM) 3 times a 
day separated by 3h euglycaemia, followed by a 12h euglycaemic period (replicating 
postprandial hyperglycaemia) had a larger effect on most of the parameters they studied than a 
constant lsmM glucose insult. If episodic glucose insults (such as those seen by Kyne-
Grzebalski et al. (1999)) have the same effect on the placental vasculature, we hypothesise that 
the future experiment suggested above would show more vascular effects (in terms of total 
VEGF and VEGFb levels) than a continuous glucose insult of equivalent total duration. 
In this chapter, the closest we have come to a similar kind of reversal experiment is by 
comparing Nls and OS, where Nls represents a single hyperglycaemic insult to normal tissue 
and where 05 represents a tissue previously exposed to hyperglycaemia but subsequently 
experiencing a period of euglycaemia. When looking at total VEGF, our results show that Ns is 
significantly different from 05 but not from Nls, and the latter two are also significantly 
different from each other (Figure 4.4); this would indicate that a single episode of 
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hyperglycaemia for 4h in normal tissue does not cause the diabetic total VEGF phenotype and 
that euglycaemia for 4h in diabetic tissue is not capable of restoring normal total VEGF levels. 
When looking at VEGFb, our results show that both N15 and 05 are significantly different from 
NS but not from each other (Figure 4.6), suggesting that in normal tissue 4h of hyperglycaemia 
is causing the decrease in VEGFb, but 4h of euglycaemia in diabetic tissue is not sufficient to 
reverse the diabetic VEGFb phenotype. 
4.5.5 Location of VEGFa and VEGFb 
The splice variant VEGFb was only discovered in 2002 (Bates et 01./ 2002). Therefore most 
studies into VEGF biology do not discriminate the actions of the two splice variants. The pan-
VEGF antibody used in most studies is directed against both variants (Varey et 01./ 2008). In 
adult tissue, global VEGF is normally found at basal levels acting as a survival factor; it is 
expressed in higher amounts only during inflammation and tissue damage, both to aid wound 
healing and as an early step in pathological angiogenesis. In the developing human placenta, 
there is physiological vasculogenesis and angiogenesis in the first trimester and a second wave 
of angiogenesis in the terminal villi of the third trimester placenta (Oemir et 01./ 1989). VEGF 
was found in the trophoblast and endothelium of all villi in the first trimester, whilst it was 
restricted only to the trophoblast of terminal villi in the last trimester and of course basal levels 
were expressed in the placental endothelium (Clark et 01./ 1996; Leach et 01., 2002). In this 
study, diabetic explants exhibited a ubiquitous distribution of total VEGF in the endothelium of 
blood vessels, the trophoblast and (minimally) the mesenchyme, whilst VEGFb was found in 
both the endothelium of blood vessels and in the trophoblast, but not in the mesenchyme (see 
Figures 4.5C-0 and 4.7C-0). This indicates that VEGFa is more ubiquitous than VEGFb. The 
number of vessels showing total VEGF in the diabetic explants was higher than that seen at Oh 
in normal tissue and agrees with previous studies which show intrinsic differences between 
diabetic and normal placentae (Leach et 01., 2004). 
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4.5.6 VEGFa in the diabetic explants 
VEGFa in our diabetic explants is increasing with respect to normal explants, as total VEGF is 
increasing and VEGFb is decreasing (see section 4.4.3). 
Data in this chapter was acquired from excised chorionic villi. Frank et 01. (1995) has shown 
that dampened VEGFa is behind impaired wound healing in diabetes. If our explants were 
being affected by wounding, we would expect a decrease in the VEGFa levels in the diabetic 
explants. This was not seen. In fact, there is clear evidence in the literature that diabetes 
increases angiogenic processes and VEGFa production both in the human placenta (leach et al., 
2004) and in other tissues, such as retinopathy in the eye, (reviewed by Crawford et al. (2009)). 
It is therefore interesting that when comparing normal and diabetic tissue (N5 and 05), the 
diabetic tissue displayed significantly more vessels expressing VEGFa after 4h in culture (05 had 
more total VEGF (Figure 4.4) and fewer VEGFb (Figure 4.6) immunopositive vessels than N5, 
indicating more VEGFa immunopositive vessels). This finding is consistent with the diabetic 
phenotype seen in the term placenta, rather than the decrease one would expect in diabetic 
wound healing. This is good evidence that excision artefacts are not affecting our results. 
Our data suggests that the increase in VEGFa in the diabetic placental explants is not modulated 
by glucose, as exposure to 15mM glucose for 4h did not change total VEGF and VEGFb 
expression (Figures 4.4 and 4.6). This insensitivity may be due to repeated exposures in vivo to 
this level of glucose - as stated earlier, postprandial levels of glucose takes several hours to 
return to normal in diabetic pregnant women (Ben-Haroush et 01., 2004), and as such the 15mM 
glucose used may not be perceived as 'hyperglycaemia' by the diabetic placenta. 
4.5.7 VEGFb in the diabetic explants 
In pre-eclampsia, VEGFb levels in the placenta have been shown to be decreased (Bills et 01., 
2009). We have now found this to be true for another pathology of the placenta, as we found 
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that levels of the anti-angiogenic splice variant VEGFb were significantly higher in the normal 
placenta than in the diabetic placenta. VEGFb has a different role to VEGFa, and is thought to 
be involved in the stability of vessels, inhibiting the actions of VEGFa by binding to its receptor 
(VEGFR-2), and therefore being a competitive inhibitor (Cebe Suarez et 01., 2006). Our data 
supports this hypothesis. On addition of glucose, VEGFb levels significantly decreased and 
became similar to that seen in the diabetic placental explants (Figure 4.6) providing evidence 
that glucose is able to regulate this splice variant in normal tissue. By decreasing the levels of 
VEGFb, more VEGFa can bind to its receptors, and therefore activate pathways such as 
angiogenesis, which are seen in diabetes. Therefore our data allows us to hypothesise that 
VEGFb may be a key molecule in the development of placental pathologies and in diabetes high 
glucose itself may affect the placental vasculature by altering VEGFb, which consequently alters 
the ratio of VEGFa/VEGFb, allowing the activation of pathways that require VEGFa without 
actually altering VEGFa and/or total VEGF levels. 
4.5.8 VEGFa/VEGFb ratio 
We saw in section 3.1.1.1 that several studies show that glucose increases expression of total 
VEGF (Nakagawa et 01., 2006; Chen et 01., 2004; Vidro et 01., 2008; Feliers and Kasinath, 2010); 
these studies would have to be revisited to show which VEGF splice variant is up-regulated or 
down-regulated, and to see whether there is a change in the ratio of the two splice variants 
following glucose insult in these in vitro systems. Our study suggests that as total VEGF 
increases, VEGFb decreases, thereby altering the ratio of the two splice variants. 
Harper and Bates (2008) review the possible implications for therapeutic approaches in tissues 
where the ratio differs, such as in cancerous tissue (Peiris-Pages et 01., 2010), non-cancerous 
tissue (Va ret et 01., 2010), and pre-eclampsia (Bates et 01., 2006). We were not able to compare 
the ratio directly due to the different detection limits of the antibodies used (MAB293 and 
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MAB3045), but the significant negative correlation found suggests that in our explants there is a 
changing VEGFa:VEGFb ratio, as when total VEGF increases and VEGFb decreases, VEGFa must 
be increasing. 
As the diabetic explants cluster further down the correlation line than the normal explants, this 
must mean that the diabetic explants have a different ratio than the normal explants. 
If the changes in these VEGF splice variants correspond to a different placental phenotype and 
the functionality of the placental exchange is disturbed, glucose would not be the only nutrient 
that would be affected, as many other parts of the maternal-fetal exchange would show 
changes. The importance of the correlation between total VEGF and VEGFb and its effects on 
the functionality of placental exchange (as measured through changes in leakage to a 76Mr 
dextran tracer) can be seen in Chapter 5. 
4.5.9 15mM glucose insult for 4h in Type 1 diabetic pregnancies 
The 4h hyperglycaemic insult was shown to affect the vasculature of the placenta. A study 
(Kyne-Grzebalski et 01., 1999) showed that even well-controlled Type 1 diabetic pregnant 
women, who had normal or slightly elevated HbA1c levels, experienced hyperglycaemic 
excursions to the levels we have studied (15mM blood glucose) postprandially. In their study, 
Kyne-Grzebalski et 01. (1999) hypothesised that these brief hyperglycaemic excursions caused 
hyperglycaemia and hyperinsulinaemia in the fetus, thus resulting in macrosomic newborns. 
We have however shown that these hyperglycaemic insults affect the placenta as well as the 
fetus, and as such, not only is the fetus receiving an increased glucose load, but if there is 
increased leakage of the placental vasculature, perhaps also non-glucose nutrients might be 
able to traverse the placental barrier and enter the fetal circulation, thus contributing further to 
the macrosomia observed. We investigate the leakiness of the placental barrier in Chapter 5. 
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4.5.10 Consequences of postprandial hyperglycaemia 
Several studies have correlated high postprandial glucose to macrosomia in the newborn, and 
some large population studies have been performed that confirm this. Combs et 01. (1992) 
analysed data from 111 diabetic pregnancies, and found that macrosomia was associated with 
postprandial glucose levels up to 32 weeks gestation. That the association does not continue 
after that period is irrelevant, as the author states himself that women who tend to be 
hyperglycaemic at anyone point in the pregnancy continue to do so at other points in the 
pregnancy; also, the study only went up to 36 weeks and did not include glycaemic levels at 
term. The authors recommended a postprandial glucose level of 7.6mM, as lower levels were 
seen to associate with small-for-gestational age offspring (Combs et 01., 1992). In their study of 
98 Type 1 diabetic women, Mello et 01. (2000) found that women with blood glucose levels 
of >S.3mM in the third trimester had a higher incidence of large-for-gestational age infants 
compared to women having >S.3mM blood glucose in the second trimester but not in the third. 
Infants from mothers with third trimester >S.3mM blood glucose blood also had a significantly 
higher incidence of hypocalcaemia and clavicular fracture than infants from mothers with blood 
glucose higher than S.3mM only in the second trimester. 
However, most papers seem to attribute the observed macrosomia to increased glucose 
concentration in fetal blood predicted by the Pedersen hypothesis, without considering that 
there might be deeper, more pronounced changes in the vasculature of the placenta. Indeed, 
Combs et 01. (1992) do hypothesise that there might be other non-glucose nutrients that might 
partly contribute to macrosomia, but instead of looking at the vascular profile permeability 
status, they looked at food intake, without finding any differences. Whilst undoubtedly high 
glucose in the mother does result in fetal hyperglycaemia, as the GLUTl and GLUT3 glucose 
transporters are independent of insulin, we have seen in this chapter that there are changes in 
the expression of angiogenic and permeability growth factors VEGFa and VEGFb directly 
attributable to glucose insult. 
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4.5.11 How VEGFb correlates to other tissues 
VEGFb has been shown to be important in the reproductive system, with the overexpression of 
VEGFb inhibiting angiogenesis in these tissues (Qiu et al., 2008), whilst inhibition of this splice 
variant reproduces the phenotype of overexpression of VEGFa (Artac et al., 2009). We have 
seen that, when subjected to glucose insult, our normal explants (NS and N1S) showed 
decreased VEGFb. Based on the literature, a decreased expression of the anti-angiogenic splice 
variant should result in a phenotype similar to that caused by an increase in the pro-angiogenic 
splice variant, i.e. a more angiogenesis-prone tissue. This is indeed the phenotype we see in 
diabetic placentae, as increased angiogenesis of fetoplacental vessels is a key feature in these 
tissues (Mayhew, 2002). 
As well as having been shown to be anti-angiogenic in various tissues, in the kidneys VEGFb has 
been found to have anti-permeability effects (Ferguson, 2007). This fits well with our results, as 
the diabetic placenta has been shown to be leakier than the normal placenta (Leach et al., 
2004), and we have shown that diabetic explants have decreased levels of VEGFb expression in 
comparison to normal explants. Therefore this anti-permeability effect might be a global effect 
not restricted to renal tissue (Qiu et al., 2010). Whether the presence of decreased VEGFb 
levels correspond to higher permeability in the placenta will be explored in Chapter 5. 
4.6 Summary 
Compared to explants from normal pregnancies (NS', placental explants from diabetic 
pregnancies (05 and 015) have a higher number of total VEGF Immunoposltive vessels and a 
lower number of VEGFb immunopositive vessels, indicating an increase in VEGFa. 
On addition of glucose, both normal tissue and diabetic tissue do not produce more total 
VEGFi however, the expression of VEGFb in normal tissue, but not diabetic tissue, decreases 
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in response to a 4h incubation with 15mM glucose, indicating different regulatory 
mechanisms between VEGFa and VEGFb. 
The significant negative correlation in total VEGF/VEGFb indicates a different VEGFa/VEGFb 
ratio between normal and diabetic explants, and therefore targeting this change in ratio 
might in future ameliorate the clinical outlook for pregnant diabetic patients. 
However, whether this ratio accurately predicts the functional role of the placenta cannot be 
ascertained with explants. Therefore, the functional effect of 15mM glucose exposure is 
investigated with a dual-perfusion methodology in Chapter 5. 
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Chapter 5 
Functional studies on term placental microvascular 
beds perfused with 15mM glucose 
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5.1 Introduction 
5.1.1 Glucose effects on the vasculature 
Hyperglycaemia in diabetes is known to increase the permeability of the endothelium 
regardless of what type (Type 1, Type 2 or gestational) of diabetes is investigated. Albumin 
retention, a measure of capillary permeability, has been associated with patients with Type 1 
diabetes (Valensi et 01., 1997). In Type 2 diabetes, transvascular permeability seems to be 
increased, as the fractional escape rate of low-density lipoprotein is increased in Type 2 diabetic 
patients compared to healthy individuals (Kornerup et 01., 2002), and this has been attributed 
to chronic high glucose, at least in monkeys (Litwak et 01., 1998). Even the presence of 
elevated glucose alone (in the absence of overt diabetes) can have an effect on permeability, as 
in a study of hypertensive patients with or without metabolic syndrome (and hence elevated 
glucose, but no overt diabetes) but all free from vascular disease, the patients with metabolic 
syndrome showed increased capillary leakage of albumin (Dell'Omo et 01., 2004). The common 
link between these studies seems to be high glucose, thus suggesting that it is this variable 
causing the leakage seen. In diabetes-induced animals, where high glucose is the main 
characteristic, blood constituents have been shown to have leaked from blood vessels in several 
tissues, such as the heart (Yamaji et 01., 1993), skeletal muscle (Beals et 01., 1993) and brain 
(Huber et 01., 2006), as well as in the retina and kidney (as discussed in section 1.3.4). 
Most of the studies above looked at diabetic animals, not hyperglycaemia in itself, and were 
studies conducted for several days. However, the mechanisms of the increase in permeability 
due to high glucose was also studied, and were found to be fast acting (start of response within 
minutes, peak of permeability at around 30 minutes) and mediated by the PKC pathway in 
porcine aortic endothelial cells (Hempel et 01., 1997), and in rat studies diabetes-induced 
leakage could be reversed by PKC inhibitors (Yuan et 01., 2000). 
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5.1.2 The Pedersen hypothesis and our experiments 
The Pedersen hypothesis (1954) is the most widely followed theory about how hyperglycaemia 
as seen in diabetic pregnancies affects the fetus, which was thought to solely account for the 
macrosomia seen in the fetus at term. This hypothesis states that whilst glucose freely crosses 
the placental barrier by facilitated diffusion, insulin is unable to cross this barrier (Keller and 
Krohmer, 1968). As the fetal pancreas starts producing insulin from 11 weeks gestation (Piper 
et 01., 2004), the in utero fetus produces insulin to counteract the hyperglycaemic environment 
derived from the diabetic mother. Thus, even though the fetus' insulin response is normal, the 
fetus is subjected to high glucose and insulin levels, replicating the diabetic phenotype in the 
womb and allowing macrosomia to occur. 
However, we have seen in the last chapter that even a 15mM glucose exposure for 4h causes 
vascular changes, in the form of lower VEGFb expression in the endothelium. This change in the 
vasculature may affect vascular permeability in the placenta, and if the integrity of the placental 
barrier is disrupted through increased leakage of nutrients, the fetus would be subjected to a 
higher amount of nutrients, encouraging excessive growth as seen in macrosomia. If there is 
increased leakage in the placental vasculature, this would indicate that the Pedersen hypothesis 
does not solely account for the macrosomia seen in diabetes. Indeed, the HbA1c levels, a 
measure of overall glycaemic control (but which does not give information about short 
hyperglycaemic excursions) cannot always predict macrosomia (Schwartz et 01., 1994). Combs 
et 01. (1992) also hypothesised that macrosomia might be partly caused by nutrients other than 
glucose, but looked at the effect of diet on the infants' weight, and did not find any significant 
differences. However, to the best of our knowledge, there is no literature looking at this 
phenomenon from a perspective of altered vascular leakage, which may be causing the 
macrosomic phenotype. In our explant methodology, we were unable to study vascular leakage, 
as this requires the separation of the fetal circulation from the maternal circulation. Therefore, 
176 
in this chapter we are looking at the effect of glucose on vascular leakage using a dual-
independent perfusion model. 
5.1.3 Glucose transport in the normal and diabetic placenta 
The main glucose transporter found in the trophoblast and endothelial layer of the placenta is 
GLUTl (Takata et al., 1992; Hahn et al., 1995; Takata et al., 1997). Glucose crosses the placenta 
mostly through facilitated diffusion in the maternal-facing microvillous and fetal-facing basal 
membrane of the trophoblast. Evidence shows that the endothelium of microvessels does not 
contribute greatly to the flux resistance to glucose (and other small hydrophilic molecules) 
(Takata and Hirano, 1997; Eaton et al., 1993; Leach et al., 1995), and that glucose passes 
directly through the paracellular clefts of the endothelium (Leach and Firth, 1997) to the fetal 
circulation. Glucose transporters in the endothelial cells are thought to playa part in the 
uptake of glucose from the fetal circulation into the endothelial cells for their own metabolism 
(Hahn et al., 1995; Hauguel-de Mouzon et al., 1997). 
Expression of glucose transporters in the trophoblast layer is asymmetrical, with a three-fold 
higher expression of GLUTl in the microvillous (maternal-facing) than on the basal membrane 
(fetal-facing) (Takata et al., 1992; Jansson et al., 1993). This, in addition to a six-fold increased 
surface area of the microvilli compared to the basal membrane (Teasdale and Jean-Jacques, 
1988), leads to greater capacity of uptake by the syncytiotrophoblast compared to the basal 
membrane, which acts as a rate-limiting step in glucose transport (Jansson et al., 1993). The 
glucose gradient between the maternal circulation and the fetal circulation also positively 
correlates with glucose uptake, as shown in an elegant placental perfusion study by Schneider 
et al. (2003). This study showed that at equal glucose concentration in both circulations, the 
maternal circulation contributed 70% of placental glucose uptake, and the fetal circulation only 
contributed 30%. This maternal contribution was increased to 95% of total placental uptake 
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when the maternal circulation was 1.1mM glucose higher than the fetal, but only dropped to 50% 
when the fetal circulation was higher by the same amount (Schneider et 01., 2003). The rate 
limiting step in glucose transport on the fetal-facing surface affects glucose release to the fetal 
circulation (maternal to fetal circulations), but only affects placental uptake in the other 
direction (fetal to maternal circuits). 
The density of GLUTl is also differentially regulated throughout pregnancy, with a doubling in 
GLUTl expression on the basal side in the third trimester compared to the second trimester, 
whilst expression on the microvillous membrane remains constant throughout pregnancy 
(Jansson et 01., 1993). By lowering the amount of glucose present in the fetal circulation by 
uptake in the placenta (but not increase in transplacental flux), the gradient between maternal 
and fetal circulations increases, and this is thought to lead to a bigger maternal to fetal 
transplacental glucose flux. 
In the diabetic placenta, there is an increase in glucose flux from mother to fetus. 
Hyperglycaemia (>20mM glucose) has been shown to downregulate the expression of GLUTl 
(Hahn et 01., 1998); however, the increased glucose gradient across the placenta 
overcompensates for this decrease. Also, insulin upregulates the expression of GLUT1 on the 
basal membrane, which is the rate-limiting step, and therefore the outcome of these changes is 
increased glucose flux to the fetus. Hence, the placental barrier might become compromised 
and its efficiency decreased, as seen in rat studies (Thomas and Lowy, 1995; Thomas and Lowy, 
1992) which showed increased leakage of glucose, perhaps as a result of the increased vascular 
permeability seen in placentae from diabetic pregnancies (Teasdale, 1981). The result from 
these changes is that the density of GLUTl doubles in the rate-limiting basal membrane whilst 
there are no changes in the microvillous membrane, leading to a 40% increase in basal 
membrane glucose uptake. 
In this chapter, we sought to analyse the rate of transfer of glucose across the placental barrier. 
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5.1.4 Role of VE-cadherin and PECAM-l in permeability 
In previous chapters we have looked at VE-cadherin as an important adhesion and anti-
proliferation molecule. Here, VE-cadherin is studied in the context of increased permeability. 
VE-cadherin is an important regulator of permeability. As seen in Section 1.2.2.1.1 and shown 
in Figure 1.9A, VE-cadherin is present in the junctional space when the endothelium is stable. It 
is anchored to the cytoskeleton by its complex with p-catenin, plakoglobin, and actin. When 
there is an increase in permeability, the molecules disassociate from the actin and VE-cadherin 
is internalised (Figure 1.9B). 
Whilst platelet-endothelial cell adhesion molecule-1 (PECAM-1) is localised to the junctional 
space, it is not involved in the junctional integrity of the paracellular cleft, and instead is 
involved in leucocyte binding and inflammatory responses (AI beida et 01., 1991). Indeed, in 
placental vasculature, PECAM-1 is present in term placental endothelium, and its expression 
increases when subjected to pro-inflammatory cytokine TNFu (Dye et 01., 2001); however, 
PECAM-1 remains at cell-cell contacts in junctional instability processes, such as increases in 
angiogenesis (Wright et 01., 2002), and is therefore an excellent endothelial marker for our 
purposes. 
S.l.S The placental dual-independent perfusion model 
Placental perfusions have been used for many years as a methodology to study placental 
function. Panigel was the head of one of the first laboratories utilising perfusions, and he wrote 
a review in 1962 on these methodological experiments, documenting the various variations in 
placental perfusion techniques (Panigel, 1962). He demonstrated that different cotyledons can 
be perfused independently of one another, and therefore, one cotyledon could be perfused 
being isolated from the rest of the placenta. 
179 
The dual-independent placental perfusion seeks to recreate in one cotyledon both the maternal 
and the fetal circulation. The two circulations in this model are completely independent of each 
other, hence the name. The flow, maternal and fetal pressure, and temperature in the 
perfusion chamber are constantly monitored and maintained at a physiological level seen in 
utero. Thus, the flow is maintained at 20ml/minute for the maternal circulation and 
Sml/minute for the fetal circulation, the pressure is maintained between 20-80mmHg for the 
maternal circulation and below 20mmHg for the fetal circulation, and the temperature is 
maintained at 3rc. Other than these key figures, there are some variations in the protocol 
(see section 5.1.6, below). 
The main purpose of placental perfusions is to carry out studies into transport of drugs, 
nutrients, etc. between the two circulations. 
5.1.6 Placental perfuSion models in the literature 
As the placental perfusion has been used for such a long time, it is natural that it would evolve 
with the times. Before Henning Schneider's contribution to the field, perfusing a placenta 
would mean delicately finding and cannulating the remnants of the spiral arteries, which was a 
very delicate and difficult process. This was made much easier by Schneider's discovery that by 
piercing the basal membrane and inserting the cannulae in the intervillous space, the same 
degree of perfusion could be achieved (Schneider et al., 1972). 
There are several variations to the placental perfUSion protocols that have been used, to suit 
different experiments. One of the most important variations is the choice of which perfusate to 
use. Blood is the best perfusate for this methodology, as non-blood perfusate was seen to 
cause mitochondrial damage (Contractor et 01., 1984) and increased leakage from vessels 
(Panigel, 1962). However, use of human blood, especially in long duration experiments, could 
be problematic: firstly for long duration perfUSion, a large quantity of blood would be needed, 
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as otherwise haemolysis occurs (Panigel, 1962), secondly the blood needs to be heparinised to 
keep it from coagulating, thirdly it could be difficult to sterilise the equipment between 
perfusions, and fourthly and very importantly, a 3h perfusion with blood media showed 
microvillous damage and oedema (Contractor et 01., 1984). For all these reasons, some 
experimenters use media instead of blood. 
A variety of media can be used as perfusate. The main problem with using media is the low 
osmolarity of the solution, which increases vascular leakage. In order to counteract this leakage, 
high molecular weight proteins, such as dextran, albumin, or Subtosan (a synthetic substitute 
for plasma), could be used to increase the osmolarity of the perfusate, reducing, but not 
completely eradicating, the leakage (Panigel, 1962; Leach and Firth, 1992). Therefore, it is 
important to monitor any eventual leaking from the vessels in control experiments. 
A feature of the ex utero perfused placental vasculature is that it can experience 
vasoconstriction, and therefore in some experiments, adenosine was used to ensure 
vasodilation. However, adenosine has been shown to disrupt the increased permeability in the 
perfusion model in response to histamine (Leach et 01., 1995), and therefore there is a concern 
that adenosine might affect other molecules capable of similar effects, such as VEGF, and is 
therefore not used in our set-up. Furthermore, as the current methodology monitors fetal and 
maternal pressure, adenosine is no longer strictly needed, as pressure can be monitored and 
perfusions discontinued if vasoconstriction occurs. 
Another consideration in the perfusion methodology is which tracer to use. Cyanocobalamin 
(812) is of a useful size to study leakage in the placenta, and is easy to label, whether 
radioactively or with a fluorescent molecule (Leach et 01., 1995). However, 812 is readily taken 
up by cells, and therefore to use it as a tracer, experimenters have used an excess of unlabelled 
cyanocobalamin, which is used to saturate its carrier-mediated uptake mechanisms prior to the 
perfusion of the labelled cyanocobalamin. Albumin is another tracer that has been used in the 
literature but has the problem that its permeability varies depending on which labelling method 
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is used (Rumbaut et al., 1999), and also that albumin can interact with other proteins in the 
media, affecting its permeability (Eaton et al., 1993). Dextran can also be used, as it is not 
absorbed by the tissue, although it is toxic if used for a long period of time. However, large 
molecular weight dextran is not metabolically active, and thus it is used in our studies. 
The sourcing of the placenta is another variable: in early studies, placentae were obtained both 
from vaginal births and Caesarean sections. However, today we know that in the process of 
detaching from the uterus and passing through the birth canal, the placenta is subjected to 
various hormones and signalling mechanisms which might cause vascular collapse. Therefore, 
our laboratory uses exclusively placentae obtained through Caesarean sections. 
5.1.7 Effect of glucose on vascular beds 
Perfused glucose has been shown in mainly animal studies to affect the vascular bed of several 
tissues. 
In a non-diabetic rat model, the vascular bed of skeletal muscle was investigated under high 
insulin (without high glucose) or l.5g/kg high glucose, and it has been shown that under high 
insulin alone, there was vasodilation of vessels but no change in vasomotion. With high glucose 
(and with endogenous insulin being produced by the rat), this effect was lost, and instead there 
was vasoconstriction and increased vasomotion (Renaudin et al., 1998). 
In glomerular (kidney) rabbit tissue perfused with 30mM glucose, angiotensin sensitivity was 
increased compared to 5.5mM glucose perfusion. When a NO inhibitor was added to the 
5.5mM glucose perfusions, the sensitivity was similar between the two groups, indicating that 
glucose in this model causes vasoconstriction via impairment of the NO signalling pathway 
(Arima et al., 1995) (see section 1.3.3.1). 
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In in situ perfused diabetic rat brain tissue, high glucose resulted in the increase of protein 
transporter multidrug resistance protein-2 but not of organic anion transporter-3 at the blood-
brain barrier (Hawkins et 01., 2007b). By using the same methodology (in situ brain perfusion), 
increased permeability of the blood-brain barrier to sucrose was observed in diabetic animals 
(streptozotocin-treated rats), and this was in conjunction with decreased occludin and ZO-l 
(Hawkins et 01., 2007a). 
Importantly for our experiment, perfused frog and mesenteric vascular beds show increased 
hydraulic conductivity (water permeability) but not reflection coefficient (macromolecular 
permeability) in response to 20mM glucose perfusion; this increased leakage was not mediated 
by free-radical production, the PKC pathway, albumin glycation or glucose metabolism (Perrin 
et 01., 2007). 
All these studies were performed in animal studies, as there would be ethical and technical 
difficulties in performing them on human tissue. No such problems exist for the human 
placenta. In this chapter, we have perfused a cotyledon of the human placenta to observe what 
effect glucose has on the placental vascular bed. 
5.1.8 Our dual-independent perfusion model 
The dual-independent placental perfusion protocol set out in Leach et 01. (2004) was used, with 
a few modifications. Firstly, the perfusion was lengthened to 3h (from the short duration in the 
Leach et 01. (2004) paper), as we wanted to represent the postprandial period accurately. A 
trial run was made with the intention to carry on for 4h, to match the explant studies more 
closely; however, we observed that we had a higher rate of failure, mostly from increased 
leakage, after that period of perfusion, and it was therefore extremely difficult to work with. 
Therefore, we decided to use a 3h perfusion instead to minimise eventual damage to the 
placental vascular bed; this duration has also been used by other groups in placental perfusions 
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when researching diabetic phenotypes concerning glucose (King et 0/., 2003; Kraemer et 0/., 
2006; Osmond et 0/.,2000). 
Media was used instead of blood, as even though blood would have given a more physiological 
simulation of the in utero environment, the duration of perfusion would probably lead to 
haemolysis and the volume of blood required for this experiment did not make the use of blood 
ethically possible. 
Both circuits were closed, instead of the open maternal circuit used by Leach et 0/. (2004). We 
closed both circuits because the duration of the perfusion meant it would have been 
uneconomical to have an open perfusion; however, to limit the build up of toxic substances 
such as lactic acid, we replaced both the maternal and fetal media every lh. 
Other than these two exceptions, our perfUSion followed the principles of the ideal perfusion 
set out above. A dextran tracer of known molecular weight (76Mr; greater than 66Mr albumin) 
was used to measure leakage in the last 10 minutes of our perfusion model. Figure S.l 
illustrates the dual-independent perfusion model. 
5.1.9 Advantages and disadvantages of using a perfusion system vs. explant culture 
The perfusion methodology represents a vast improvement over both explants methodologies 
and cell culture studies, as it gives a functional read-out by allowing measurements of 
permeability and transport between the two circulations. An important factor is that the entire 
placental infrastructure is in place in perfusions, as opposed to having isolated tissue in the 
explants culture, leading to a more physiological model. Another improvement is that as the 
whole perfused vascular tree remains intact, there are no excision artefacts. 
One of the disadvantages of using a perfusion methodology is the short duration of the 
perfusion, as perfused placental cells remain viable for a maximum of 48h, compared to 11 days 
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for explants. However, this is not of concern to us, as our perfusions were of much shorter 
duration. 
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Figure 5.1: Diagram (A) and photo (B) illustrating the dual-independent perfusion model. The media 
flows from the maternal reservoir through five maternal cannulae to the intervillous space in the placenta, 
and from the fetal reservoir through one fetal cannulae to a fetoplacental vein supplying the perfused 
cotyledon of the placenta. The maternal circulation is drained from the placenta through a drainage tube 
in the clamp back to the maternal reservoir, whilst the fetal circulation is drained from the placenta 
through the corresponding artery to the vein supplying the fetal circulation, back into the fetal reservoir. 
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5.1.10 Perfusion of normal placentae and placentae from diabetic pregnancies 
Placental perfusions have been used on both normal and diabetic placentae, with very 
illuminating results. In normal placentae, both glucose uptake and flux were higher when the 
glucose concentration gradient was higher in the maternal circulation than the equivalent 
gradient being higher in the fetal circulation (Schneider et 01., 2003). This indicates that when 
the mother is hyperglycaemic, the glucose moves easily from mother to fetus, but when the 
mother is hypoglycaemic, the reverse does not happen to the same degree. Both placental 
blood flow (Kuhn et 01., 1991) and the rate of glucose utilisation (Osmond et 01., 2000) are 
reduced in GDM placentae compared to normal placentae, even though the glucose transfer 
across the placenta is increased in diabetes (Osmond et 01., 2000). The former two could 
perhaps be an adaptation to the latter, as the placenta seeks to maintain normal nutrient 
exchange capabilities. 
In our lab, Leach et 01. (2000, 2004) have characterised the normal and Type 1 placenta after a 
30 minute perfusion. In a series of placental dual-independent perfusions, our laboratory 
sought to define both the normal and diabetic placental barrier phenotype, by perfusing 
placentae for a 20 minute equilibration period, immediately followed by tracer perfusion and 
paraformaldehyde perfusion fixation. 
In normal placentae, 92.9% of vessels exhibited VE-cadherin immunopositive (Leach et 01.,2004) 
and 98% showed occludin immunopositive junctions (Leach et 01., 2000), combined with 
negative to very weak immunoreactivity to anti-phosphotyrosine in 19.2% of vessels, a marker 
for junctional instability. VEGF immunoreactivity was low and localised to the trophoblast layer 
of terminal villi (Leach et 01., 2004). The functional result of these findings was that the 
placental vasculature was minimally leaky to 76Mr dextran tracer. 
In contrast, perfused Type 1 placentae exhibited only 49.4% VE-cadherin immunopositive 
vessels, whilst 74.3% of vessels showed strong immunoreactivity to anti-phosphotyrosine. 
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VEGF immunoreactivity in Type 1 placentae was higher and more ubiquitously expressed (in the 
trophoblast and endothelium of stem, intermediate and terminal villi). The functional result of 
these findings was numerous vascular profiles exhibiting 76Mr dextran tracer leakage. Of the 
molecules studied in Leach et 01. (2004) only PECAM-l remained at similar levels in placentae 
from diabetic pregnancies compared to normal placentae (96.3% vs. 96.6%). 
The phenotype of placentae from gestational diabetes is somewhat in between the two 
extremes (normal and Type 1 diabetes): 79.6% of vessels showed VE-cadherin immunoreactivity 
and 96.0% occludin immunoreactivity, whilst anti-phosphotyrosine immunoreactivity was 
observed in 56.4% of vessels (Babawale et 01., 2000). No information on VEGF levels or 
localisation, or on tracer leakage, for GDM was given in these or any other papers. 
Interestingly, these placental vascular disturbances were found in placentae of women who had 
otherwise normal pregnancies (except for the presence of diabetes), and no further 
microvascular complications (such as retinopathy or nephropathy). 
5.2 Aims and objectives 
There were three aims in this chapter. 
The first aim was to evaluate whether 3h lSmM glucose insult in an ex vivo model altered 
expression of: 
• VE-cadherin 
• Total VEGF 
• VEGFb 
The second aim was to observe whether the changes in expression of these molecules resulted 
in a change in the functionality of the human placenta in response to a 3h 15mM glucose 
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exposure to the placenta from the maternal circulation, as measured by 76Mr dextran tracer 
leakage. 
The third aim was to see whether the expression of total VEGF and/or VEGFb could be good 
predictors of vascular leakage in the human placenta exposed to lSmM glucose. 
5.3 Methods 
5.3.1 Materials 
The source and catalogue number for all Materials mentioned in this chapter are listed in 
Appendix 1. 
5.3.2 Dual-independent perfusion model 
Placentae (n=12) were taken from normal pregnancies undergoing term elective Caesarean 
sections in Queen's Medical Centre, Nottingham (and with the same donor demographic 
requirements as those outlined in section 2.3.2), with informed patient consent and ethical 
approval. 
Immediately after delivery, the placenta was transferred to a 3i C chamber with the umbilical 
cord kept clamped until cannulation, to prevent the collapse of the fetoplacental vessels. A 
vein and an artery supplying one randomly chosen cotyledon were each cannulated with a 
nasogastric (Smm) tube to establish the fetal circulation within 20 minutes of arrival of the 
placenta, and the cotyledon was then clamped and sealed in a Perspex chamber to allow for a 
closed circuit. Five Smm nasogastric tubes (which branched from one higher-calibre line) were 
inserted in the intervillous space through the basal plate of the cotyledon, and drained through 
a drain point in the Perspex chamber, to establish the maternal circulation. The cannulation 
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process was completed within 30 minutes of delivery to minimize hypoxic damage to the 
placenta. 
Both circulations were connected to peristaltic pumps providing a 20ml/min flow to the 
maternal circulation and a 5ml/min flow to the fetal circulation, replicating the physiologic flow 
rates seen in utero (Panigel, 1962). A 20 minute open circuit equilibration period was started, 
to reverse any eventual hypoxic and ischaemic changes due to the delivery of the placenta 
(Leach and Firth, 1992), and to wash away any blood in the finest branches and capillaries. 
During this period, both maternal and fetal circulations were open circuits. After this 20 minute 
equilibration period with oxygenated perfusate (M199 with added albumin (5g/I), heparin, 
dextran (20,OOOMr; 8g/l) and sodium bicarbonate (2.2g/1), lOmM glucose was added (to give a 
total of 15mM glucose) to the maternal circuit of the experimental group (n=6), but not to 
those in control perfusions (n=6). Both the maternal and fetal circulations were closed at this 
stage. The maternal and fetal flows were maintained at 20 and Sml/min, respectively, and 
maternal and fetal perfusion pressures were 20-80mmHg and below 20mmHg, respectively. 
Both the maternal and fetal circulations were checked at this point and throughout the 
experiment for leakage; if at any point there was any significant leakage (defined as a loss of 
more than 10% of perfusion media from the respective circulations), the experiment was 
defined as unsuccessful and terminated. Due to this, 6 perfusions had to be terminated early 
and discarded, and the remaining 6 were successful (n=3 for both euglycaemic and 
hyperglycaemic perfusions). 
Microvascular beds were perfused for 3h, changing the media every hour. In the last 10 
minutes, a 76Mr dextran tracer (76Mr; O.5mg/ml; conjugated with Tetramethyl Rhodamine 
Isothiocyanate (TRITC)) was introduced to the fetal circuit of all perfusions. Following fetal 
perfusion fixation (1% w/v PFA, 30 minutes) tissue biopsies were immersion fixed for 45 
minutes, rinsed in PBS, and then snap frozen in liquid nitrogen cooled isopentane. 
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5.3.3 Sampling of perfusion media and glucose measurements 
During the dual-independent placental perfusion, 1ml samples of perfusion media were taken 
from both maternal and fetal circulations hourly, immediately before replacement of the media. 
This media was then frozen for subsequent use for glucose measurements. 
Measurement of glucose concentration at each timepoint was performed first using Medi-test 
Glucose test strips for urine (RPC), using perfusion media with 5mM and 15mM glucose as 
measurement controls. The test-strips used colour values corresponding to 'negative' (0), 
'normal' (O.BmM), 50mg/dl (2.BmM), 150mg/dl (B.3mM), 5OOmg/dl (27.BmM), and >1000mg/dl 
(>55.6mM) glucose. 
Secondly, we measured glucose concentration in the samples using a HemoCue Glucose 201+ 
(HemoCue AB) blood glucose analyser. Each sample was tested in triplicate. Perfusion media 
with 5mM and 15mM glucose (known concentrations) were also analysed to assess the 
reliability ofthe machine to measure perfusion media samples. 
Lastly, glucose concentration measurements were performed with a YSI Model 2300 STAT PLUS 
Glucose and Lactate Analyser. Perfusion media with OmM, SmM, 10mM, 15mM and 20mM 
glucose (known concentrations) were also measured in triplicate to assess the reliability of the 
machine to measure perfusion media samples. 
5.3.4 Immunofluorescence (with VE-cadherin, total VEGF, VEGFb, PECAM-l and tracer) 
Immunofluorescence (using the methodology from Chapter 2) was performed on slices of 
samples using antibodies against VE-cadherin (555661, BD Biosciences; 5 ~ g / m l ) , , total VEGF 
(MAB293, R&D Systems; S ~ / m l ) , , VEGFb (MAB3045, R&D Systems; S ~ g / m l ) , , and the 
endothelial marker PECAM-l (BBA7, R&D systems; S ~ m l ) . . Goat anti-mouse FITC-conjugate 
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(F-0257, Sigma-Aldrich, 20Ilg/ml) was used as a secondary antibody for all primary antibodies 
(VE-cadherin, total VEGF, VEGFb and PECAM-l antibodies). 
5.3.5 H&E staining 
Haematoxylin and Eosin (H&E) staining was performed to allow structural detail to be evaluated. 
Slides were rehydrated in tap water, submerged for 5 minutes in Harris Haematoxylin, and 
washed in a bath of running tap water until the water cleared. They were then dipped in acid 
alcohol for 10 seconds, washed until there were no streaks on the slides, and dipped in Lithium 
Carbonate/Scott's Tap Water. Slides were then submerged in 1% Eosin for 5 minutes, and 
washed again in tap water. A series of dehydration steps were then performed, by dipping the 
slides in 50%, 70%, 90% and 100% alcohol for 10 seconds each. Finally, slides were dipped in 
fresh and finishing xylene for 2 minutes each, and mounted with DPX. 
5.3.6 Analysis of data 
The percentage of immunopositive vessels was analysed using selective random sampling and 
unbiased counting (as previously described in section 2.3.9 and Figure 2.2). The vessels which 
showed staining were sub-divided according to their location, using a 1-3 scale (location 1 being 
cytoplasmic localisation; location 3 being junctional localisation, see Figure 2.3A-D) for VE-
cadherin only. The percentage of vessels showing leakage was detected using the PECAM-l 
staining as a guide to where vascular profiles were in the FITC channel, and switching to the 
TRITC channel of the same area to see whether there were any hotspots around the vascular 
profiles (signifying leakage of 76Mr dextran tracer from the fetal circulation). 
GraphPad Prism version 5.01 statistical software was used for statistical analysis. The Mann-
Whitney U test was used to evaluate statistical significance for most groups. When analysing 
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the tracer leakage (functionality of the perfused placenta), our euglycaemic perfusion was also 
compared to tracer leakage from a 1h euglycaemic perfusion, with all conditions being the 
same except for duration, to make sure our longer 3h perfusion did not cause a functional 
change in the placenta. For correlations between tracer leakage and total VEGF or VEGFb 
Spearman correlation was used. For the glucose concentration analysis, the euglycaemic 
perfusion samples were compared to each other and to the hyperglycaemic samples with a 
Mann-Whitney U test (SmM maternal vs. SmM fetal and SmM fetal vs. lSmM fetal) . 
5.4 Results 
5.4.1 Functional characteristics of 3h perfusion 
The 3h perfusion exhibited normal pressure readings, which stayed constant for the duration of 
the perfusion at 20-80mmHg for the maternal circulation, and <20mmHg for the fetal 
circulation (Fig. 5.2). 
Figure 5.2: Representative trace of maternal (red trace) and fetal (blue trace) pressure throughout the 3h 
perfusion. There is no change in pressure in either circulation in the 3h perfusion. The change in pressure 
seen in the fetal trace at the end of the perfusion corresponds to the PFA fixation stage and the handling 
of the placenta following this. 
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Comparison with a previous set of 1h perfusions showed that there was no significant 
difference (p>0.05) in the number of vessels showing leakage, thus ensuring the integrity of the 
placental endothelial barrier during the 3h perfusion (Figure 5.3) . 
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Figure 5.3: Evaluation of 3h perfusion on functionality of the placenta. No significant differences (p>O.OS) 
were found between a Ih eugluycaemic perfusion and a 3h euglycaemic perfusion in the leakage of 76Mr 
dextran. Data (n=3 for both Ih control perfusion and for 3h euglycaemic perfusion) was analysed using 
Mann-Whitney U test. 
Furthermore, H&E staining showed normal placental morphology and no damage to tissue 
(Figure 5.4) . 
5,4.2 Molecular phenotype of the perfused placenta 
The expression of VE-cadherin, total VEGF and VEGFb in euglycaemic and hyperglycaemic 
perfusions is illustrated in Figure 5.5. 
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Figure 5.4: H&E staining of perfused placenta, showing normal morphology. A: Stem villous with 
a central vessel surrounded by fibrin (orange colour) . A syncytial knot can be seen in the process 
of separating from the trophoblast (arrow), a normal process in term placentae. B: Intermediate 
and terminal villi . In both micrographs, the morphology of the tissue shown looks normal. 
Magnification : x200. Scale bar: SOum. 
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Figure 5.5: Molecular phenotype of euglycaemic and hyperglycaemic perfused placentae. A: 
VE-cadherin phenotype in euglycaemic perfused placentae, found mostly at junctional locations. B: 
VE-cadherin phenotype in hyperglycaemic perfused placentae, displaying more VE-cadherin in 
cytoplasmic location than the euglycaemic perfusions (Al. C: Total VEGF phenotype in euglycaemic 
perfused placentae, showing few vessels immunopositive for VEGF, and some trophoblast 
immunoreactivity, but only minimal mesenchymal immunoreactivity. D: Total VEGF phenotype in 
hyperglycaemic perfused placentae, which display more vessels immunopositive for total VEGF than 
the euglycaemic perfusions (C). E: VEGFb phenotype in euglycaemic perfused placentae, showing 
vessels immunopositive to VEGFb, and some trophoblast (mesenchymal immunoreactivity shown in 
Fl. F: VEGFb phenotype in hyperglycaemic perfused placentae, showing fewer VEGFb 
immunopositive vessels than the euglycaemic perfusions (El. Glucose thus alters the perfused 
placenta molecular phenotype by reducing VE-cadherin junctional localisation, increasing total VEGF, 
and decreasing VEGFb immunoreactivity. Eu: euglycaemia, Hy: hyperglycaemia, arrow: VE-cadherin 
junctional location, v: vessel, t: trophoblast, m: mesenchyme, asterisks: non-vascular VEGF splice 
variants immunoreactivity. Magnification: x200. Scale bars: lOOum. 
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5.4.2.1 VE-cadherin results 
In both euglycaemic (Figure 5.5A) and hyperglycaemic (Figure 5.5B) perfusion, VE-cadh erin wa s 
localised mostly in the paracellular junctions of the endothelial cells, giving beads-on-a-string 
pattern of staining, with little VE-cadherin having cytoplasmic localisation, giving diffuse 
staining. There was a statistically significant decrease (p<0.05) in VE-cadherin -immunopositive 
vessels on addition of 15mM glucose (Figure 5.6) . 
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Figure 5.6: Effect of high glucose on percentage of vessels immunopositive to VE-cadherin. Data (n=3 fo r 
both euglycaemic and hyperglycaemic perfusions) was analysed using Mann-Whitney U test . a:p<O.OS 
relative to euglycaemia . 
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There was also a statistically significant decrease (p<0.05) in junctional VE-cadherin (location 3, 
as defined in Figure 2.3) in hyperglycaemic perfused placentae compared to euglycaemic-
perfused placentae, and a statistically significant increase (p<0.05) in cytoplasmic localised VE-
cadherin (location 1, see Figure 2.3) in the placentae perfused with hyperglycaemic media 
compared to the placentae perfused with euglycaemic media (Figure 5.7). 
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Figure 5.7: Effect of high glucose on localisation of VE-cadherin in immunopositive vessels. Data (n=3 for 
both euglycaemic and hyperglycaemic perfusions) was analysed using Mann-Whitney U test. a: p<O.05 
relative to cytoplasmic location in euglycaemic perf us ions, b: p<O.Ol relative to junctional location in 
euglycaemic perfusions. 
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5.4.2.2 Total VEGF results 
Total VEGF was immunolocalised to the fetal vessels in the chorionic villi, partly in the 
trophoblast and minimally in the mesenchyme in normal euglycaemic placentae; this pattern of 
total VEGF localisation was unchanged in the hyperglycaemic perfusions (Figures 5.5C-0). 
Only the total VEGF in the placental vessels was counted, as per the aims of this chapter. There 
was a significant increase in total VEGF expression (p<O.Ol) in the placentae perfu sed with 
hyperglycaemic media compared to the euglycaemic media (Figure 5.8). 
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Figure 5.8: Effect of high glucose on percentage of vessels immunopositive for total VEGF. Data (n=3 for 
both euglycaemic and hyperglycaemic perfusions) was analysed using Mann-Whitney U test. a: p<O.Ol 
relative to euglycaemic perfusion. 
198 
5.4.2.3 VEGFb resu lts 
Under both euglycaemic and hyperglycaemic perfusions, VEGFb immunolocated in fetal vessels' 
endothelium, perivascular layer and trophoblast (Figure 5.5E-F) . The percentage of VEGFb 
immunolocalisation in the latter two tissues was not counted as it did not answer the aims of 
this chapter. There was a significant decrease in VEGFb immunopositive vessels in the 
hyperglycaemic perfusion group compared to the euglycaemic group (p<0.05) (Figure 5.9) . 
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Figure 5.9: Effect of high glucose on percentage of vessels immunopositive for VEGFb. Data (n=3 for both 
euglycaemic and hyperglycaemic perfusions) was analysed using Mann-Wh itney U test. a: p<O.05 relative 
to euglycaemic perfusion. 
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5.4.3 PECAM-l immunoreactivity and tracer leakage 
Immunopositive vessels were not counted, but on visual inspection all vessels were 
immunopositive to PECAM-1, except vessels with very severe tracer leakage. This was true for 
both euglycaemic and hyperglycaemic perfusions (Figure 5.lOA and C). 
Leakage was analysed by comparing PECAM-l immunolocalisation, to find vascular profiles (as 
PECAM-1 is known not to be affected by glucose), on the FITC channel, and detection of 76Mr 
dextran, observed as 3 or more hotspots in the TRITC channel (Figure 5.108 and D). 
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Figure 5.10: Functional phenotype of euglycaemic and hyperglycaemic perfused placentae. A: 
PECAM-l immunoreactivity in euglycaemic perfused placenta (Eu), highlighting where vessels (v) are 
located, taken in the FITC microscope channel. B: Corresponding TRITC microscope channel 
illustrating the same field of view as A, showing there is tracer leakage (vt) in one vessel out of four 
highlighted. C: PECAM-l immunoreactivity in hyperglycaemic perfused placenta (Hy), highlighting 
where vessels (v) are located, taken in the FITC microscope channel. D: Corresponding TRITC 
microscope channel illustrating the same field of view as C, showing there is more vessels showing 
tracer leakage (vt). Eu: euglycaemia, Hy: hyperglycaemia, v: vessels, vt: vessels with tracer hotspots. 
Magnification: x200. Scale bar: 100um. 
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By comparing the PECAM-l immunoreactivity in the FITC channel with the tracer leakage 
hotspots in the TRITC channel , we found that there was a mild significant increase (p<O.OS) in 
tracer leakage in the vessels of the hyperglycaemic perfusion compared to the euglycaemic 
perfusion (Figure 5.11). 
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Figure 5.11: Effect of hyperglycaemia on tracer leakage. Data (n=3 for both euglycaemic and 
hyperglycaemic perfusions) was analysed using Mann-Whitney U test. a: p<O.Os relative to euglycaemia. 
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5.4.4 Correlation of tracer leakage to total VEGF and to VEGFb 
Spearman correlation analyses were conducted between the percentage of vessels exhibiting 
tracer leakage and total VEGF and splice variant VEGFb. 
Spearman correlation between tracer leakage and total VEGF revealed a non-significant (p>0.05) 
positive correlation with a Spearman r value of 0.5429 and an alpha value >0.05. (Figure 5.12). 
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Figure 5.12: Non-significant (a>O.05) positive (r=O.5429) correlation between total VEGF and tracer 
leakage. Data (n=6) was analysed with Spearman correlation. 
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A statistically significant (p<0.05) negative correlation was revealed between tracer leakage and 
VEGFb with a Spearman r value of -0.8857 and an alpha value <0.05 (Figure 5.13). 
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Figure 5.13: Significant (u<O.OS) negative (r=-O.88S7) correlation, between VEGFb and tracer leakage. 
Data (n=6) was analysed with Spearman correlation. 
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5.4.5 Glucose measurements 
The results shown is section 5.4.5.1 and 5.4.5.2 refer to measurements with the YSI Model 2300 
STAT PLUS Glucose and lactate Analyser. The results of the glucose measurements by 
HemoCue Glucose 201+ blood glucose analyser are shown in Appendix 3. 
5.4.5.1 Measured glucose readings vs. actual glucose concentrations 
The YSI Model 2300 STAT PLUS Glucose and Lactate Analyser gave the most precise results for 
the known concentration samples, although the 5mM and lSmM glucose concentration 
samples seemed to be consistently low (Table 5.1). 
Control readings: 
OmM glucose 0 0.02 0.05 
SmM glucose 3.92 3.89 3.85 
lOmM glucose 10.5 10.3 10.3 
lSmM glucose 13.9 14.1 14.1 
20mM glucose 20.5 20.4 20.8 
Table 5.1: Glucose measurements (using YSI Model 2300 STAT PLUS Glucose and lactate Analyser) of the 
known glucose concentration control samples. 
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5.4.5.2 Glucose measurement results 
As a reminder, at the start of the experiment the fetal circulations of both groups were 
perfused w ith 5mM glucose. It was only the maternal circulations which were perfused with 
either 5mM glucose (for the so-called 'euglycaemic perfusions') or 15mM glucose 
('hyperglycaemic perfusions' ). 
In the fetal circulation media samples taken at 1h and 2h, there was a significant difference 
(p<O.05) in the glucose concentrations from the euglycaemic and hyperglycaemic perfusions 
(5mM and 15mM glucose in the maternal circulations, respectively), whilst the media sampled 
at the end of the perfusion protocol (3h) did not reveal any differences. There were also no 
significant differences (p>O.05) between the fetal and maternal circulation samples from the 
euglycaemic perfusions (Figure 5.14). 
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Figure 5.14: Glucose measurements in the maternal and fetal circulations of the euglycaemic and 
hyperglycaemic perfusions. The hyperglycaemic perfusion maternal circulation was not included in the 
analysis, given its known higher glucose concentration. Data (n=3 for all timepoints and circulations) was 
analysed using Mann-Whitney U test. a: p<O.OS relative to 1h euglycaemic perfusion fetal circulation, 
b:p<O.05 relative to 2h euglycaemic perfusion fetal circulation. 
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5.5 Discussion 
5.5.1 Summary of results 
The statistically significant decrease of both VE-cadherin junctional localisation (Figures 5.5A-B 
and 5.7) and VEGFb expression (Figures 5.5E-F and 5.9), and the statistically significant increase 
in total VEGF expression (Figures 5.5C-D and 5.8) seen in hyperglycaemic perfusions compared 
to euglycaemic perfusions indicate that there might be a phenotypic change in the vasculature 
of the perfused placenta after a 3h 15mM glucose insult. Indeed, we found that the 
functionality of the hyperglycaemic-perfused placenta had changed, and was mildly but 
statistically significantly more leaky to 76Mr dextran (Figures 5.10B and D and 5.11). There was 
a significant correlation (a<0.05, r=-D.8857) between VEGFb and the percentage of vascular 
profiles showing leakage (Figure 5.13), but not between the latter and total VEGF (Figure 5.12). 
Similarly to Chapter 4, as total VEGF increased, and VEGFb decreased, VEGFa must have 
increased, therefore the ratio VEGFa/VEGFb must have changed; this indicated that the 
VEGFa/VEGFb ratio might be a good predictor of vascular leakage under hyperglycaemic 
conditions, and that this ratio may contribute towards the increased vascular leakage seen in 
the diabetic placenta. Repeated postprandial glucose events of long duration (3h) may result in 
overt placental vascular changes in diabetic pregnancies. 
5.5.2 Expression of VE-cadherin 
VE-cadherin was shown to be decreased after 3h perfusion with 15mM glucose, compared to 
5mM glucose. This was perhaps surprising given the results of Chapter 3, which showed an 
increase in VE-cadherin expression in normal placental explants incubated for 4h with 15mM 
glucose. This highlights the importance ofthe 3D architecture and a more physiological method 
with flow present in the perfused vascular bed as opposed to the limited 3D architecture of the 
explants with no flow. The placental perfusion protocol uses intact placental tissue, without 
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any vascular injury except at the site of cannula insertion. The vasculature in explants instead 
displayed considerable injury, as they were severed from the main placenta organ in the 
excision process. The sample of placenta which was fixed before the excision process (Figure 
2.6C) although unusable for counting due to the high number of red blood cells remaining in 
the tissue, did show a majority of vessels with intenSity 3 VE-cadherin immunoreactivity, 
resembling the phenotype seen in normal perfused placenta. This could indicate that the tissue 
injury from the excision process in Chapter 3 caused the initial decrease in VE-cadherin 
immunopositive vessels, hence explaining the difference in our VE-cadherin results between 
Chapter 3 and Chapter 5. 
Leach and colleagues have shown that in short normal placental perfusions, VE-cadherin 
expression ranges between 92.9-99.3% of all vascular profiles (Babawale et 01., 2000; leach et 
01., 2004). In our 3h euglycaemic perfusion (Figure 5.5A), we are seeing 86.3% immunopositive 
vessels (Figure 5.6), a decrease of around 10 percentage points from previous studies. This 
could be due to the long duration of perfusion, as some vessels could be under stress from 
lactic acid produced by the stressed placenta. However, we have also observed that the 
functional role of the placenta was not disturbed, as tracer leakage after the 3h perfusion was 
statistically similar to that of a 1h perfusion (Figure 5.3). Furthermore, most (88.2%) of the VE-
cadherin immunoreactivity was in a junctional location (Figure 5.7), and therefore is 
contributing to junctional integrity. 
Hyperglycaemia (Figure 5.5B) caused a decrease in VE-cadherin immunoreactivity to 76.6% 
(Figure 5.6). Interestingly, this is similar to the 79.6% VE-cadherin immunopositive vessels seen 
in GDM (Babawale et 01., 2000). This makes logical sense, as GDM presents in the second or 
third trimester of pregnancy after vascular maturation, and is therefore a shorter duration of 
insult than Type 1 diabetes where the vasculogenesis, angiogenesis and maturity of the 
placenta occur in a hyperglycaemic environment. 
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However, if we look at the difference between euglycaemic and hyperglycaemic VE-cadherin 
immunoreactivity (hence taking into account the lower VE-cadherin seen in our euglycaemic 
perfusion), the decrease in VE-cadherin immunopositive vessels in GDM compared to normal 
placentae in Babawale et al. (2000) is around 19 percentage points, whilst in our 3h perfusion it 
is around 10 percentage points (Figure 5.6), and furthermore the VE-cadherin junctional 
location (location 3) decreases in our hyperglycaemic perfused placentae compared to the 
euglycaemic perfused placentae (72.5% vs. 88.2%, a difference of ",,15 percentage points) 
(Figure 5.7). In this analysis, the decrease in VE-cadherin immunoreactivity in hyperglycaemia 
compared to euglycaemia is about half of that seen in GDM. This would mean that one 
hyperglycaemic insult is not sufficient to create the VE-cadherin phenotype seen in GDM, and 
therefore multiple hyperglycaemic insults and/or other factors contribute to the GDM 
phenotype. This would give hope for treatment of GDM patients after diagnosis, as the damage 
to the placental vasculature could be limited by monitoring and counselling the patient. 
VE-cadherin is a junctional protein, which regulates cell-cell adhesion through adherens-
junctions. However, one must remember that these types of junctions are not the only 
regulators of endothelial leakiness, as tight junctions play an important and size-limiting role. 
Thus, whereas VE-cadherin is lost from 10% of vessels, concomitant loss of tight junctional 
integrity in large vessels is also needed for the altered phenotype of increased leakage. We 
shall discuss leakage in our perfusion model in section 5.5.5. 
5.5.3 Expression of total VEGF 
Total VEGF levels after the euglycaemic perfusion (Figure 5.5C) were 7.7% of all vessels (Figure 
5.8). This is a very small percentage of vessels, and corresponds well with the findings of Leach 
et al. (2004), who saw only minimal VEGF immunoreactivity in normal perfused placentae. 
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Under 3h 15mM glucose insult, the level of total VEGF increases substantially (Figure 5.50), 
being found in 38.8% of vessels (Figure 5.8). This is a very large increase, and we would have 
previously expected a large increase in permeability as a result. However, a couple of 
considerations need to be made. 
VEGF increases permeability in part by VEGFR-2 phosphorylating VE-cadherin, which in turn will 
disrupt the junctional stability (Esser et 01., 1998). However, as discussed in section 5.5.2, there 
was only about a 15 percentage point difference in VE-cadherin junctional localisation (location 
3) in response to hyperglycaemia compared to euglycaemia (Figure 5.7). This suggests that not 
all VEGFR-2 are being activated by VEGF. 
We know that VEGFb acts as a competitive inhibitor of VEGFa (Cebe Suarez et 01., 2006). 
Therefore, more total VEGF being present does not necessarily mean more VEGFa bound to 
VEGFR-2, and therefore more total VEGF would not necessarily mean an increase in VEGF-
induced leakage. This theory is in agreement with a perfusion study by Brownbill et 01. (2007), 
where VEGF-containing perfusions for 30 minutes from the fetal circulation had no effect on 
the tracer leakage they observed. 
Another consideration is that adherens junctions (and VE-cadherin) are not the only junctions 
which need to be disrupted to cause an increase in permeability. Tight junctions also need to 
be destabilised before increased leakage can occur. It has been shown in rat retinas (Antonetti 
et 01., 1999) that following VEGF injection there was an increase in occludin phosphorylation 
which was maximal 45 minutes following injection and had started to reverse by 90 minutes 
(i.e., phenotype not permanent). Another study showed that this occludin phosphorylation was 
caused via PKC activation by VEGF (Harhaj et 01., 2006). Importantly, this pathway is mediated 
by the VEGFR-2 receptor, so this is also potentially subject to VEGFb competitive inhibition. 
None of these studies test the effect of VEGFb on occludin. Therefore, analysis of VEGFb is 
essential to understand the mechanisms at play in a 3h hyperglycaemic perfusion. 
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5.5.4 Expression of VEGFb 
VEGFb was present in 51.0% of vessels after a 3h euglycaemic perfusion (Figures 5.5E and 5.9). 
This was somewhat lower than what Bates et 01. (2006) found in normal placental samples, but 
their samples included amnion, chorionic villi and stratum basale, whilst we were looking at 
VEGFb expression in placental vessels only, so a difference in expression between our results 
and Bates' is not of concern. 
After a 3h hyperglycaemic perfusion (Figure 5.5F), 38.6% of vessels were immunopositive for 
VEGFb (Figure 5.9), representing a decrease of 12 percentage points compared to euglycaemic 
perfusion (Figures 5.5E and 5.9). Decreases in VEGFb expression have been found in diabetic 
vascular complications such as diabetic retinopathy (Perrin et 01., 2005), as well as in common 
diabetic pregnancy complications, such as pre-eclampsia (Bills et 01., 2009; Bates et 01., 2006). 
However, to the best of our knowledge, this is the first time that VEGFb decrease has been 
shown following such an acute, short and mild (only one 3h 15mM glucose hit) insult. 
In an abstract by Reeve et 01. (2006), VEGFb levels in vessels from GDM placentae were not 
seen to be significantly different from normal placentae, whilst the levels in placentae from 
Type 1 diabetics were significantly lower than normal and GDM placentae. However, there was 
a progressive decrease in VEGFb from normal>GDM>Type 1. The standard deviation was higher 
than in our experiments, possibly because the glycaemic levels present in the placentae 
immediately before perfusion could have been different (Le., some could have been in a 
hyperglycaemic environment immediately before delivery, some in an euglycaemic 
environment). However, the non-significant decrease between VEGFb levels in GDM 
compared to the normal placentae was of 10 percentage points (normal 50%, GDM 40%) 
(Reeve et 01., 2006), which is similar to our data. Therefore, VEGFb may playa role in GDM 
pathological phenotypic changes. 
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The decrease in VEGFb represents an uneven decrease compared to the increase in total VEGF 
(VEGFb 12 percentage point decrease, total VEGF >30 percentage point increase, Figures 5.9 
and 5.8, respectively). If VEGFb were acting as a competitive inhibitor of VEGFa, as described 
by Cebe-Suarez et 01. (2006), VEGFb would be the determinant splice variant that regulates 
VEGF-induced leakage, as an increase in VEGFa would not be sufficient if the VEGFR-2 receptor 
responsible for mediating its effects were already being bound by the inhibiting splice variant 
VEGFb. 
5.5.5 Tracer leakage 
After the 3h euglycaemic perfusion (Figure 5.10B), 10.6% of vascular profiles showed tracer 
leakage to 76Mr dextran tracer (Figure 5.11). This compares well with the study of leach et 01. 
(2004) which shows 'minimal' tracer glucose in normal placentae perfused only for a 20 minute 
equilibration period followed by a ten minute tracer perfusion. Furthermore, in their abstract, 
Reeve et 01. (2006) reveal that there were 10.75% of normal vascular profiles leaky to 76Mr 
dextran tracer, which is similar to our findings. 
In our hyperglycaemic perfused placentae (Figure 5.100), we observed 17.9% of vascular 
profiles leaky to 76Mr dextran tracer (Figure 5.11). This relates well with studies on diabetic 
patients which have shown increases in permeability in other tissues (Yamaji et 01., 1993; Beals 
et 01., 1993; Huber et 01., 2006). We can add the placenta to the list of tissues that become 
leakier in response to high glucose. Hempel et 01. (1997) have shown that, at least in porcine 
aortic endothelial cells, the increased permeability is due to activation of the PKC pathway; this 
pathway is therefore a possible cause of the increased leakage we observed in our perfused 
placentae. In the same paper, the authors discuss the fast response of this increase in 
permeability (peak permeability after 20mM glucose insult at 40 minutes), and this also fits in 
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well with our experiments, as we have seen an effect after 3h acute, as opposed to chronic, 
hyperglycaemic insult. 
The difference in leakage between euglycaemic and hyperglycaemic perfused placentae is 7 
percentage points (Figure 5.11), which relates well with the 10 percentage point decrease in VE-
cadherin immunoreactivity (Figure 5.6) and the 12 percentage point decrease in VEGFb 
expression (Figure 5.9), but less so to the 31 percentage point increase in total VEGF expression 
(Figure 5.8). This could indicate that VEGFb decreases are more predictive of vascular leakage 
than total VEGF increases in those tissues that express the b splice variant. 
Our 17.9% vascular leakage also relates well with the findings of Reeve et 01. (2006) that show 
76Mr dextran tracer leakage in 20.12% of vascular profiles in GDM placentae. These very 
similar results indicate that the phenotype seen in GDM can be caused by a single postprandial 
glucose excursion, and that subsequent hyperglycaemic insults may add very little to the final 
phenotype. Of course though, the phenotype we observed in this chapter may be reversible, 
and may need further hyperglycaemic insults to become permanent. 
In their paper of perfused Type 1 placentae, Leach et 01. (2004) do not give the percentage of 
vascular profiles showing leakage. The leakiness of the Type 1 placenta is, however, likely to be 
more than in either the functional phenotype we observed in section 5.4.3 or the GDM 
phenotype, as in Leach et 01. (2004) the Type 1 placenta has a much more pronounced 
phenotype in terms of increases of total VEGF and decreases of VEGFb. 
In the hyperglycaemic perfusion, the functional effect of the increased total VEGF and 
decreased VEGFb was a mild but significant increase in leakage (from 10.6% to 17.9%, Figure 
5.11). We would not expect to see too much change in the functional phenotype of the 
placenta, as we must remember that even poorly controlled diabetic patients, although with 
complications such as macrosomia, are capable of successfully carrying a pregnancy, and 
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therefore any functional changes in the vasculature of their placentae must be subtle in nature, 
otherwise their offspring would not survive. 
VEGFb has been shown to be important in vascular permeability. However, whether the VEGFb 
decrease shown here is a cause or consequence of the increased leakage, has not been 
investigated. However, as VEGFb has been shown in human glomerular endothelial cells to 
cause decreased permeability (Bevan et 01., 2008), it is likely that this is the case in our placental 
perfusion model. The causality of the VEGFb decrease could be investigated by performing a 
timecourse experiment, where the tracer leakage is monitored and the beginning of leakage 
observed. If a decrease in VEGFb is detected shortly before the occurrence of tracer leakage, 
then VEGFb is a possible cause of the increased permeability, whilst if the tracer leakage 
precedes the decrease in VEGFb, then the decreased splice variant is an effect of increased 
permeability. Such an experiment might require several preliminary experiments to ascertain 
the timepoint of increased leakage, and further experiments to identify the timing of VEGFb 
decrease. An in vitro cell culture experiment investigating the causality of VEGFb decrease 
could also be used, simplifying the setup but losing the 3D placental architecture present in the 
perfusion model, hence leading to a less accurate physiological model. 
Whether the amount of VEGFa present is also important, and hence whether the ratio of 
VEGFa/VEGFb is critical in the vascular dysfunction exhibited by leakage, will be discussed next. 
5.5.6 Correlation between VEGF splice variants and tracer leakage 
There was a positive significant correlation (p<O.OS) between VEGFb and the percentage of 
vascular profiles exhibiting leakage (Figure 5.13), but not between total VEGF and tracer 
leakage (p>O.05, Figure 5.12). As VEGFa is a pro-permeability and VEGFb is an anti-permeability 
splice variant, this result indicates that it is the proportion of the variants (ratio) rather than 
absolute quantities of the two molecules (total VEGF) that is important in the formation of leaks 
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in the otherwise normal vasculature in response to 15mM glucose, with alteration of the VEGFb 
splice variant being a predominant feature. 
This is a clinically powerful correlation, as if this is shown to hold true not only in normal 
placentae subjected to one hyperglycaemic insult but also in diabetic placentae with multiple 
hyperglycaemic and other insults, it could pave a way for further treatment. We already know 
that HbA1c levels cannot fully account for the macrosomia observed in diabetic pregnancies 
(Schwartz et al., 1994), and that postprandial high glucose more accurately reflects the status of 
the placental-fetal unit (Jovanovic-Peterson et al., 1991; Kyne-Grzebalski et al., 1999). However, 
if the VEGFb to leakage correlation holds true for the conditions mentioned above and if the 
VEGFa/VEGFb ratio could be accurately measured, we could have an accurate predictor of 
vascular dysfunction in the placenta, and a predictor of macrosomia in the infant. 
5.5.7 Our 3h perfusion model 
It was mentioned in section 5.1.6 that a possible complication of using media instead of blood 
as a perfusate, is that media might cause leakage of the vasculature regardless of glycaemic 
levels. This was a concern to us, especially since we had a longer duration of perfusion than our 
laboratory usually employs (lh). However, we can see in Figures 5.3 and 5.11 that only 10.6% 
of vessels in the euglycaemic perfusion showed leakage, which is an acceptable level for the 
analysis ofthe effect of hyperglycaemia on the leakage of dextran. In addition, when compared 
to a 1h normal placental perfUSion, which are normally performed in our laboratory, there is no 
statistically significant difference (10.6% vs. 11.5%, respectively, Figure 5.3). Furthermore, the 
pressure readings from both maternal and fetal circulations remained constant throughout the 
perfusion (Figure 5.2); therefore, no blockages and/or significant leaks occurred (Panigel, 1962), 
as these would have been shown in the pressure trace. 
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VE-cadherin immunolocalised to the junctional space in around 88% of vessels in euglycaemia, 
dropping to around 73% in hyperglycaemia (Figure 5.7). Although these values are higher than 
in explants (perhaps due to the excision artefacts in the latter), even the euglycaemic 
immunopositive vessels were fewer than seen in previous perfusions, where 92.9-99.3% of 
vessels were immunopositive for VE-cadherin (8abawale et 01., 2000; Leach et 01., 2004). 
5.5.8 PECAM-l immunoreactivity 
PECAM-1 immunoreactivity did not change in the hyperglycaemic perfusion compared to the 
euglycaemic perfusion (Figure 5.10A and C), and was lost from the endothelium only when 
there was severe 76Mr dextran tracer leakage. In fact, in this experiment it was used primarily 
to visualise more clearly the endothelium around blood vessels in order to count tracer leakage. 
It has been shown that 24h exposure to high glucose (30mM) does not affect PECAM-110cation 
at the junctional space in HUVEC, and only after 13 days was PECAM-1 affected by the 
hyperglycaemic environment (Baumgartner-Parzer et 01., 1995). Furthermore, in short duration 
perfusions comparing placentae from Type 1 diabetic pregnancies to normal placentae, PECAM-
1 expression remained similar (96.3% vs. 96.6%, respectively) (Leach et 01., 2004), 
demonstrating that in placental vessels long term exposure to high glucose, as seen in Type 1 
diabetic pregnancies, has no effect on PECAM-1 immunoreactivity. Therefore, PECAM-1 was a 
useful marker to highlight the vasculature. 
5.5.9 Glucose measurement methods 
We detailed in Section 5.3.2 how we sampled the media to calculate the glucose concentration 
in it. To summarise, we attempted to calculate the glucose concentrations in this media by 
three methods: urine test-strips, HemoCue 201+ blood glucose analyser and YSI Model 2300 
STAT PLUS Glucose and Lactate Analyser. The most precise results were obtained with the YSI 
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Model STAT PLUS Glucose and Lactate Analyser (Table 5.1), and are discussed in sections 5.5.9.2 
and 5.5.10. The results from the HemoCue Glucose 201+ blood glucose analyser are shown in 
Appendix 3, and both this and the urine strips are discussed in section 5.5.9.1. 
5.5.9.1 Problems arising from glucose test strips and HemoCue Glucose 201+ measurements 
When using the glucose test strips, normally used for urine glucose testing, according to the 
manufacturer's instructions, the resulting colour values for the 5mM, 15mM and 25mM glucose 
standards all corresponded to the colour values at around 27.8mM glucose. As this did not give 
any valuable information, this test was discontinued. Human urine does not have the same 
osmolarity as human blood or our perfusion media, and this could have been the cause of the 
failure of the test-strips to accurately record the glucose concentrations in our media. 
Thus, we then attempted the measurement of glucose concentration with the HemoCue 
Glucose 201+ glucose analyser, normally used for measuring blood glucose concentrations 
(according to the manufacturer). The control 5mM glucose perfusion media tested gave values 
of 4.5mM, 7mM and 8.6mM glucose (average 6.7mM glucose) and the control 15mM glucose 
tested gave values of 14.5mM, 20.5mM, and 20.6mM glucose (average 18.6mM glucose). 
These were very inaccurate values with great variation between them, and therefore the data 
from the perfused media samples would have been inaccurate, and no conclusions could be 
discerned from it (for results, see Appendix 3). 
A search of the literature revealed that the HemoCue Glucose 201+ analyser is not ideal for 
measuring glucose in our perfusion media. Bellini et 01. (2007) showed that this system tended 
to overestimate glucose values by around 1mM glucose. Furthermore, a study by Deshpande et 
01. (1996) reveals that the HemoCue Glucose 201+ analyser is more accurate in plasma than in 
whole blood, and identifies haematocrit as being a confounding factor in blood. Our perfusion 
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media contains albumin and dextran to replicate the osmolarity of blood, and therefore may be 
confounding our results. 
Most research groups which measure glucose transport across the placenta use radiolabelled 
glucose, for example Schneider's group (2003). This may indeed be the most accurate and 
precise method of measuring glucose flux in the placenta. Also, the flux is measured in 
~ m o l / m i n / g , , and therefore even an accurate measurement would have been meaningless, as 
we did not measure the weight of the perfused cotyledon. However, as measuring glucose flux 
across the placenta was not one of our main aims for these experiments, these additional 
methods were not included in our experimental design. 
5.5.9.2 YSI Model 2300 STAT PLUS Glucose and lactate Analyser measurements 
Following the methods discussed in section 5.5.9.1, we then sought a more accurate and 
precise method of measuring glucose, to allow the identification of the small differences that 
we expect from our data. We therefore performed measurements again using the YSI Model 
2300 STAT PLUS Glucose and lactate Analyser. This latter method gave the most precise results, 
although the known glucose concentrations of 5mM and 15mM glucose gave consistently low 
readings (see Table 5.1). The results obtained by using this method will be discussed in the next 
section (5.5.10). 
5.5.10 Glucose concentrations in perfused media 
The results show that in response to hyperglycaemia in the maternal circulation (compared to 
euglycaemia in the maternal circulation), there is increased glucose flux across the placenta 
(and hence increased glucose concentration in the fetal circulation) in the first and second 
hours of the perfusion. In contrast, in the third hour there is less glucose movement from the 
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maternal to the fetal circulation (Figure 5.14). This is an interesting result which has 
implications for glucose management in the diabetic pregnancy, as even short maternal 
hyperglycaemic periods (lh) result in peaks in fetal blood glucose. In a laboratory setting, this 
short period between onset of hyperglycaemia and increased glucose transfer to the fetal 
circulation implies that shorter perfusions might be appropriate for future perfusion studies 
into glucose effects. 
The placenta seems to show an adaptation to the hyperglycaemic insult by the third hour, with 
glucose levels returning to levels similar to the euglycaemic perfusions. However, at 3h, the 
standard deviation increased with respect to earlier timepoints (Figure 5.14), indicating a 
variation in individual placentae response to hyperglycaemia. Decreased flux across the 
placenta may be due to a decrease in GlUTl transporters in the trophoblast, as reported by 
Hahn et 01. (1998), who observed a decrease in GlUTl mRNA and protein after a 24h 25mM 
glucose cell culture experiment with human trophoblast cells. Individual differences in this 
adaptation may have caused the variation we observed in our results. 
There was no significant difference between the maternal and fetal euglycaemic perfusions. 
According to Schneider (2003), where there are equal maternal and fetal glucose 
concentrations, the maternal circulation provides 70% to the glucose uptake of the placentae, 
whilst the fetal circulation only contributes to 30%. This should theoretically lead to a 
significant difference between the maternal and fetal glucose circulations. At the 3h sampling, 
the euglycaemic maternal sample showed a small (non-significant) decrease compared to the 
euglycaemic fetal circulation (see figure 5.14). The small sample size and the variation seen 
among our samples could be masking the difference. 
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5.5.11 Critique of experimental design 
The perfusion model we used in this chapter is the best physiological method we could have 
used under our circumstances. However, even though it represents a vast improvement over 
the explants methodology used in Chapters 2-4, it does not completely simulate the in utero 
environment. One of the problems is that the placental perfusion is metabolically stable, which 
might be unlike the placenta in pregnancy. Another point of note is that perfusions are unable 
to observe parameters such as changes in blood flow (Bourget et 01., 1995). However, the 
placental perfusion model is still to date the closest model to the in utero environment. 
It is noteworthy that there is no osmolarity control in this experiment. We saw in Chapter 3 
that mannitol was not a good control for glucose experiments in our settings. We could have 
used L-glucose if necessary, but it proved unnecessary, as the normal range of blood osmolarity 
is 280-303mOsm/I, and our perfusion media was 292 mOsm/1 for the euglycaemic perfusate 
and 302mOsm/1 for the hyperglycaemic media, i.e., both were within the normal range. 
Therefore, we decided that the use of a control was unnecessary, as the difference in 
osmolarity in such perfusates was of non-significant physiological importance. 
5.5.12 The emerging diabetic phenotype 
In this chapter, we have seen how high glucose can simulate the diabetic phenotype of high 
VEGFa, lowered VEGFb, disturbed junctional stability, and most importantly, differences in the 
functionality of the placenta in respect of leakiness of the vascular endothelium. However, we 
must remember that high glucose represents only half of the diabetic phenotype. The 
Pedersen hypothesis (1954) as explained in section 5.1.2 states that the fetus is exposed to high 
insulin levels in utero in response to high maternal glucose. How hyperinsulinaemia affects the 
phenotype of the human perfused placenta will be explored in section 6.2.2.4. 
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5.6 Summary 
Our results indicate that there is an altered phenotype in the normal placenta when exposed 
to a single lSmM glucose insult for 3h. This phenotype resembles the placental phenotype 
seen in GDM, but not Type 1 diabetes, in terms of VE-cadherin immunolocalisation, VEGFb 
expression, and importantly, the functional change in vascular leakage to 76Mr dextran tracer. 
We have therefore succeeded in re-creating a diabetic phenotype with a single lSmM glucose 
insult. 
VEGFb was then seen to be significantly correlated (a<O.OS) to the tracer leakage in our 
perfusion model, indicating that the measurement of the proportion of this splice variant 
compared to total VEGF might be an important predictor of vascular leakage, at least in 
normal placenta subjected to short (3h) hyperglycaemic insult. 
Whether the diabetic phenotype can be recreated, and whether VEGFb plays the same 
important role in the development of vascular leakage for the other main complication in the 
diabetic pregnancy, fetal hyperinsulinaemia, is a major avenue for further investigation. 
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Chapter 6 
General Discussion 
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6.1 Summary of findings 
There are three main findings that have arisen from this piece of research that contribute to the 
body of knowledge in the placental vasculature field. 
Firstly, the observation that a single lSmM glucose insult provokes a change in the phenotype 
of the vasculature of a normal term placenta by increasing the total VEGF expression and 
decreasing VEGFb expression (hence VEGFa must be increasing and therefore the ratio of the 
two splice variants must be changing) in the endothelial layer, recreating the phenotype seen in 
the diabetic milieu. 
Secondly, the fact that VEGFb is differentially regulated by glucose than its splice variant VEGFa 
in the placenta, as glycaemic insult decreases VEGFb expression whilst total VEGF expression 
does not change in explant culture. This pattern of downregulation was altered in placentae 
from Type 1 diabetic pregnancies, where no downregulation of VEGFb expression was seen on 
further glycaemic insult. 
Thirdly, the leakage to macromolecules seen in the perfUSion model as a result of a 3h 
perfusion with lSmM glucose is significantly correlated with VEGFb but not total VEGF, a 
functional read-out which indicates that VEGFb is important in this process. As VEGFb 
decreased and total VEGF increased in hyperglycaemic perfusions compared to euglycaemic 
perfusions, VEGFa must be increasing, thereby changing the VEGFa/VEGFb ratio. This ratio may 
act as a predictor of vascular dysfunction in the placenta. 
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6.2 General Discussion 
6.2.1 Possible models for glucose effects on placental vascular leakage 
Three different possibilities for how glucose could be affecting the expression of total VEGF, 
VEGFb, VE-cadherin and leakage of the placental vasculature seen after acute lSmM glucose 
insult are here proposed: 
The first model (Figure 6.1A), valid only in the explants, is that glucose exerts its effects on the 
trophoblast, and the trophoblast releases signalling molecules and hormones into the media 
which will then travel to the endothelial layer, which will subsequently become leaky under the 
effects of these molecules. Signalling molecules may be transported via the media to the 
endothelium in the explants studies. This is not possible in the perfused placenta as the two 
circulations are separate, and therefore the endothelium would not be exposed to any secreted 
substance in the maternal circulation. This model could theoretically be a possibility in the 
explants, as there is only one reservoir for the media (the well of the plate) and therefore 
secreted substances could be transferred through the media to the endothelium; however, the 
distance the media would have to travel in possibly collapsed vessels to the capillaries in 
terminal villi means that it is unlikely that the media the trophoblast is exposed to would reach 
the endothelium of the smallest vessels. 
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Figure 6.1A: Modell (in blue). Glucose exerts its effects 
on the trophoblast. It then releases pro-permeability 
molecules which diffuse through the trophoblast and 
mesenchymal layers. Here, they exert their effects on 
the endothelium, altering the expression of vascular 
VEGFa and VEGFb, resulting in a leakier phenotype. In 
explants only, the cytokines, hormones etc. could be 
secreted into the media, and may exert their pro-
permeability effects on the endothelium by this route. 
B. Model 2: c. Model 3: 
Glucose Glucose 
Maternal Circulation 
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Figure 6.1B: Model 2 (in red). Glucose passes through 
both trophoblast and endothelium through facilitative 
diffusion to be released into the fetal circulation. 
Glucose then exerts its effects on the endothelium from 
here, altering the vascular expression of VEGFa and 
VEGFb, resulting in a leakier phenotype. 
Trophoblast 
t VEGFa 
tVEGFb 
Figure 6.1C: Model 3 (in green). Glucose passes through 
the trophoblast by facilitative diffusion, but due to the 
rate-limiting step of GLUT-1 transport on the fetal-facing 
basal layer, it does not immediately cross the endothelial 
barrier. Glucose then exerts its pro-permeability effects 
from the placenta, increasing vascular VEGFa and 
decreasing vascular VEGFb and resulting in a leakier 
phenotype, without having to transport to the fetal 
circulation to have an effect. 
The second model is that glucose passes through both the trophoblast layer and the endothelial 
layer by facilitative diffusion, and exerts its effects on the vasculature in the fetal circulation 
(Figure 6.1B). This might be partly true at the beginning of the perfusion (lh and 2h), as we 
have seen in section 5.4.5.2 and Figure 5.14 that there is glucose flux to the fetus at 1h and 2h. 
However, by the end of the perfusion (3ht there was no longer any significant difference in 
glucose concentrations between euglycaemic and hyperglycaemic fetal circulations and there 
was a high glucose gradient between the fetal and maternal hyperglycaemic circulations; 
therefore, most of the glucose in the maternal circulation has not traversed the placenta to the 
fetal circulation. Thus, there might also be other models at play. 
The third model is that glucose passes through the trophoblast layer by facilitative diffusion, but 
due to the rate-limiting step of GLUTl transporters on the basal (fetal-facing) layer, exerts its 
effects on the endothelium from the placenta, without having to diffuse through to the fetal 
circulation to exert its effects (Figure 6.1C). When looking at the 3h media samples, i.e., at the 
end of the perfusion, both maternal and fetal circulations show a non-significant decrease in 
glucose concentrations compared to the 2h media samples (Figure 5.14), although the results 
might be obfuscated by the high variation in the 3h samples. These results indicate that some 
glucose is being used by the placenta, and therefore Model 3 is the most likely to be occurring 
at the end of the perfusion. 
However, the paracrine cross-talk between the trophoblast and the endothelium, whereby high 
glucose causes the trophoblast to elevate VEGF, NO and other inflammatory mediators which 
then affect endothelial VEGF and VE-cadherin, may have occurred but was not tested. 
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6.2.2 Clinical implications of this study 
6.2.2.1 The Pedersen hypothesis: the whole stOry? 
The Pedersen hypothesis predicts that complications in diabetic pregnancies are due to the 
fetal hyperinsulinaemia caused by the maternal hyperglycaemia, as glucose readily crosses the 
placenta (Pedersen, 1977). Indeed, even in non-diabetic pregnant women, altered glucose 
production partially explained fetal weight variations and thus macrosomia (Rohl et al., 2001; 
Ahlsson et al., 2010). In diabetic pregnancies, the outcome of the combination of 
hyperglycaemia (which is a major anabolic fuel) with hyperinsulinaemia (a major anabolic 
hormone) is an increase in fat (Fee, 1960) and protein stores. As fetal hyperinsulinaemia only 
occurs after 20 weeks gestation (when the fetal pancreas starts producing insulin), this weight 
gain occurs mostly in the third trimester. However, it has also been discovered that maternal 
HBAlc levels (representing average glycaemic levels in the prior few months) do not fully 
account for the increased macrosomic rates in the offspring of diabetic women, and that the 
postprandial glycaemic levels of the mother were more relevant in predicting macrosomia 
(Kyne-Grzebalski et al., 1999). 
However, the Pedersen hypothesis does not take into account any eventual changes that high 
glucose might have on the placental vasculature. We have shown in this thesis that even single 
short duration insults (3 and 4h) are sufficient to cause increased leakage of the feto-placental 
endothelium, changing in the process the pattern of pro- and anti-permeability molecules. This 
vascular dysfunction may therefore playa part in the aetiology of the diabetic pathology in the 
fetus. Therefore, the Pedersen hypothesis, whilst still very relevant to this topic, is not the only 
factor in the fetal milieu of a diabetic pregnancy, as had been assumed until now, but rather 
working in conjunction with increased leakage of the human placenta. 
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6.2.2.2 Our study and metabolic syndrome 
A current topic in the literature is neonatal macrosomia as a risk factor for developing 
metabolic syndrome as an adult. It is thought that the in utero environment of a diabetic 
pregnancy predisposes the fetus to subsequent weight gain and insulin resistance. 
The effects of GDM to the fetus were observed in Pima Indians, a population known to be 
genetically predisposed to Type 2 diabetes (Dabelea et 01., 2000). In that study, pairs of siblings 
were studied, the gestation of the younger of the pair having been complicated by GDM, the 
older sibling's gestation having been normal. Siblings who had been exposed to a diabetic 
environment in utero were found to be significantly more obese (50% increase in BMI) at 21 
years of age compared to the older sibling. 
Exposure to Type 1 diabetes in utero also shows an increased predisposition to develop 
metabolic syndrome, as a small study of the offspring of 15 pregnant Type 1 diabetic women 
found more insulin-resistant individuals than in the control group (16 controls with Type 1 
diabetic fathers) (Sobngwi et 01., 2003). Another study showed a doubling in the risk of 
becoming overweight and developing metabolic syndrome in offspring with gestations 
complicated by GDM and Type 1 diabetes (Clausen et 01., 2009). Interestingly, the risk of 
metabolic syndrome was higher in GDM than in Type 1, a possible repercussion of glucose 
slowing down fetal growth in the first trimester when hyperinsulinaemia is not a feature 
(Creasy and Resnik, 1999). 
It is interesting that both Type 1 and GDM pregnancies are affected by increased offspring 
predisposition to metabolic syndrome, as they are different diseases with different aetiologies. 
However, maternal hyperglycaemia links them both, and therefore may be an important factor 
in predicting metabolic syndrome occurrence later on in life. In these experiments, not only 
have we shown that maternal hyperglycaemia has further effects than the Pedersen hypothesis 
predicts, but the increased leakage of the placental barrier may have further effects than just 
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the immediate in utero environment and may contribute to the later development of metabolic 
syndrome seen in the studies above. Being able to predict when hyperglycaemic insult is 
increasing the leakage of feto-placental vessels is thus very important. 
6.2.2.3 Prediction of leakage in the placental vasculature: use of chorionic villous sampling? 
As we saw in Chapter 5, VEGFb expression significantly correlates with vascular leakage. When 
an antibody specific to VEGFa becomes available, it will be possible to accurately calculate the 
ratio of VEGFa/VEGFb, which could prove important. With further research, both VEGFb levels 
alone and the VEGFa/VEGFb ratio could translate clinically as a tool to predict when the feto-
placental vessels are leaky in the pregnancy. However, in order to do this, one would need to 
sample the placenta in the third trimester. 
Chorionic villous sampling (CVS) is a technique used for diagnostic purposes for chromosomal 
and genetic conditions in the fetus, and would be an ideal procedure to obtain samples for 
further analysis of VEGFb or the VEGFa/VEGFb ratio. However, it is used primarily in the late 
first trimester (12-14 weeks gestation), and this timing is too early to directly use the results 
from our term placenta perfusions, as it is known that the dual-independent model cannot 
simulate the first trimester (Bourget et 01., 1995; Vahakangas and Myllynen, 2006). 
Fortunately, a study has been performed regarding CVS in second and third trimester 
pregnancies (Smidt-Jensen et 01., 1993). The indications for CVS in women undergoing this 
procedure in the third trimester were 'abnormal fetus or oligohydramnios' (gestational weeks 
15-38) or 'intrauterine growth restriction' (IUGR) (gestational weeks 27-35). Among the 58 
women of the former indication, there was a total of 12 unintended losses of the fetus (7 
spontaneous abortions and 5 stillbirths) -- not an uncommon outcome for abnormal fetuses --
but there were no losses among those who had normal test results and who intended for the 
pregnancy to continue. There were also no unexpected losses among the women with the 
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IUGR indication. Furthermore, after their late CVS there were no immediate complications 
(except for lower back pain and contractions for less than 30 minutes), and there was no 
correlation between increased feto-maternal bleeding and gestational age when CVS was 
carried out. Thus, CVS has been shown to be as safe in third trimester pregnancies as in first 
trimester pregnancies, and would be an ideal procedure to clinically measure VEGFb or the 
VEGFa/VEGFb ratio in placental vessels. 
However, a fully quantitative protocol would be needed to quantitate VEGFb or VEGFa/VEGFb 
levels if a clinical application is eventually reached, rather than our pseudo-quantitative work 
with immunofluorescence. Vessels could in this case be carefully separated from the other 
placental tissues, and Western blotting performed to evaluate protein levels. 
If in further experiments VEGFa and VEGFb were shown to be secreted into the fetal circulation 
and if their levels (on their own or with a calculated ratio) were predictive of vascular leakage, it 
could be useful to sample cord blood and test for VEGFa and VEGFb levels. In this case, ELISA 
would be an appropriate technique to quantitatively analyse protein levels. 
6.2.2.4 Fetal hyperinsulinaemia perfusion studies 
In this thesis, we investigated the effects of glucose on the placental vasculature. However, 
maternal hyperglycaemia is only half of the diabetic in utero environment, the other half being 
fetal hyperinsulinaemia. Thus, it is important to study the effect of fetal hyperinsulinaemia to 
see whether it contributes to the diabetic phenotype observed in Type 1 (leach et 01., 2004) 
and GDM (Babawale et 01., 2000) placentae. 
One of the consequences of maternal hyperglycaemia, as seen in diabetic pregnancies, is that 
glucose enters the fetal circulation by facilitated diffusion. The rate-limiting step in this transfer 
of glucose is the capacity of the insulin independent glucose transporter GlUTl (Takata and 
Hirano, 1997), levels of which have been shown to be increased in the syncytiotrophoblast of 
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placentae of women with Type 1 diabetes (Jansson et 01., 1999) but not GDM (Jansson et 01., 
2001); this may contribute to the increased glucose transport in diabetic pregnancies. 
The fetal pancreas starts to develop between 4 and 6 weeks gestation, the f3-cells appear at 
10.5 weeks, and by 20 weeks insulin production starts and the fetus is now responsible for its 
glucose homeostasis (Jaffe, 1991). Thus, although insulin cannot traverse the placental barrier 
in appreciable amounts, as the fetus is subjected to hyperglycaemia, the fetal pancreas will 
produce increased insulin to compensate and to return to a euglycaemic environment. This 
forms the basis for the Pedersen hypothesis (1954) of fetal hyperinsulinaemia. 
During pregnancy, the control of insulin action in the placenta passes from the mother, as 
insulin receptors are localised on the syncytiotrophoblast in the first trimester, to the fetus, as 
insulin receptors are present in the endothelium of the fetal vessels at term (Desoye et 01., 1994; 
Jones et 01., 1993). As the second and third trimester (after insulin production starts in the 
fetus) of pregnancy is characterised by longitudinal expansion of chorionic villous trees, the 
presence of high insulin in the fetal circulation might affect the vasculature in the placental villi, 
affecting the exchange function of the placenta. The effect of high insulin on the vasculature 
should be the focus of further work. 
Our laboratory has performed an as-yet unpublished study with insulin perfusion from the fetal 
circulation, with the intention to study the immunolocalisation of several key angiogenic and 
permeability molecules. This author studied VEGFb expression in these experiments (see 
Appendix 4); however, the other results are equally important and a summary of these results, 
performed by colleagues, is given here. 
The molecules being studied were the important adherens junction molecules VE-cadherin and 
f3-catenin, the important tight junctional molecule occludin, and total VEGF. The leakage of the 
vasculature to 76Mr dextran tracer was also observed under fetal circulation hyperinsulinaemia 
and control perfusions. Colleagues (M. Barclay, J. lucas, R. lewis, A. Ikram, P. Rodgers, S. 
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Walker) performed the analysis of the above molecules, whilst the author of this thesis was 
responsible for the VEGFb immunoreactivity (see Results in Appendix 4). 
The junctional profile of the insulin perfused placentae was significantly different from that of 
the normal placentae. There were significantly fewer vascular profiles immunoreactive for p-
catenin and occludin (in stem villi), indicating that both adherens and tight junctions 
respectively were being destabilised. p-catenin is usually bound to a complex including VE-
cadherin, holding the latter at the junctional space. When p-catenin is displaced to the nucleus, 
VE-cadherin is free to diffuse out of the junctional space. The only abnormality from this 
altered profile was VE-cadherin, which did not show any significant differences in 
immunopositive vessels. However, the author of that analysis (M. Barclay) admits that she did 
not differentiate between cytoplasmic and junctional locations of immunoreactivity, as the 
author of this thesis did herself in previous chapters. Therefore, it is not possible to know 
without further analysis if there was more VE-cadherin localisation in the cytoplasm, which 
would indicate adherens junctional instability. However, the results for p-catenin, a molecule 
intrinsically linked to VE-cadherin junctional localisation, and occludin (analysed by J. Lucas, R. 
Lewis and A. Ikram for the former and P. Rodgers for the latter) certainly suggest VE-cadherin 
junctional instability to have occurred. 
The junctional instability seen above suggests that endothelial activation might be ongoing. 
Immunofluorescence with an anti-VEGF antibody indeed showed that there was more total 
VEGF present in the insulin perfused placentae than in the normal placentae, indicating that 
there may be increased vascular permeability in the insulin perfused placentae. 
The authors finally looked at the integrity of the barrier function of the placenta by looking at 
the leakage to 76Mr dextran tracer. It was shown in these experiments that the insulin 
perfused placentae showed significantly more leakage than normal perfused placentae. 
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My part within this project revealed that there was a significant decrease in the number of large 
vessels (found in stem villi) immunopositive for VEGFb in response to insulin perfusion 
compared to normal perfusion (p<O.OS, Figure A4.3). This was matched with loss of the tight 
junctional molecule occludin from the same area. Microvessels (in intermediate and terminal 
villi) did not show any differences in VEGFb expression. The mesenchymal layer surrounding 
the large vessels of the stem villi and the maternally-facing trophoblast layer did not seem to be 
affected in terms of VEGFb expression by hyperinsulinaemia. The trophoblast is the tissue 
furthest away from the fetal circulation, and thus in contact with the maternal circulation, and 
therefore any changes affecting the trophoblast may affect the maternal environment. These 
studies indicate that fetal hyperinsulinaemia affects the feto-placental vasculature but as insulin 
does not cross the placenta it does not affect the maternal circulation. 
6.2.3 Critique of experimental design 
6.2.3.1 Explants vs. perfusion 
The chorionic villous explant methodology has the potential to be a very useful technique, 
allowing the easy in vitro manipulation of placental tissue to answer several research questions 
regarding the placenta. It is a relatively easy technique which can elucidate the effects of long-
duration insult with glucose on junctional and permeability molecules. However, one difficulty 
is that it is not a universal methodology; it must be adapted to suit each experimental aim. We 
wished to use this technique to study expression of VEG F splice variants and VE-cadherin on the 
endothelium of placental blood vessels. To the best of our knowledge we were the first group 
to do so, as this technique has to date only been used to study trophoblast function. 
During the course of our validation experiments, however, we discovered a flaw in the explant 
methodology for this use: high number of profiles immunopositive for VEGF and low VE-
cadherin localisation to the junctional space (Figures 2.8 and 2.9). We hypothesised that this 
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was due to a wound healing effect that was initiated by the excision procedure. However, we 
have only observed the effect of this possible wound healing effect on VE-cadherin and VEGF; 
other cytokines expressed in wound healing might be produced and be affecting the tissue. 
This point is worthy of note, and any experimenters who are considering the use of explants in 
their set-up should include a validation experiment to see how their chosen target is being 
affected by the wound healing effect we have observed. Strangely, this topic has not been seen 
before in previous explant studies. Although wound healing is a process that normally only 
affects the endothelium of blood vessels and not the trophoblast layer, the latter is bathed in 
the same media as the vessels, and paracrine molecules that would normally be secreted by the 
endothelium in wound healing could be affecting the trophoblast. Perhaps this is the cause of 
the unexplained trophoblast degeneration seen in some explant methodologies. 
In the context of this thesis, if a wound healing process caused by excision artefacts was 
occurring, it would mean that our experiments would only show a physiological effect of 
glucose if the total number of vessels showing immunostaining increased; if the total number of 
immunopositive vessels stayed the same but the intensity of staining increased, only the vessels 
already affected by the excision artefacts would be affected by the hyperglycaemic condition. 
In contrast, the perfusion methodology has been extensively used to study the transfer of 
molecules across the placental barrier, which involves the endothelium, and thus the lack of 
any negative effects of the perfusion model on the blood vessels' lining has been extensively 
documented. 
One of the important findings in this thesis was that VEGFb could be an indicator of vascular 
dysfunction in diabetes. We have inferred that a single dose of lSmM glucose, a level seen in 
diabetic pregnancies, can change the VEGF splice variants ratio in both the 4h explants model in 
Chapter 4, and the 3h perfusion model in Chapter 5 (see section 4.4.3 for reasoning on ratio). 
From these experiments, we have concluded that glucose might be regulating the leakage of 
macromolecules from the vasculature through altering levels of VEGFb (Figure 5.13), this being 
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regulated by glucose, whilst total VEGF was not correlated with tracer leakage (Figure 5.12). 
However, the timings in the two models differ: in the explants a more physiologically relevant 
4h timepoint was used, whilst in the perfusion a shorter 3h duration of perfusion was employed. 
The perfusion technique has a high failure rate: other groups have found that the failure rate 
for perfusions is around 75%. Our group has found that the chance of leakage (and hence 
perfusion failure) of media from either circulation increases with time, and therefore we chose 
the more reliable 3h perfusion rather than the less reliable 4h perfusion. 
Another limitation of the dual-independent placental perfusion model is that it is not 
representative of the first trimester placenta (Vahakangas and Myllynen, 2006; Bourget et 01., 
1995). Use of first trimester placental tissue with explants or other methods may provide 
valuable information for this earlier gestational period and for Type 1 diabetes, as in this 
pathology glucose insult starts in the first trimester. 
6.2.3.2 Antibodies used 
The two VEGF antibodies used in this thesis were MAB293 and MAB3045 for total VEGF and 
VEGFb respectively. MAB293 was used because there are currently no commercial antibodies 
specifically for VEGFa. Once one is developed, the VEGFa/VEGFb ratio can be calculated 
directly, rather than having to deduce that VEGFa must be increasing when VEGFb expression is 
decreasing and total VEGF expression is increasing (see section 4.4.3). 
Currently, the only method to quantitatively calculate the VEGFa/VEGFb ratio is using RT-PCR; 
amplifying mRNA using different primers yielding a 130bp product (corresponding to VEGFa) 
and a 64bp product (corresponding to VEGFb) (Nowak et 01., 2008). Protein levels, however, 
are not always reflected by mRNA levels, and therefore an antibody for VEGFa protein would 
prove useful. 
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Another criticism of the two antibodies used is that they have different detection limits, 
whereby MAB3045 detects more protein than MAB293, leading to an inconsistency in the 
results. If the detection limits for the two antibodies had been similar, the proportion of 
VEGFb/total VEGF could have been calculated, which would have been truly representative of 
the VEGFa/VEGFb ratio. Antibodies with comparable detection limits would therefore be 
preferable in these types of experiments. 
6.2.3.3 Alternative methods to the use of immunofluorescence for quantitation of results 
The other main critique of this study is that the expression of VE-cadherin and the VEGF splice 
variants has been analysed entirely by immunofluorescence, which is a pseudo-quantitative 
technique, and therefore cannot give exact values to the expression of these molecules. This 
could have been performed through Western blotting. However, Western blotting would not 
indicate the location Uunctional or cytoplasmic) of VE-cadherin, and therefore would not be 
physiologically relevant. For the VEGF splice variants, likewise, it would not indicate the 
location of the splice variants in the maternally-facing trophoblast or in the fetal-facing 
endothelium of the fetal blood vessels. In our experiments, we have shown that in response to 
high glucose in the maternal circulation, the expression of these VEGF splice variants was 
significantly different, and the splice variants were differentially regulated, in the fetal 
endothelium; therefore the effects of glucose have resulted in effects on the other side of the 
placental barrier. To quantitate levels of total VEGF and VEGFb in a relevant way, it would be 
necessary to isolate trophoblast from endothelium, and then analyse the resulting separated 
tissue with Western blotting. This analysis is an essential future step if further experiments 
indicate a potential clinical use for VEGF splice variants levels and/or ratio between the two. 
We have observed in the placental perfusion that VEGFb (but not total VEGF, Figures 5.13 and 
5.12, respectively) in the feto-placental vessels correlates with feto-placental vascular leakage. 
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To quantitate these amounts through Western blotting without first separating trophoblast 
from endothelium could obfuscate results, as in vivo the trophoblast is not in contact with the 
endothelium, and thus VEGFa/VEGFb levels here probably would not correlate with endothelial 
dysfunction, as the two circulations are exposed to different environments and stimuli. 
Another criticism could be that ELISA was not performed. This could have given valuable 
information on the amount of VEGF splice variants secreted into the fetal circulation, and thus 
whether effects downstream of this release could be expected. ELISA was indeed attempted on 
several occasions, but unfortunately did not give interpretable results, and this avenue of 
research was thus abandoned, due to the limited samples available. An ELISA on the samples 
from the fetal circuit (rather than from the maternal circuit) of the perfusion experiment would 
be the most physiologically relevant, as it would indicate release of VEGF splice variants in the 
circulation which would be most likely to affect the placental vasculature and fetus. 
6.2.4 Regulation of factors influencing VEGF splicing 
Our studies show that glucose affects the alternative splicing of VEGFa and VEGFb, but we have 
not investigated the mechanisms behind this change. In order to fully understand the 
mechanisms behind this splicing switch, the SR proteins responsible for selection of the splice 
variant to be produced, ASF/SF2 and SRp40 for VEGFa and SRp55 for VEGFb, need to be studied 
under conditions of high glucose. To the best of our knowledge, this has not been performed in 
the literature at present. Being the prototypical SR protein, most studies have focused on 
ASF/SF2. 
SR proteins are post-translationally modified via several mechanisms, including glycosylation 
(Soulard et 01., 1993), methylation (Rho et 01., 2007), and, most well studied, phosphorylation. 
This latter modification is controlled by SRPKl-2 and members of Cdc2-like nuclear kinases 
(Clk/Sty and Clk2-4). The regulation of SR proteins through post-translational modifications in 
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general, and phosphorylation in particular, allows alternative splicing to occur without new 
protein synthesis (Stamm, 2002), and thus a splice selection switch can be observed relatively 
quickly after the stimulus, with degradation of the existing splice variant and replacement with 
the new, a process that can take less than one hour after the initial stimulus. This fits well with 
our observations of changes in splicing (decrease in VEGFb, Figures 4.6 and 5.5) 3h and 4h after 
initial glucose insult. 
SR protein phosphorylation status is thought to regulate two processes, the first of which is the 
localisation of the protein in the cell (cytosolic, nuclear speckles, or nuclear splicing site). This 
change in localisation has been well studied for ASF/SF2. The change in localisation from 
cytosol to nucleus is due to phosphorylation by SRPKl-2 of serine residues (Aubol et 01., 2003), 
which then results in transport to nuclear speckles (Lai et 01., 2000). In the nucleus, Clk/Sty and 
Clk2-4 hyperphosphorylate ASF/SF2, which causes the translocation from speckles to splice site, 
and protein:protein binding to U1 70kDa subunit occurs, allowing U1 snRNP to the 5' splice site 
(Eperon et 01., 2000; Kohtz et 01., 1994; Wu and Maniatis, 1993). When two sites are in 
competition, such as is the case for VEGF pre-mRNA splicing, ASF/SF2 seems to favour the 
proximal site (Ge and Manley, 1990; Krainer et 01., 1990); this is indeed the case for VEGF, as 
ASF/SF2 is required for VEGFa splicing (Nowak et 01., 2008). After splicing has occurred, protein 
phosphatase 1 (PP1) dephosphorylates SR proteins to signal for their return to the cytoplasm. 
The dephosphorylation of ASF/SF2 leads to an increase in binding to nuclear export factor 
TAP/NFX1, leading to an increase in cytosol localisation. PP1 has a different cellular localisation 
depending on where the protein they are regulating is found (Trinkle-Mulcahy et 01., 2003). 
Thus, insights into splicing regulation could be garnered by looking at the localisation of 
proteins involved in splicing and their regulators. This is an important avenue for future 
investigation to elucidate the exact mechanisms behind effects of glucose that we observed on 
total VEGF and VEGFb. 
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The second process regulated by phosphorylation of SR proteins is the binding to the splicing 
machinery snRNPs. Phosphorylation of ASF/SF2, for example, enables tighter binding to the U1 
70kDa subunit (Xiao and Manley, 1997), and decreases binding to TAP/NXFl (Huang et 0/., 
2004). The binding of RS domains to RNA also changes with phosphorylation, affecting splicing 
(Shen and Green, 2006; Xiao and Manley, 1997). Therefore, studies looking at whether SR 
proteins are in complexes with specific proteins (such as U1 snRNP and RNA or TAP/NXFl) can 
also shed light on the regulation of splicing. 
looking at SR phosphorylation can also be useful, but does not provide a definite answer as to 
whether the proteins are participating in splicing, as both hypophosphorylation and 
hyperphosphorylation have been shown to inhibit splicing (Cao et 0/., 1997). It is thought that 
when the RS domain is hyperphosphorylated, the interaction between it and U1 snRNP 
becomes too strong, inhibiting Ul snRNP's disassociation from the splice site, therefore 
reducing splicing. Additionally, it has been shown that both hypophosphorylation (by PP1 
addition) and hyperphosphorylation (by ClK/Sty and SRPK1 overexpression) cause a diffuse 
nuclear distribution of ASF/SF2 protein (Prasad et 0/., 1999). 
Although glucose studies have not been performed in the literature at the present time, other 
studies that are of potential importance to our study have been conducted. Insulin receptor 
activation by insulin has been shown to increase phosphorylation of SRp40 and SRp55, two SR 
proteins known to regulate VEGF splicing, and result in splice site selection change (Jiang et 0/., 
2009; Patel et 01., 2005). These changes were mediated by the PI3K pathway (important in 
VEGF's role as a survival factor and NO production (see section 1.2.1.3), and resulted in 
alternative splicing of PKCJ311 (PKC is an important pathway in hyperglycaemia (see section 
1.3.3.1) and is capable of decreasing VEGFb production (Nowak et 01., 2010)), which leads to 
increased glucose uptake. PKB-/- tissue also showed a decrease in SRp55 phosphorylation. A 
TNFu (a pro-inflammatory cytokine) increase has been shown to cause the dephosphorylation 
of ASF/SF2 and PKB through an increase in ceramide (involved in apoptosis) and allosteric PPl 
239 
activation. This might be of relevance to our study if our wound healing assumption is correct. 
ASF/SF2 and SRp55 have been shown to be regulators of tissue factor in human monocytic cells 
(Tardos et 01., 2008). Alternative splicing of tissue factor has been shown to be increased in 
Type 2 diabetic patients due to the combined effect of hyperglycaemia and hyperinsulinaemia 
(Boden and Rao, 2007). 
The investigation of the effects of glucose on the splice factors involved in VEGF spliCing, 
namely ASF/SF2, SRp40, and SRp55, would thus be an important future step for the full 
understanding of mechanistic details of the findings reported in this thesis. 
6.2.5 Future work 
6.2.5.1 Reversal of phenotype studies 
In this thesis, we have found that the diabetic phenotype could be replicated with a single 3h or 
4h hyperglycaemic (15mM glucose) insult. However, in a pregnancy, the postprandial values 
eventually return to basal level until the next meal. Whether the effects of our hyperglycaemic 
insult are permanent or reversible, and whether further insults worsen the phenotype, could 
therefore change the clinical outcome of the pregnancy: if the changes are reversible, prompt 
treatment could limit damage to the placenta and hence the fetus. Thus, it could prove 
clinically useful to experiment on whether or not hyperglycaemia followed by a period of 
euglycaemia, followed by another glycaemic insult, reverses the phenotype observed. 
Although perfusions are the best physiological model of the in utero environment, the duration 
required and frequent change of media would make it impractical to use as a model in this 
instance, and explants have the possible added complication of excision artefacts. An 
experiment trying to research this question was therefore twice attempted by the author of this 
thesis in a HUVEC cell model of permeability (see Appendix 5 for materials and methods). 
However, these experiments revealed that changing the media, a necessary step to study 
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reversal of hyperglycaemic phenotype, was disrupting the HUVEC monolayer, leading to holes 
forming in the monolayer, and therefore the permeability measurements taken were worthless. 
Time and financial constraints meant that this experiment had to be abandoned. 
In order to investigate whether the phenotype which results from glucose insult is reversible or 
not, the experiment detailed above (and in Appendix 5) requires a re-design, and careful 
consideration should be given to the methodology used. 
6.2.5.2 Investigations on 'wound healing' in chorionic villous explants cultures 
The chorionic villous explant methodology would be an ideal model to study the reversibility 
experiments described in section 6.2.5.1, as it allows longer duration experiments and lower 
failure rate than the perfusion model and is more robust than experiments with HUVEC cell 
cultures (see section 6.2.5.1 for experimental difficulties with HUVECs). However, it does not 
allow permeability studies, and has the confounding factor of a possible 'wounding' response 
caused by the excision artefacts observed. 
However, our experiments were not designed to definitively show if there was a wound healing 
response or if the increase in VEGF and decrease in VE-cadherin seen in Chapter 2 were due to 
wound healing or other processes. The main evidence in favour of the wound healing theory is 
the recovery seen by 24h; this shows a decrease in VEGF and increase in VE-cadherin compared 
to the earlier timepoints. Furthermore, the tissue which was excised after washing and fixation 
showed low VEGF and high VE-cadherin immunoreactive vessels as expected of uninjured tissue. 
However, this latter evidence is only qualitative due to the high amount of blood trapped in the 
vessels which makes counts unreliable (Figure 2.6A-D). In addition, the fact that high VEGF and 
low VE-cadherin is only seen in explants but not in perfused placentae indicates that the 
artefacts are probably being caused by a disturbance in the 3D architecture, and a 'wound' 
could be just such a disturbance. In further experiments investigating wound healing, other 
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possibilities, such as the roles of VEGF as a survival factor and endothelial proliferation, should 
be also investigated. 
To investigate the theory of wound healing response, a full spectrum of inflammatory cytokines, 
anti-inflammatory cytokines and other molecules that affect the wound healing response 
should be studied in explants. If our hypothesis on the wounding of ex plants is correct, the 
cytokines expressed should match the pattern seen in wound healing (for a review listing the 
molecules involved in wound healing, see Singer and Clark (1999)). If a wound healing process 
was proven to be occurring, other experiments investigating how this was being resolved would 
be necessary, to see if there is a plateau in wound healing after 24h, or if the process is ongoing. 
6.2.5.3 VEGFa/VEGFb ratio in insulin perfusion studies 
Section 6.2.2.4. and Appendix 4 detail our group's research into fetal hyperinsulinaemic 
perfused placentae in a currently unpublished study. Unfortunately, S. Walker and this author 
used different euglycaemic perfused placentae to calculate total VEGF and VEGFb expression. 
Furthermore, J. lucas, R. lewis and A. Ikram used another set of euglycaemic placentae for their 
tracer leakage studies. These discrepancies mean that it is not possible to perform a correlation 
analysis between total VEGF and tracer leakage and between VEGFb and tracer leakage (as 
performed in Chapter 5 for hyperglycaemic perfusions) without a complete re-count of these 
results with the same control placentae. 
6.2.5.4 Diabetic and hyperglycaemic/hyperinsulinaemic perfusion models 
In Chapter 5, we described our hyperglycaemic perfusions on normal placentae; further to 
these experiments, two more critical studies should be performed using perfusion models. The 
first of such studies should be to perfuse normal placentae for 3h with both hyperglycaemia in 
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the maternal circuit and hyperinsulinaemia in the fetal circuit, to see whether concurrent insult 
with these two pathological conditions affect the placenta any differently. Secondly, perfusions 
on diabetic placentae, both from Type 1 and GDM, should be performed with both maternal 
hyperglycaemia and fetal hyperinsulinaemia, to compare with normal placentae, and also 
perfused with only either hyperinsulinaemia or hyperglycaemia. In addition, radiolabelled 
glucose could be used if transplacental flux and/or glucose consumption is being studied. 
However, the diabetic perfusion studies are likely to take a significant amount of time to 
complete, due to the scarcity of such tissue combined with the high failure rate of the perfusion 
model due to cannulation and leakage problems. This is the reason why we perfused only 
normal placentae in our experiments. 
The exploration of these topics could further knowledge that might lead to clinically predicting 
dysfunction in the human placenta, therefore aiding the treatment of diabetic pregnant women. 
6.3 Concluding remarks 
This thesis has implications in two areas of research: VEGF biology and materno-fetal health. 
In this thesis, we have identified the anti-angiogenic and anti-permeability molecule VEGFb as 
an important player in the control of vascular integrity, and we have seen that VEGFb levels 
might even act as a predictor of vascular dysfunction. Our findings thus suggest that future 
studies investigating VEGF actions should certainly include this splice variant, to establish 
whether it is this splice variant or VEGFa or even their relative proportions, which is important 
in each of VEGF's effects and roles. This will have implications in many fields, as VEGF is seen as 
a key molecule in diverse pathologies, e.g., diabetes or cancer. 
The Pedersen hypothesis states that it is the fetal hyperinsulinaemia seen in response to 
maternal hyperglycaemia that causes the fetal macrosomia seen in diabetic pregnancies. 
However, this prevailing theory does not take into account that maternal hyperglycaemia alone 
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(Le., independently of high insulin) might be causing some changes, nor does it consider that 
the placenta itself might be affected, as any placental vascular changes have the potential to 
affect the fetus and its development. 
In this thesis, we have shown that hyperglycaemia itself can affect the functional phenotype of 
the placenta. Furthermore, these effects were seen with a single acute glucose insult, and were 
independent of insulin. Therefore, the Pedersen hypothesis would appear to be an incomplete 
model of the pathology seen in diabetic pregnancies, and this should be considered in the care 
of the diabetic pregnant woman. 
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Materials 
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Sigma-Aldrich 
Agarose (A9539) 
Albumin from Bovine Serum (A7906) 
Albumin, tetramethylrhodamine isothiocyanate bovine (A2289) 
Anti-Mouse IgG (whole molecule) - FITC antibody produced in goat (F0257) 
Anti-Rabbit IgG (whole molecule) - TRITC (T6778) 
Collagenase from Clostridium histo/yticum (C6885) 
D-(+)-Glucose (G6152) 
D-Mannitol (63559) 
Dextran from from Leuconostoc mesenteroides Mr 15000-30000 (04626) 
Dextran from Leuconostoc spp. Mr 15000-25000 (31387) 
Endothelial Cell Growth Supplement from bovine neural tissue (E2759) 
Ethanol (458600) 
Fetal Bovine Serum (F7524) 
Gelatin (G9391) 
Maltodextrin test sticks according to Ph. Eur. (80104-1EA-F) 
Medium 199 (M5017) 
Monoclonal A n t i - ~ - C a t e n i n n antibody produced in mouse, clone 6F9 (C7082) 
Paraformaldehyde (P6148) 
Normal Human Serum (H4522) 
Phosphate Buffered Saline tablets (P4417) 
Sodium Bicarbonate (S8875) 
Sodium Chloride (S3160/63) 
Streptomycin Sulfate salt (S9137) 
Tetramethylrhodamine isothiocyanate - Dextran (T1162) 
Triton, t-Octylphenoxypolythoxy ethanol X-100 (T8787) 
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Fisher Scientific 
Acetone (A/0560/17) 
D-Glucose anhydrous (G/0500/53) 
Iso-Pentane (P/1030/l7) 
Propan-2-ol (P/7490/17) 
Toluidine Blue 0 (BP107-1O) 
Xylene (W/010/17) 
R&D Systems 
Monoclonal Mouse Anti-Human CD31/PECAM-1 Antibody (BBA7) 
Monoclonal Mouse Anti-Human VEGF Antibody (MAB293) 
Monoclonal Mouse Anti-Human VEGF16Sb Antibody (MAB3045) 
Substrate - HRP (DY998) 
Substrate Reagent Pack (DY999) 
Life Technologies (Glbco and Invitrogen) 
Fungizone (15290-018) 
Medium 199 X 1 (22340-020) 
Occludin, Rabbit Polyclonal Antibody (71-1500) 
Trypsin-EDTA, 0.05% (25300) 
Raymond A. Lamb 
DPX (Lamb/DPX) 
Eosin 1% (Lamb/100/D) 
Haematoxylin (Harris) (Lamb/230/D) 
OCT embedding medium (Lamb/OCT) 
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Pharmacy stores 
Novorapid (100U/ml) 
Penicillin 600J,lg/vial 
Vector Laboratories, Inc 
ImmEdge Hydrophobic Barrier Pen (H-4000) 
Vectashield Mounting Medium for Fluorescence (H-1000) 
BD Blosciences 
Purified Mouse Anti Human C0144 (555661) 
Costar, Corning 
Transwell Permeable Supports, 12 mm inserts (3460) 
CP Pharmaceuticals 
Monoparin 5000 IU in 1ml 
KM Skipp 
22mm cork disks 
NHS Logistics 
Sutures Oexon II (FVP189) 
Santa Cruz Biotechnology 
Rabbit anti-human PECAM-1 (C-20) Antibody: sc-1505R 
Scientific Laboratory Supplies 
12 well plates (353043) 
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VYGON 
Lipid Resistant 3-way Stopcock (875.00) 
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Appendix 2 
Diabetic donors of tissue 
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This is the diabetic donor information referred to in section 4.3.2. 
Duration of 
Donor disease Age of mother Treatment Complications 
Humolog mix 
Patient A 8 years 20 years old 2x daily No retinopathy 
Novorapid 
Patient B 21 years 35 years old 3x daily, detemri No retinopathy 
Insulintard 
Patient C 8 years 32 years old x2 daily No retinopathy 
Patient D 10 years 25 years old Actrapid No retinopathy 
Donor HbA1c at term Gender of baby Weight of baby Gestation at birth 
Patient A 65mmol/mol Male 3.37kg 38 weeks 
Patient B 45mmol/mol Male 2.89kg 37 weeks 
Patient C G8mmol/mol Male 4.30kg 37 weeks 
Patient 0 97mmol/mol Female 4.00kg 38 weeks 
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Appendix 3 
Glucose concentration in perfused media samples 
from fetal and maternal circuits - HemoCue 
Glucose 201+ analyser measurements 
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These are the HemoCue Glucose 201+ analyser results from the sampling of perfusion media, as 
described in section 5.3.2. 
Standards {perfusion media with known (5mM and 15mM) concentrations of glucose): 
• 5mM glucose readings: 4.5mM, 7mM, 8.6mM 
• 15mM glucose readings: 14.5mM, 20.5mM, 20.6mM 
Note the inaccuracy and high variation in the standards. 
Euglycaemia (5mm glucose) 
End of, Fetal (mM) Maternal (mM) 
Placenta 1 8.0 8.8 
1st hour Placenta 2 8.7 8.2 
Placenta 3 9.0 8.5 
Placenta 1 7.4 7.9 
2nd hour Placenta 2 6.5 5.9 
Placenta 3 6.5 6.3 
Placenta 1 8.0 8.8 
3rd hour Placenta 2 6.5 5.9 
Placenta 3 6.2 6.5 
Hyperglycaemia {5mM glucose 
End of, Fetal (mM) Maternal (mM) 
Placenta 1 5.5 14.6 
1st hour Placenta 2 9.1 9.50 
Placenta 3 7.0 10.5 
Placenta 1 5.9 14.3 
2nd hour Placenta 2 9.6 15.7 
Placenta 3 8.2 13.4 
Placenta 1 9.4 18.5 
3rd hour Placenta 2 6.3 14.0 
Placenta 3 7.2 12.9 
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Appendix 4 
Supplementary methods and results 
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These are the supplementary methods and results referred to in section 6.2.2.4. 
A4.1 Methods 
A4.1.1 Insulin 30 minute perfusion 
Term placentae (n=6; delivered by Caesarean section) were taken from normal pregnancies 
undergoing term elective Caesarean sections in Queen's Medical Centre, Nottingham, with 
informed patient consent and ethical approval. Lobules were chosen and cannulated as 
described in Chapter 5. Briefly, both maternal and fetal circulations were independently 
perfused with perfusion media which simulated phYSiological conditions regarding osmolarity, 
temperature and vessel pressure, and from delivery of the placenta to complete cannulation no 
longer than 30 minutes elapsed. After a 20 minute equilibration period with oxygenated 
perfusate (M199 with added albumin, heparin, dextran (20,OOOMr) and sodium bicarbonate, as 
described in Chapter 5), fetal media was switched to one which contained 251lU/ml insulin and 
the lobules were perfused for a further 30 minutes in an open (non-recirculated media) circuit. 
In the last 10 minutes, TRITC-dextran (76Mr; O.5mg/ml) was added to the fetal circulation. In 
control perfusions, the perfusion media did not contain added insulin. Placental lobules were 
fixed with 1% w/v p-formaldehyde (30 minute perfusion) and prepared for 
i mmu noh istochemistry. 
A4.1.2 Immunofluorescence 
The immunofluorescence protocol performed was the same as the one described in the 
previous chapters. Primary antibody against VEGFb (MAB3045, R&D Systems, 5Ilg/ml) was 
used in conjunction with an goat anti-mouse human secondary antibody (F-0257, Sigma-Aldrich, 
20Ilg/ml). 
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A4.1.3 Analysis of data 
Analysis of immunopositive profiles was performed initially by counting the number of profiles 
immunoreactive to VEGFb, but differently from previous chapters, the immunoreactivity to 
VEGFb of the trophoblast and mesenchyme was also studied. In addition, the vascular profiles 
counted were divided into stem villi, intermediate villi, and terminal villi, to observe whether 
there was a different localisation of VEGFb in insulin perfused placenta. 
Mann Whitney-U tests were used for statistical analyses. 
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A4.2 Results 
A4.2.1 VEGFb immunolocalisation 
After the normal (without added insulin) placental perfusion, VEGFb was localised in 50.2% of 
vessels, in 51.0% of the trophoblast layer, and in the mesenchyme of 80.8% of stem villi,. After 
the insulin perfusion, VEGFb was found in 46% of vessels, in 48.9% of the trophoblast layer, and 
in 81.7% of stem villi mesenchyme, (Figure A4.1). This resulted in no significant differences 
(p>0.05) between the normal and insulin perfusions. 
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Figure A4.1: Effect of insulin perfusion on total VEGFb immunoreactivity. Insulin perfusion had no effect 
(p>O.OS) on the total number of vessels, trophoblast or stem villous stroma tissues showing VEGFb 
immunoreactivity. Data (n=3 for both normal and insulin perfusions) was analysed using Mann-Whitney U 
test. 
Further analysis revealed that VEGFb was present in 54% of trophoblast surrounding stem villi , 
46% of trophoblast surrounding intermediate villi, and 54% of trophoblast surrounding termina l 
villi of normal perfused placentae. In insulin perfused placentae, VEGFb was present in 
trophoblast in the following percentages: surrounding stem villi 53.6%, surrounding the 
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intermediate villi 41.5%, surrounding the terminal villi 52.0% (Figure A4.2) . Again, there were 
no significant differences in the trophoblast immunoreactivity between these different groups 
(p>0.05). 
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Figure M.2: VEGFb localisation in trophoblast tissue. There was no significant difference (p>O.OS) in the 
number of stem, intermediate, or terminal villous trophoblast showing VEGFb immunoreactivity. Data 
(n=3 for both normal and insulin perfusions) was analysed using Mann-Whitney U test. 
However, when analysing the difference in vessels from different villi, we observed that there 
was a significant decrease in the number of stem villi showing VEGFb immunoreactivity, as 
normal perfused placentae showed 75.3% of vessels immunopositive for VEGFb, whilst insulin 
perfused placentae showed only 51.2% of VEGFb immunopositive vessels (p<O.OS) . The 
percentage of VEGFb immunopositive vessels in both intermediate villi (45.7% in normal 
placentae, 43.7% in insulin perfused placentae) and terminal villi (45.4% in normal placentae 
and 46.1% in insulin perfused placentae) was not significantly different between normal and 
insulin groups (p>O.OS, Figure A4.3). 
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Figure A4.3: VEGFb localisation in large (stem) and microvessels (intermediate and terminal) . Data (n=3 
for both normal and insulin perfusions) was analysed using Mann-Whitney U test. a: p<O.OS relative to 
vessels in stem villi perfused with normal media. 
A4.3 Conclusion 
There was a significant decrease in the number of large vessels (found in stem villi) 
immunopositive for VEGFb in response to insulin perfusion compared to normal perfusion 
(p<O.OS, Figure A4.3). Microvessels (intermediate and terminal) did not show any differences in 
VEGFb expression. The mesenchymal layer surrounding the large vessels of the stem villi and 
the trophoblast layer did not seem to be affected in terms of VEGFb expression by the 
hyperinsulinaemia. The trophoblast is the tissue furthest away from the fetal circulation, and 
thus in contact with the maternal circulation, and therefore any changes affecting the 
trophoblast may affect the maternal environment. 
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Appendix 5 
Reversal of glucose-induced phenotype cell culture 
study: materials and methods 
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These are the materials and methods referred to in section 6.2.5.1. 
Human umbilical vein endothelial cells (HUVEC) were isolated from 3 separate placentae, 
pooled in a single T25 flask and grown in growth medium M5 (Medium 199 with 5% heat 
inactivated fetal bovine serum (FBS), lOOIU/ml penicillin, 100g/ml streptomycin, 2f.1g/ml 
fungizone, 1501lg/ml endothelial cell growth supplement and 501lg/ml heparin) at 37°C and 5% 
CO2 in air. 
At 90-100% confluence, HUVECs were detached and seeded onto transwells (12mm, O.4llm) at 
a cell density per well of 105, with 200111 of MS in the apical chamber and 700111 of MS in the 
basal chamber. When confluence was achieved, the media was changed to MO containing 
TRITC-albumen tracer (68kDa, SOmM) containing lSmM glucose for 3h. The media was 
sampled (triplicate aliquots of 20111) from the basal chamber every hour, with immediate 
replacement of the sampled media. The transendothelial electrical resistance (TEER), a 
measure of endothelial permeability, was measured with an EVOM resistance meter (World 
Precision Instruments). 
After the 3h hyperglycaemic incubation, the media was then immediately replaced with MO 
containing TRITC-albumen tracer containing SmM glucose for a further hour, repeating the 
TEER measurement and media sampling at the end of this period. The media was then replaced 
again with MO containing lSmM glucose and TRITC tracer for a further 3h. Again, the media 
was sampled (triplicate aliquots of 20111) from the basal chamber every hour, with immediate 
replacement of the sampled media. 
At the end of this second 3h incubation, the TEER was calculated, and the e)(periment 
terminated. 20111 of the media which had been replaced at every step of the e)(periment (first 
3h hyperglycaemic media, euglycaemic media, and second hyperglycaemic media) was then 
analysed with a DYNEX Microtiter Plate MFX Fluorometer (e)(citation = S30nm, emission = 
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590nm), and the concentration of the tracer in the media was then calculated. Leakage on 
TRITe-albumin was also calculated for transwells without cells as a control. 
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Publications 
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Published review 
L. Leach, A. Taylor and F. Sciota (2009) Vascular dysfunction in the diabetic placenta: 
causes and conseguences. Journal of Anatomy, Vol. 215, No.1, pp. 69-76. 
Published abstracts 
Flavia Sciota and Lopa Leach. Effects of glucose on expression of 
VEGF165a!VEGF165b splice variants in human normal and diabetic placental 
microvessels. British Microcirculation Society conference, University of Exeter, April 
2010. 
Flavia Sciota and Lopa Leach. Effects of glucose on the expression of VEGF splice 
variants in normal and diabetic placenta, International Federation of Placental 
Associations (IFPA) Adelaide, Australia conference, October 2009. 
Flavia Sciota and Lopa Leach. Hyperqlycaemia increases Vascular Endothelial Growth 
Factor (VEGF) expression and vascular leakage in human placental vasculature, British 
Microcirculation Society, University of Birmingham conference, April 2009. 
Flavia Sciota and Lopa Leach. Insulin perfusion decreases expression of the splice 
variant VEGF16Sb in large vessels of the human term chorionic stem villi but not in 
microvessels, European Microcirculation Society Budapest, Hungary conference, August 
2008. 
Flavia Sciota, Dalbir Dhiraj and Lopa Leach. Effects of hyperglycaemia and hypoxia on 
the vascular endothelium of the placenta, Anatomical Society of Great Britain and 
Ireland conference, University of Nottingham conference, July 2008. 
Flavia Sciota and Lopa Leach. Effects of hyperglycaemia on Vascular Endothelial 
Growth Factor (VEGF) and Vascular Endothelial-cadherin (VE-cadherin) expression in a 
placental villous explant culture, British Microcirculation Society, King's College London 
conference, April 2008. 
Flavia Sciota and Lopa Leach. Effect of hyperglycaemia on vascular endothelial growth 
factor (vEGF) and vascular-endothelial-cadherin (VE-cadherin) expression in a placental 
villous explant culture, Anatomical Society of Great Britain and Ireland, University of 
Oxford conference, January 2008. 
Flavia Sciota and Lopa Leach. Role of VEGF in Diabetic Angiogenesis: Evaluation of 
Human Placental Villous Explant Cultures, Anatomical Society of Great Britain and 
Ireland, Durham University conference, July 2007. 
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